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Chapter 1 
Introduction - Drying for Protein Stabilization and its 
Formulation Aspects 
 
This chapter is intended to be published in the book “Drying Technologies for Biotechnology 
and Pharmaceutical Applications: Current Status and Future Trends”, edited by Davide 
Lechuga, Satoshi Ohtake, Ken-Ichi Izutsu (John Wiley & Sons, Inc.) and was prepared by 
Jacqueline Horn, Hanns-Christian Mahler and Wolfgang Friess. 
 
Abstract 
Drying can significantly improve the stability of protein drugs compared to liquid formulation 
and mostly, freeze-drying (lyophilisation) is employed for drug products for that respect. 
However, chemical degradation, like formation of disulfide bonds, oxidation, deamidation or 
glycation as well as physical instability, conformational or colloidal also occur in the dried 
state. Due to the complexity of the protein molecules a comprehensive analysis with a 
multitude of methods such as particle analysis, chromatography, circular dichroism or 
infrared spectroscopy are necessary. Typical excipients in drying include sugars, polyols or 
polymers. The two leading hypotheses for their ability to stabilize proteins in the dried state 
are the water replacement and the immobilization in an amorphous glass. Each step of 
freeze- or spray- drying process like freezing, droplet formation, water removal affects protein 
stability in different ways. Interfacial related stress occurs in almost all process steps 
whereas concentration effects are important during freeze-concentration or droplet formation. 
 
Keywords 
Protein stability, freeze-drying, spray-drying, physical instability, chemical instability, water 
replacement, glass dynamics, residual moisture, glass transition 
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Introduction 
Between 2010 and 2014, fifty-four novel biopharmaceuticals were approved in the US or 
Europe, with almost one third of them being monoclonal antibodies. Amongst others, further 
biopharmaceuticals approved included hormones, enzymes, vaccines and fusion proteins [1]. 
In total, more than 200 biopharmaceuticals are currently on the market, typically for 
refrigerated storage (2-8°C) and either in liquid or lyophilized dosage form [2]. 
This chapter is intended to discuss mechanisms of protein stabilization in liquid and dried 
formulations as well as the corresponding analytical methods. Furthermore, the impact of the 
drying process itself on protein stability is summarized. 
1. Protein Stability 
Protein stability is related to the primary sequence and the higher order molecular structure 
(secondary, tertiary and quaternary structure). Protein instabilities can be categorized as 
physical or chemical instabilities [3]. The latter include the formation or the breakage of 
covalent bonds resulting in new chemical entities. Examples include deamidation, 
fragmentation and oxidation. Physical instabilities, in contrast, are defined as altered physical 
state of the protein, including unfolded state, aggregation and precipitation. In practice, both 
chemical and physical instability reactions occur simultaneously for proteins, and can also 
lead to each other. For example, attractive protein-protein interactions may become stronger 
as a consequence of chemical changes such as oxidation or deamidation, and hence, both 
oxidation or deamidation in combination with aggregation may be found. 
External stresses are drivers for protein instability. In particular, these factors include 
interfaces (such as air/liquid and ice/liquid), temperature (heat) and light. Formulation 
parameters such as protein concentration, pH, ionic strength, and quality and quantity of 
excipients determine the stability  and can – to some extent – stabilize (or destabilize) the 
protein against external stresses [4,5]. 
 
1.1. Physical Instability of Proteins 
Physical instabilities can include changes in secondary or tertiary structure (conformational 
instability) or formation of multimers (aggregates, precipitation) (colloidal instability). 
Conformational and colloidal instability can be interconnected, as changes in higher order 
structural change may expose structural elements such as hydrophobic parts of the protein 
previously buried within the fold, which may also change aggregation propensity.  
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Important conformational instability pathways are thermal or chemical denaturation, and also 
cold denaturation has been discussed in this context [3]. Thermal denaturation is the 
unfolding of the protein upon increase of temperature. The melting temperature (Tm) at which 
half of the protein is denatured can be measured by differential scanning calorimetry (DSC). 
But also other methods which trace unfolding during a temperature ramp provide comparable 
information, such as FT-IR [6]. The Tm value of biopharmaceuticals should be well above the 
intended storage temperature, as well as accelerated conditions (higher temperature) that 
may occur temporarily during storage, processing or shipment and during formulation 
development and/or stability testing. Cold denaturation, i.e. denaturation at low temperatures 
is typically less relevant for the stability of biopharmaceuticals, but has been discussed being 
a concern during the freezing step in freeze-drying (3.1.1) [7]. Proteins can also be unfolded 
by chaotropic agents, called chemical denaturation. Guanidinium hydrochloride or urea 
concentration series has been used to gain information about the free energy of unfolding 
[8,9]. 
Colloidal instability reflects the association of individual protein molecules to larger species. 
These protein molecules can be native or conformationally altered, and thus, more prone for 
association. Colloidal instability is mainly driven by repulsive and attractive forces between 
protein molecules. The strength of these forces mainly depends on charge and charge 
distribution of the molecules and on surface hydrophobicity. Thus, important factors affecting 
the colloidal stability via the charge and charge interactions are charge and charge 
distribution of the protein molecules themselves as well as pH, buffer composition and ionic 
strength of the formulation. The net repulsion or attraction between protein molecules can be 
characterized by the osmotic second virial coefficient [10–12]. 
As a result of the interplay between conformational and colloidal instability, aggregates can 
form. These aggregates can be dimers, oligomers, soluble aggregates and larger subvisible 
and visible particles and precipitates, recently also called protein particles or proteinaceous 
particles (Figure 1-1) [13]. 
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Figure 1-1. Scheme of possible aggregation mechanisms of proteins. Stress factors as temperature, pH or 
ionic strength may induce different aggregation pathways. Interfacial stress is mainly driven by air-liquid 
or solid-liquid interfaces such as the ice-liquid interface during freezing. Blue proteins represent native 
protein structure, whereas the red ones are partially or completely unfolded. The figure is modified from 
[13]. 
 
1.2. Chemical Instability of Proteins 
Various chemical changes in the protein primary sequence can occur. This includes 
breakage or formation of disulfide bonds, deamidation, oxidation and glycation, which are 
described in more detail in the following and also isomerization, hydrolysis, ß-elimination and 
racemization, for all of which the reader is referred to literature [3,14,15]. 
 
1.2.1. Disulfide Bond Formation 
In case cysteine residues are present in the primary protein sequence, oxidation of two 
cysteine residues may result in formation of a cystin linkage or disulfide bond. This can occur 
1) within one protein molecule leading to a different conformation or 2) two protein molecules 
inducing the formation of covalent aggregates [16,17]. 
In case disulfide bonds are already present in a given molecule, there is also the risk that the 
bond may be reduced, and disulfide bonds re-form in a different pattern. This can lead to 1) 
disulfide exchange in a given molecule (mispairing), leading to different conformation or 2) 
disulfide formation between two molecules leading to covalent aggregates or 3) a protein 
molecule staying in its reduced form. Latter has been a significant issue during fermentation 
of antibodies [18]. Copper sulfate can provide protection against this disulfide reduction by 
acting as oxidizing agent [19]. It was shown for ß-galactosidase that the freeze-dried 
formulation was more susceptible to the disulfide degradation pathway than the aqueous 
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solution and in the freeze-dried samples covalent disulfide bonds were formed whereas in 
solution noncovalent soluble aggregates resulted [20]. 
 
1.2.2. Deamidation 
Deamidation is another common degradation pathway. Thereby, an asparagine or glutamine 
amide side group is transformed into the corresponding carboxylic acid and the release of 
ammonium makes the reaction effectively irreversible [3]. The reaction is accelerated either 
at acidic (pH <4) or at basic/neutral conditions (pH >6) based on different mechanisms. The 
latter mechanism via an intramolecular cyclization process forming a succinimide as 
intermediate is more common in protein formulations. The pentacyclic intermediate of 
asparagine is more stable than the hexacyclic one of glutamine and therefore asparagine 
reacts faster than glutamine. With more than just one asparagine or glutamine in the primary 
sequence, different deamidated protein species can result [3,15,21,22]. Consequently, pH 
and acidity in the dried state are the key factors concerning this instability pathway. 
Deamidation leads to changes in the charge heterogeneity in a molecule affecting charge 
based inter- and intramolecular interactions. In case deamidation occurs in a part of the 
molecule that relates to potency or binding, such as the CDR region of a monoclonal 
antibody, partial or full loss of efficacy may result [23]. 
 
1.2.3. Oxidation 
Some amino acids are sensitive to oxidation including methionine, tryptophan as well as 
cysteine (see 1.2.1), histidine, and tyrosine. The oxidation process is usually mediated by 
reactive oxygen species and influenced by various intrinsic or extrinsic factors, such as 
protein structure and folding, pH, metals and light. Reactive oxygen species can result from 
metal-induced Fenton reactions, side-chain oxidations of polymers such as excipients, 
contaminants e.g., peroxides in excipients, light and other sources [24]. 
 
1.2.4. Glycation 
Glycation - also referred to as Browning or Maillard reaction - is the non-enzymatic reaction 
of a reducing sugar with a primary or secondary amine e.g. lysine residues. The amine 
reacts with the carbonyl group to a Schiff base, a reactive species which reacts further to 
more stable N-glycosylated amines of brown colour, giving the reaction its name. Sugars are 
frequently used as protein stabilizers in dried formulations and the Maillard reaction is the 
reason why non-reducing sugars like sucrose or trehalose are used instead of reducing 
Chapter 1 
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sugars like glucose, lactose, fructose or maltose. One also has to be aware of the fact that 
sucrose may invert into the reducing sugars glucose and fructose at elevated temperatures 
or acidic conditions [25,26]. 
 
1.3. Analysis of Protein Stability 
Protein drug stability is investigated in long-term stability studies at intended and accelerated 
storage conditions. Due to the various potential chemical and physical changes, a broad 
panel of analytical methods is recommended and typically applied. Stress parameters used 
in development to evaluate formulation parameters such as pH, type/amount of excipients 
are temperature, light, mechanical stress by shaking or freeze-thaw stress [27,28]. Typical 
standard analytical tools for routine stability testing include turbidity, color, pH, osmolality, 
subvisible particles, visible particles, purity methods e.g. evaluating size, charge or 
hydrophobicity based separation, and measurement of content. Further methods, such as 
spectroscopic techniques can serve for biophysical characterization or extended 
characterization, and monitoring of other critical excipients may monitor related changes. 
 
1.3.1. Particle Analysis in Protein Formulations 
Particle analysis has become very important given aggregation and precipitation is a typical 
instability pathway for most proteins. It has been speculated that protein aggregates / 
particles can lead to enhanced immune response to the protein drug molecules [29,30]. 
Recently it has been suggested that protein aggregates / particles are only relevant for 
modulating the immune response if substantially chemically modified e.g. by oxidation 
[31,32]. 
The amount or size of particles has to be evaluated by several different methods (e.g. light 
obscuration, nanoparticle tracking analysis, dynamic light scattering). Additionally, visual 
inspection should be performed during formulation development, since it is mandatory as in-
process testing during manufacturing (100% inspection and pulling drug product units with 
any visible particulate present) and quality control (release and stability). The size of particles 
visible for the human eye is a topic of debate. In fact, the size, type, number, color, refractive 
index of particulates, but also the method of detection (unaided eye vs. magnification, 
color/type of background, light intensity, inspection duration, capability and ability of the 
operator) affect the outcome of the test. This is why it is not reasonable to define a “size” of 
visible particles. Number and size of smaller particles in the subvisible region (>2 µm) are 
quantified by e.g. light obscuration or microscope methods (according to USP <788> and 
Ph. Eur. 2.9.19). Recently, micro-flow imaging has also been suggested for quantification, 
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yet this method has significant shortcomings which render it currently no viable option for 
quality control purposes. 
The determination of particles in the nanometer region may provide an additional level of 
characterization. For example, nanoparticle tracking analysis (NTA) and resonant mass 
measurement (RMM) are emerging technologies used for detection of particles in the 
submicron (<1 µm) size range. High molecular weight species, i.e. soluble aggregates are 
detected by size exclusion chromatography (1 – 50 nm) (1.3.2).  
All the technologies mentioned have their specific measurement (size) range, and 
advantages and disadvantages and should be used complementarily. Some methods are 
generally used for quality control, such as light obscuration, visible particle inspection and 
size-exclusion chromatography, while others serve solely for extended characterization. 
 
1.3.2. Other Purity Tests for Proteins 
Chromatographic methods are widely used to identify physical and chemical changes of 
proteins. Size exclusion chromatography (SEC) is the analytical workhorse for the 
characterization and quantification of soluble higher molecular weight species (protein 
aggregates) and soluble fragments. Complementary methods to SEC are asymmetrical flow 
field-flow fractionation (AF4) or analytical ultracentrifugation (AUC). Purity testing also 
includes capillary electrophoresis (CE-SDS) or related gel-based methods, such as sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Chemical changes can be 
monitored e.g. by reversed-phase, hydrophobic interaction, hydrophilic interaction, ion 
exchange chromatography (IEC) or isoelectric focusing (IEF). IEC and IEF are well 
established methods for the characterization of charge heterogeneity, but due to the faster 
analysis and the less complex method development, there is a trend towards CE techniques 
like capillary isoelectric focusing (cIEF) and capillary zone electrophoresis (CZE) [33,34]. 
 
1.3.3. Analysis of Higher Order Structure 
Circular dichroism (CD) can be used to identify changes in secondary (far-UV CD, 190 –
 250 nm, peptide bond conformation) and tertiary (near-UV CD, > 250 nm, absorption of 
aromatic amino acids and cystine) protein structure based on the difference in absorption of 
left- and right-handed circularly polarized light. The location and intensity of characteristic 
bonds (α-helices, ß-sheets, unordered structures) at certain wavelengths are used for 
analysis. Dry powders need to be rehydrated for CD analysis ignoring the potential impact of 
reconstitution [35]. 
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Fourier transform infrared spectroscopy (FTIR) enables liquid as well as solid state analysis 
of the secondary protein structure. It is based on the Amid I C=O stretching band at 
1700 cm-1 to 1600 cm-1. The drawback of this method is the low sensitivity not being able to 
detect smallest structural changes of the protein structure, in particular if only single domains 
of the protein are affected [36]. Fluorescence, UV and RAMAN based methods may be used 
orthogonally. More innovative higher order structure analysis methods include hydrogen-
deuterium exchange (HDX). 
 
2. Protein Stability in the Dried State 
2.1. Theoretical Considerations 
Compared to the aqueous solution the dried state is characterized by a matrix that reduces 
protein mobility, and less water (as residual moisture), which is mediating many chemical 
reactions [37,38]. The pharmaceutical industry developed various drying techniques suitable 
for protein stabilization, mainly adopted from food industry [39,40]. This includes vacuum-
drying [41,42], fluid bed drying [43], film-drying [44], freeze-drying [45], spray-drying [46] or 
spray-freeze-drying [47] of which freeze-drying is clearly dominant and preferred. All drying 
methods have in common that stabilizers are required to ensure protein stability. 
Dry products which provide good protein stability are typically based on amorphous matrices. 
For the classic low molecular sugar, mostly sucrose matrices, two hypotheses regarding the 
stabilization mechanism are discussed [48,49], which however cannot explain all cases of 
stabilization or destabilization. In some cases the water replacement theory helps explain the 
stabilization effect and in other cases the vitrification concept. The debate about the 
preferable hypothesis is still ongoing [49]. 
 
2.1.1. Water Replacement Hypothesis 
As the name “water replacement theory” implies, the sugar molecules replace the hydrogen 
bonds of water at the surface of the protein. Thus, the sugar molecules stabilize the native 
conformation of the protein and thermodynamically stabilize against unfolding [50]. 
Theoretically, a sugar monolayer around the protein molecule should be adequate to retain 
complete protein activity replacing water at all hydrogen bonding sites. The fact that an 
increasing sugar to protein ratio leads to increased protein stability up to a saturation limit 
supports the water replacement theory. A similar molar ratio of sugar to protein of around 
350 - 400 was shown to be sufficient for freeze- and spray dried monoclonal antibodies 
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[51,52]. Saturation was also shown for five different proteins at a similar or lower molar ratio 
[53]. Hydrogen bonding between sugar and protein can be assessed by FT-IR [54]. 
 
2.1.2. Glass Dynamics Hypothesis and Vitrification [55] 
The second hypothesis on stabilization of proteins in the dried state is the so called “glass 
dynamics” or “vitrification” hypothesis, which is based on kinetic considerations. The mobility 
of the protein molecules is limited in the glassy matrix. As a consequence, reactions between 
protein molecules, but also of protein molecules with water or oxygen, are slowed down, as 
the time-scale of reactions is prolonged. This reduced mobility is reflected in α- and ß- 
relaxations of the matrix [49]. It is not clear yet, which of these relaxations is more relevant 
for protein stability or whether it is the combination of both. The α-relaxation, also called 
global or slow dynamics or primary motions, reflects slow translational and rotational motions 
on a seconds-to-months time scale. The motions correlate with the viscosity of the entire 
system and are therefore related to the glass transition [56,57]. In contrast, ß-relaxations, 
also named secondary motions or Johari-Goldsteins relaxations [57], are local dynamics in 
spatial proximity which influence motions at a time scale of picoseconds. Since small 
distances between protein molecules drive protein aggregation slowing down ß-relaxations is 
suggested for improving protein stability [49,56]. Excipients with low molecular weight, e.g. 
glycerol and sorbitol, may be able to increase local ß-relaxation times, but decrease global α-
relaxation times, hence antiplasticizing ß-motions and plasticizing α-motions at the same 
time [56,58,59]. 
 
2.2. Analysis of the Dried State 
As described above, vitrification in an amorphous matrix with low mobility and hydrogen 
bonding is important to stabilize proteins in the dried state. To characterize these features, 
typically three basic routine tools can be utilized: differential scanning calorimetry (DSC), X-
Ray powder diffraction (XRD) and residual moisture determination (Karl-Fischer or TGA). 
Also other more sophisticated tools have been applied and the reader is referred to the 
primary literature e.g. on small angle X-ray scattering (SWAXS), dielectric relaxation 
spectroscopy (DRS), dynamic mechanical analysis (DMA), fluorescence spectroscopy, 
nuclear magnetic resonance (NMR), positron annihilation lifetime spectroscopy (PALS), 
hydrogen/deuterium exchange mass spectroscopy (HDX MS) [60,61] or solid-state NMR 
[62]. 
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2.2.1. Investigation of Endo- and Exothermic Processes: Glass transition 
and Crystallization 
Differential scanning calorimetry (DSC) is the standard tool for the determination of the glass 
transition temperatures (Tg) of amorphous solids. It can also be used to characterize 
crystallization events, polymorph variants, relaxation behaviors, Tg of the freeze-concentrate 
(Tg’) and melting points [63]. The DSC comparatively measures the heat capacities of a 
sample and a reference pan during cooling and heating cycles. Endothermic events (e.g. 
melting point) are characterized by a positive heat flow, hence energy input, whereas 
exothermic events (i.e., crystallizations, relaxations) set energy free and thus, lead to a 
negative signal. The Tg characterizes the temperature at which amorphous solids transform 
from a glassy, rubbery state into a state with viscous flow accompanied by a distinct 
decrease in viscosity. This event is not related to a formal phase change, but a step in the 
DSC baseline occurs as the heat capacity changes. Storage temperatures of amorphous 
solids should not exceed Tg, as in this case macroscopic collapse of the formulation would 
result. Furthermore, protein stability can be drastically decreased upon storage above or 
close to Tg as the molecular mobility jumps up [64–66]. Furthermore, it is essential to assess 
the storage stability of amorphous solids since the metastable amorphous form tends to 
transform into a stable crystalline polymorph, potentially indicated by an exothermic 
crystallization peak depending on kinetics. 
 
2.2.2. Sample Morphology – Crystalline or Amorphous Matrix? 
XRD is the method of choice to gain information about sample morphology. The operation 
principle is the reflection of X-rays in an angle dependent manner. Diffraction angles and 
patterns can be assigned to distinct structures based on Bragg’s law. Thus the absence of 
peaks indicates an amorphous structure and peak patterns allows for the differentiation of 
crystalline polymorphs. Mannitol for example forms at least four different polymorphs in 
addition to the amorphous form. Both, the form itself as well as polymorphic transitions have 
to be considered regarding long term storage stability. The hemihydrate form is prone to 
transform into one of the anhydrates (α-, ß- or δ-polymorph). The released crystal water is 
transferred into the amorphous phase acting as plasticizer.  Ultimately Tg is decreased, the 
mobility of the system increased and instability reactions between protein molecules 
enhanced. The released water may also be an important reaction partner itself e.g. for 
hydrolytic reactions. The most stable crystalline mannitol form is the ß-polymorph. It was 
shown that both spray- and freeze-drying rendered mainly the ß-polymorph if no protein was 
present in the formulation. Increasing lysozyme concentrations stimulated the formation of α-
Introduction - Drying for Protein Stabilization and its Formulation Aspects 
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mannitol during spray-drying and of δ-mannitol upon freeze-drying [67]. Thus, not only 
process differences, but also formulation differences affect which polymorph forms. 
 
2.2.3. Residual Moisture 
The residual moisture content is an important quality attribute of the dried material. A higher 
water content may be directly related to reduced protein stability with water molecules acting 
as reaction partner or as plasticizer increasing molecular mobility. Thus, it is important to 
evaluate the impact of differently dried material on long-term stability. The duration and 
especially temperature of the secondary drying in freeze-drying is the most decisive step for 
the amount of moisture remaining. Typically, a residual moisture content below 2% is being 
aimed for, considering many reactions would generally be slowed down below this level [68], 
although this clearly depends on the specific product (protein, formulation etc.). Further 
drying to very low amounts of moisture may lead to so-called overdrying [69]. Karl-Fischer 
titration is the standard method for determination of the residual moisture. Thermogravimetric 
analysis (TGA) could also be used and recently spectroscopic analysis for non-destructive 
high throughput analysis has been introduced [70,71].  
 
2.3. Excipients Used to Stabilize Proteins in the Dried State 
Most proteins require additional stabilizers to retain their activity during drying and 
subsequent storage. The amount of stabilizer which can be added may be limited by 
physiological considerations since parenterally applied solutions, obtained after 
reconstitution, should preferably be isotonic. The amount of stabilizer needed may follow 
different rules. On the one hand, the higher the ratio of stabilizing sugar to protein molecules 
the better the stability and the increment of stability improvement levels off at higher ratios 
[51]. On the other hand, at  higher protein concentration, less stabilizer may be needed due 
to a self-stabilization of the protein by steric repulsion of vicinal protein molecules and a 
reduced interface to protein molecule ratio at which denaturation could occur [72]. Although 
equal numbers of protein molecules are damaged, the relative fraction at higher protein 
concentration is lower [72,73]. In freeze-drying, one distinguishes between cryo- and 
lyoprotectants whereby some excipients combine both features. Cryoprotectants are known 
from nature as protectors against freezing induced stress [74] and lyoprotectors protect 
against drying induced stress. Stabilizers used for spray-dried products are comparable to 
the ones used in freeze-drying. More important in spray-drying is the Tg of the excipients 
which should be higher than the process temperature in order to prevent viscous flow. During 
spray-drying it also needs to be considered that the water content of the formed particles and 
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thus the product Tg depends on the moisture level of the drying environment and differs 
between the different stages of a spray-dryer, as does the temperature. Thus, the situation 
may be rather complex. Since freeze-drying is conducted at low temperatures, this factor is 
of minor importance and secondary drying temperature, especially in the temperature ramp 
phase going into secondary drying, and storage temperature should not exceed the 
formulation Tg. 
 
2.3.1. Sugars 
Disaccharides are the most commonly used protein stabilizers. Due to their small size and 
flexibility, they are able to cover the protein surface acting directly on the protein. During 
drying, they typically form amorphous matrices as a key parameter for stabilization. They 
combine cryo- and lyoprotectant characteristics and the mechanism of stabilization has been 
discussed above in more detail.  
The most frequently utilized sugars in freeze- and spray-drying are sucrose and trehalose. 
Both of them are non-reducing sugars, hence not susceptible for Maillard reactions. Due to 
its less stable glycosidic bond, sucrose may invert into the reducing monosaccharides 
glucose and fructose, even in freeze-drying studies, more markedly at low pH (Figure 1-2) 
and significantly high temperatures [75–79]. 
 
 
Figure 1-2. Progression of Maillard reaction in freeze-dried disaccharide matrices (2.5 % m/V) determined 
by the release of the monosaccharide glucose via an enzymatic reaction. Trehalose (black) and sucrose 
(white) were lyophilized with BSA (1 % m/m) and stored under controlled humidity conditions (22% rel. 
humidity) at 45 °C, reproduced with permission from [79]. 
Both sucrose and trehalose show relatively high Tg values with 75 °C and 118 °C, 
respectively, which is advantageous for spray-drying and for storage [80]. Particularly, 
trehalose shows one of the highest Tg values compared to the other sugars and also the 
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relaxation time and the concluding fragility of the glass are important factors for its usage as 
stabilizing excipient [81,82]. On the other hand, trehalose solutions showed a higher viscosity 
compared to sucrose solutions [83]. 
Trehalose is more prone to crystallization during freeze-concentration [84] which could lead 
to a loss of cryoprotective function and protein stability problems. The crystalline modification 
may transform into the amorphous state in the course of the freeze-drying process and thus 
may not be obvious when only testing the final product [76,85]. Upon spray-drying of protein 
solutions containing sugars as stabilizers, the plasticizing effect of moisture and thus 
stickiness of the resulting particles needs to be carefully considered (see also 2.2.3) [86,87]. 
Specifically for spray-drying of proteins for inhalative use other sugars can be considered as 
the drying behavior may be different rendering aerodynamically more favorable particles and 
lactose and glucose are preferred and approved for use in dry powder inhalers. 
 
2.3.2. Polyols 
The group of polyols which are frequently used for drying of proteins includes e.g. glycerol, 
sorbitol and mannitol, showing different characteristics. The first two are plasticizing agents 
but may also improve protein stability in the dried state [58,59,88]. Due to their low Tg 
(glycerol -93 °C [89] and sorbitol 0 °C [90]), they are not suitable as the only stabilizer for 
dried protein formulations as they do not render a solid material at room temperature. Thus, 
they need to be used in combination with other excipients having higher Tg [56]. Glycerol at 
low concentrations exhibits an antiplasticizing effect to the local motions of a protein 
formulation. The temperature needs to be below a critical antiplasticization temperature, 
which interestingly increases with lower glycerol concentrations [91]. Various studies explain 
an improved protein stability in presence of glycerol by the increased relaxation time of local 
fast dynamics (ß-relaxation) while the timescales for global relaxations is lowered 
[56,58,88,92].The improved protein stability may also be explained differently by an 
increased density of the packing reducing the free volume. Small voids left by larger glass 
forming molecules such as sucrose are filled by the plasticizer [56,93]. The smaller glycerol 
molecules are additionally sterically more suitable at gaining access to the surface of the 
protein molecules compared to larger excipients. Once the free volume is saturated by 
glycerol, the plasticizing characteristics dominate and glycerol acts as lubricant, accelerating 
the dynamics on all timescales [56]. 
Adding sorbitol to sucrose or trehalose-based antibody formulations led to a decrease of the 
global relaxation time τ and, in some cases, improved stability. Sorbitol did not affect the 
native structure stability in combination with trehalose, but with sucrose. Thus, the global 
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relaxation time τ could not predict stability adequately [59]. The combination of sucrose and 
sorbitol was beneficial also for other proteins and the effect may not be polyol specific but 
also small amino acids were suitable [94]. Upon spray-drying, the stabilizing effect of sorbitol 
on an IgG antibody was comparable to the effect of trehalose [86]. 
Polyols like mannitol do not have plasticizer properties, but are used as bulking agents in 
freeze-drying. Bulking agents crystallize during the process and do not stabilize protein 
molecules but render robust scaffolds for good cake appearance (see also 2.2.2). It is 
important to achieve complete mannitol crystallization in order to prevent subsequent 
crystallization during storage. Spray-dried mannitol remains amorphous und is hence able to 
stabilize the protein in an amorphous matrix. 
 
2.3.3. Polymers 
Polymers can also stabilize proteins in the dried state. Usually, polymers show high Tg which 
makes them suitable stabilizers by increasing the Tg of the whole formulation. The 
macromolecules differ in their stabilization mechanism from small molecules like sugars. 
Polymers hinder the protein interactions sterically, they increase the viscosity of the solution 
and hence slowing down the mobility, or they react via preferential exclusion [38]. 
Furthermore, they prevent pH drops of phosphate buffers during freezing or the 
crystallization of excipients. Commonly used polymers include serum albumins, 
polyvinylpyrrolidone, dextran, polyethylenglycole or hydroxyethylcellulose of different 
molecular weight [38]. 
Polymers may not only be beneficial, but can also negatively affect protein stability. Phase 
separation triggered by the polymer can be detrimental for proteins [95]. As a high Tg is not 
the only factor for a stable dried protein formulation, hydroxyethylstarch did not improve the 
protein stability compared to sucrose and trehalose [82]. One reason is the less efficiency in 
forming hydrogen bonds with proteins as for example demonstrated for freeze-dried 
formulations of LDH containing dextran or trehalose [96]. Human serum albumin containers 
free sulfhydryl groups, and thus, may lead to covalent aggregation (heteroaggregation) with 
cysteine-containing proteins. Also, the regulatory and safety status of the choice of excipients 
may in some cases be unfavorable for the choice of polymers for some parenteral products. 
 
2.3.4. Amino acids 
A stabilizing effect of amino acids on proteins is still unclear. Forney-Stevens et al. screened 
15 amino acids regarding the stabilization of two model proteins, rHSA and ACT, in the 
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freeze-dried state [94]. It seems as if the positive amino acids, which are also larger in size 
than the other amino acids, have an advantageous stabilization effect. Added in small 
amount to sucrose, they formed amorphous lyophilizates. In contrast, glycine is  a crystalline 
bulking agent and also phenylalanine crystallizes during freeze-drying, if the ratio of amino 
acid to sugar exceeds a certain limit [97]. Arginine also exhibited beneficial effects as 
amorphous stabilizer on freeze-dried protein formulations [98]. The arginine counter-ion 
plays an important role and chloride performed best regarding stabilization [98]. Concerning 
spray-drying isoleucine was reported to improve flowability of the powder and protein stability 
of an IgG1 antibody [99]. 
 
2.3.5. Further Excipients: Metal ions / HP-ß-CD / Surfactants / Buffers 
Surfactants adsorb to interfaces with a higher tendency than proteins. Thereby, they keep 
protein molecules off the interface where proteins may unfold. The most critical  interfaces 
are the ice/freeze-concentrate interface formed during the freezing step in freeze-drying and 
the air-liquid interface generated upon droplet formation during spray-drying [100]. 
Stabilization of protein molecules by direct binding has been shown for albumin fusion 
proteins and albumin with a lipophilic binding pocket [101], whereas binding to other proteins 
is still up to debate. Typical surfactants used are the non-ionic polysorbate 20 and 80. 
Cyclodextrins (CDs) are ring-shape molecules consisting of at least six glucose molecules. 
They are amphiphilic with a hydrophilic outer surface and a rather hydrophobic interior. The 
CDs limited solubility can be improved by substitution e.g. with hydroxypropyl- or sulfobutyl- 
groups. By incorporating hydrophobic moieties of a distinct size in their interior, CDs can 
improve solubility or reduce hydrophobic interactions. It was also shown that the CD 
derivatives have surfactant similar characteristics which make them suitable stabilizers 
against interface induced stresses [102], however, probably acting via different mechanism 
than non-ionic surfactants [103]. Concentrations higher than 1 % leads to a lyoprotectant 
behavior and also a good stability of spray-dried trypsin has been shown by CDs due to their 
glass forming characteristics [104]. 
Buffers are added to protein formulations to keep the pH consistent. The pH is one of the 
most important parameters in protein formulations as it affects all instability pathways, 
chemical reactions, colloidal interactions, as well as conformational stability (see also 1.1 and 
1.2). Additionally the counter-ion effect has to be considered when comparing the typically 
negatively charged buffer salts phosphate or citrate to histidine or Tris. Concerning the dried 
state, histidine has been shown to be beneficial for protein stability [105] (see also 2.3.4). On 
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the other hand, crystallization of buffer salts may have a detrimental effect on protein stability 
(see also 3.1.1). 
Metal ions, specifically divalent cations like zinc, copper or calcium can bind to specific 
protein binding sites and may in some cases stabilize (but also destabilize) the native protein 
conformation. It was reported that phosphofructokinase stability was substantially improved if 
the divalent metal ions were added to a  sucrose based formulation [106]. Spray-dried 
formulations of recombinant human growth hormone were stabilized by zinc in combination 
with polysorbate 20 without any sugar stabilizer by formation of a dimer complex [107]. 
 
3. How Does the Process Influence Protein Stability? 
3.1. Process of Freeze-drying 
The freeze-drying process can be separated into the steps freezing including annealing, 
primary drying at low product temperature under reduced pressure in order to remove ice 
from the frozen system by sublimation and secondary drying at higher product temperature 
and reduced pressure to desorb water from the product. Each step requires special 
consideration in the context of drying protein products. 
 
3.1.1. Freezing 
Freezing is the first step after dispersing the liquid solution into the product containers and 
can already be detrimental for proteins. Several factors of influence are discussed. Cold 
denaturation describes the unfolding of proteins at low temperature due to a lower barrier in 
Gibbs free energy of unfolding [108]. It is difficult to determine the impact of cold denaturation 
on protein stability because ice formation and freeze concentration are two phenomena 
which influence protein stability and occur in parallel during freezing. Cold denaturation is 
assumed to be of minor relevance since the freezing step is rather short and often occurs at 
temperatures below the product temperature in freeze-drying [7]. 
Another major critical effect during freezing is the formation of a freeze-concentrated liquid as 
a very densely structured hexagonal crystal lattice [109–111]. Both the protein concentration 
and the excipient concentrations increase. Especially for proteins sensitive to native-like 
aggregation, highly concentrated areas could promote particle formation during freezing 
[111]. 
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Another phenomenon occurring during freeze-concentration is the crystallization of buffer 
components due to their limitation in solubility. In some cases, a pH shift of more than three 
pH units is the result. A famous example is sodium phosphate buffer in which the basic 
disodium salt is the less soluble component and precipitates during freezing. This shifts the 
acid-base balance towards the base since the base is removed from the equilibrium. Protons 
are set free and decrease the pH [108] which lead to denaturation of sensitive proteins, e.g. 
LDH [112]. Potassium phosphate in contrast leads to a pH increase since the monobasic salt 
precipitates during freezing [113,114]. Further pH shift inducing buffers are succinate or 
tartrate. To prevent this phenomenon low buffer concentrations or high protein 
concentrations can be used or buffers may be selected which are not prone to pH-shift like 
histidine, glycine, citrate or Tris. Addition of 0.25 M sucrose already prevented the pH shift to 
a large extent for both sodium and potassium phosphate buffer [114]. Thus the whole 
formulation composition influences the freezing behavior and hence the impact on protein 
stability. A recent article proposed the use of counter ions which balance the pH shift of the 
buffer salt [115]. They investigated tetramethylammonium chloride (TMACl) whose anion is 
incorporated into the ice crystal structure during freezing leading to a concentration 
dependent basification. When used together with sodium phosphate buffer, the concluding 
acidification by the phosphate is diminished by the TMACl. 
Freeze concentration concerns all excipients. For example a 0.9 % sodium chloride solution 
concentrates 24-fold [89]. This enormous increase in ionic strength may influence the protein 
stability by reducing repulsive charge interactions. On the other hand it was shown that 
sodium chloride could prevent aggregation of rHA upon lyophilization which was correlated to 
a water uptake in short spatial proximity to rHA facilitating refolding into the native rHA [116]. 
The freeze concentration of sugars is one important factor for the cryopreservation of 
proteins. High sugar concentrations result in high viscosities  which slow down the molecular 
mobility of the system and hence prolong unfolding kinetics of the proteins [117]. 
In addition, the ice-liquid interface itself can be detrimental for the protein. Proteins adsorb to 
the ice surface which promotes unfolding. The extent of unfolding at the ice-liquid interface is 
protein dependent. Infrared spectroscopy could show that the IgG and LDH structure 
changed at the ice-liquid interface leading to a higher ß-sheet content, whereas the structure 
was unchanged in the freeze concentrated liquid [118]. Regarding rhIFN-γ, aggregate 
formation could not be linked to the adsorption at the ice-liquid interface but most likely 
occurred at the air-liquid interface during reconstitution [100]. The ice-liquid interface may 
make the protein more susceptible for unfolding or structural perturbation. By addition of 
surfactants like polysorbates, interface related damages are usually prevented. 
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The amount of interfacial area and the ice crystal size respectively depend on the chosen ice 
nucleation technique. The typical so called uncontrolled nucleation technique is the shelf-
ramped freezing which leads to a high number of small ice crystals formed from bottom to the 
top due to a high degree of supercooling. Overall the surface area may be rather 
heterogeneous as the degree of supercooling varies within a batch as crystallization occurs 
at random. Recently several different techniques to induce controlled ice nucleation were 
established [119]. Controlled nucleation techniques lead to nucleation at defined product 
temperature for the entire batch. Comparative studies of controlled nucleated and randomly 
nucleated protein formulations could show changed physical characteristics, for example 
faster reconstitution times for highly concentrated mAb formulations, however, did not 
improve the protein stability [120,121]. 
 
3.1.1.1. Annealing 
Annealing, also called thermal treatment, is the increase in temperature during the freezing 
step after the initial freezing prior to primary drying. Thereby, bulking agents like mannitol or 
glycine should crystallize completely and the ice crystal size should be increased providing 
larger pores and lower cake resistance to vapor flow. The increase in temperature is 
recommended to be close to the Tg’ of the solute in order to increase the mobility of the 
system [122]. Crystalline bulking agents should be fully crystalline after the freeze-drying 
process, since they are responsible for the formation of a mechanically stable cake structure. 
Furthermore, bulking agents usually exhibit a low Tg’ (mannitol -35 °C [123]) causing 
difficulties in drying and storage stability. Additionally, during the annealing step, undesired 
crystallization of amorphous stabilizers like trehalose can occur. This crystallization resulted 
in a unfolding of BSA measured in freeze/thaw studies performed at typical mannitol 
annealing temperatures of -20 °C [124]. 
 
3.1.2. Drying 
After freezing the chamber pressure is reduced to initiate the drying process. Primary drying 
removes mainly the ice formed during freezing (80-90% of water) and during secondary 
drying at higher shelf temperature the water kept in the freeze-concentrate evaporates. 
As the main part of the protein is phase-separated from the ice and located in the cryo-
concentrated region, one could assume that the primary drying is not the main stress on the 
protein. Nevertheless, if primary drying is carried out above Tg’, the mobility of the 
amorphous phase is increased which could enhance interactions between the protein 
molecules or protein molecules and reaction partners. Furthermore, product temperatures 
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above Tg’ e.g. induced by too high chamber pressure or too high shelf temperature could 
induce macroscopic collapse. It was shown that collapse is not necessarily detrimental to 
protein stability [125], but other quality attributes like macroscopic appearance or 
reconstitution times may be affected. 
The subsequent secondary drying to remove water which is bound stronger to the solids is 
commonly performed at 20 °C or higher. By desorption of water molecules parts of the 
protein’s hydration shell are removed. Many proteins require water in their active sites for 
their biologic function, hence removal of this water may induce loss of activity [126]. 
Regarding the macroscopic appearance, the product temperature should stay below Tg 
during secondary drying in order to prevent macroscopic collapse. However, collapse does 
not need to be a drawback concerning protein stability [97,125]. 
Currently many development projects focus on highly concentrated protein formulations 
mainly of monoclonal antibodies. The solutions may exhibit high viscosity and consequently 
a higher concentration of excipients like salts is required to reduce the viscosity. The 
formulations may also show a higher cake resistance to vapor flow and can exhibit very long 
reconstitution times. Additionally, the ratio of stabilizing excipient molecules to protein 
molecules may be lower compared to low protein concentration formulation as isotonicity 
limits the excipient concentrations. Colandene et al. demonstrated a marked increase in Tg’ 
and Tc with increasing mAb concentration which was much more pronounced for Tc [127]. 
Thus, drying above Tg’, but below Tc was easily possible preserving cake structure as well 
as protein stability.  
 
3.1.3. Typical Defects in Lyophilized Products beyond Protein Stability 
For marketed lyophilized drug products appealing cake appearance is a critical factor. 
Defects like loose cake, larger cracks, shrinkage, vial fogging, melt down or collapse may be 
give rise to complaints or rejects although not related to protein stability [128]. Melt down and 
collapse are both related to high product temperatures commonly at the end of primary 
drying [129]. Cracks on top of the cake or shrinkage usually occur when amorphous matrices 
are used as main excipient. This is due to tension within the cake, when the desorbing water 
forces its way through the cake. As a result, the cake either cracks or shrinks by detaching 
from the vial wall, which both leads to relaxation [130–132]. Formulation creeping upwards at 
the vial surface after filling and subsequent drying in this position is called vial fogging. 
Abdul-Fattah et al. showed that it can be reduced by several factors of formulation or process 
design. However, most effective was the use of hydrophobic vials [133]. 
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3.2. Process of Spray-drying 
In contrast to freeze-drying, spray-drying is a one stage process. Two major stresses occur. 
Firstly, upon atomization an enormous air-liquid interface is generated which triggers protein 
adsorption and aggregation. Secondly, drying at higher temperature is performed which can 
be critical for the conformational stability of the protein and may lead to oxidation [129]. 
 
3.2.1. Protein Stability during Droplet Formation 
First, the solution is atomized into a spray. In this step, the main stress results from the newly 
generated enormous air-liquid interface. Protein molecules adsorb to the air-liquid interface. 
This results in high local protein concentration fostering intermolecular interactions and 
potentially partial unfolding [134]. Ultimately soluble or insoluble aggregates can be formed. 
Addition of surfactants is the method of choice to protect the protein by preventing its 
adsorption. The addition of polysorbate was confirmed to reduce the extent of protein surface 
aggregation and increase protein stability e.g. for BSA, rHGH, LDH and recombinant IL-11 by 
ESCA and stability assays [107,135–137]. Different nozzle types are available and the stress 
induced by the shear or temperature effect of the nozzle itself needs to be considered 
[138,139]. 
 
3.2.2. Protein stability during the drying phase 
During the drying phase, as the water evaporates, the temperature is a highly critical factor 
[135]. It requires a careful balance. The droplet temperature must not exceed the protein 
melting temperature as long as the protein is still in solution. At the same time, the 
temperature has to be high enough to ensure drying results in a non-sticking powder with 
adequate residual moisture [140]. The temperature setting have to be decided against the 
background of the ongoing endothermal drying process which keeps the droplet temperature 
low as long as substantial evaporation proceeds close to inlet air temperature conditions for 
a short time. The dried particles ultimately face the outlet temperature conditions for longer 
time. The residual moisture typically is higher as compared to freeze-dried products and may 
be reduced in an additional drying step at higher temperature and vacuum similar to 
secondary drying in freeze drying [99,141]. This may also help to reduce the risk of 
recrystallization of amorphous excipients. Amorphous excipients like sucrose, trehalose or 
cyclodextrins have been demonstrated to be essential for protein stabilization during the 
drying phase [86,142–144]. During spray-drying also oxidation can occur as air is used as 
the typical drying gas. Addition of methionine has been shown to prevent rhIL-11 from 
oxidation and formation of related species [137].  
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Chapter 2 
Objectives of the Thesis 
Analytical tools that are capable to monitor the freeze-drying process are increasingly 
required for improved process understanding [1]. The optical fiber system (OFS) was already 
shown to measure temperature during the freeze-drying process and, moreover, to be 
potentially able to detect glass transition or crystallization events directly in the freeze-dryer 
[2]. This potential was investigated in freeze/thaw and freeze-drying experiments and 
compared to the standard DSC and FDM measurements (Chapter 3). The impact of different 
saccharides and proteins, excipient concentration and heating rate was comprehensively 
studied. Mannitol (Man) crystallization was characterized by OFS and DSC. The potential of 
the OFS as analytical tool in lyophilisation processes was investigated with collapse and non-
collapse lyophiliation cycles of different sugar solutions. 
The first step in freeze-drying, the freezing step, already determines many of the final product 
characteristics as pore size or excipient crystallinity and affects protein stability. Therefore, 
the impact of the freeze-concentrate composition consisting of the bulking agent Man, the 
protein stabilizer trehalose (Tre) and the protein BSA was characterized upon freezing, 
annealing at -20 °C and after thawing (Chapter 4). DSC, IR and XRD were used to 
characterize the frozen solutions while IR, CD, turbidity, LO and HP-SEC facilitated the 
determination of the BSA structure and the formation of aggregates in liquid samples before 
and after freeze-thawing. Crystallization of the excipients was correlated to protein unfolding 
and aggregate formation in different Man/Tre/BSA ratios. This study was performed in 
cooperation with Prof. Alptekin Aksan and Sampreeti Jena from the University of Minnesota. 
Freeze-drying is time- and cost-intensive due to its low process temperatures and the hence 
long drying times [3]. Fast freeze-drying at higher product temperatures (Tp) would hence 
enable shorter process times at reduced production costs. Typically, amorphous sugar 
formulations would collapse if dried at high Tp. Therefore, the crystalline bulking agent Man 
was added to sucrose (Suc) to freeze-dry at high Tps without defects in cake appearance 
despite collapse of the Suc matrix (Chapter 5). The aim was to minimize process time 
without harming cake structure and protein process stability. The freeze-dried cakes were 
comprehensively studied regarding their physical characteristics (residual moisture (RM), 
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glass transition temperatures (Tg), Man crystallinity and reconstitution times) and regarding 
protein process stability (particle and aggregate formation). The results were compared to 
conservative freeze-drying at low Tp and hence long drying time. 
A 4/1 Man/Suc ratio was required for complete Man crystallization. This high proportion of 
crystallizing bulking agent prevented a higher stabilizer content that may be necessary for 
adequate protein stabilization. Therefore, alternative bulking agents were to be identified 
which: (1) crystallize at lower bulking agent to Suc ratio compared to Man and (2) have no 
negative impact on cake characteristics and protein stability. Crystallizing amino acids (AA) 
(phenylalanine, leucine, isoleucine, methionine, glyine) were identified as potential bulking 
agents and were thoroughly investigated in different AA/Suc ratios (Chapter 6). XRPD was a 
key method to detect AA crystallization. Suitable cake appearance was a prerequisite for 
further selection. The AA/Suc lyophilizates had to withstand macrocollapse despite fast 
freeze-drying at high Tp. Residual moisture, Tg values as well as reconstitution times 
complemented the analyses of the freeze-dried AA/Suc samples. Protein process stability 
(turbidity, sub-visible particles and aggregate formation) was tested with the three most 
promising bulking agents (phenylalanine, isoleucine and leucine). 
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Abstract 
The collapse temperature (Tc) and the glass transition temperature of freeze-concentrated 
solutions (Tg’) as well as the crystallization behavior of excipients are important 
physicochemical characteristics which guide the cycle development in freeze-drying. The 
most frequently used methods to determine these values are differential scanning calorimetry 
(DSC) and freeze-drying microscopy (FDM). The objective of this study was to evaluate the 
optical fiber system (OFS) unit as alternative tool for the analysis of Tc, Tg’ and crystallization 
events. The OFS unit was also tested as a potential online monitoring tool during freeze-
drying. Freeze/thawing and freeze-drying experiments of sucrose, trehalose, stachyose, 
mannitol and highly concentrated IgG1 and lysozyme solutions were carried out and 
monitored by the OFS. Comparative analyses were performed by DSC and FDM. OFS and 
FDM results correlated well. The crystallization behavior of mannitol could be monitored by 
the OFS during freeze/thawing as it can be done by DSC. Online monitoring of freeze-drying 
runs detected collapse of amorphous saccharide matrices. The OFS unit enabled the 
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analysis of both Tc and crystallization processes, which is usually carried out by FDM and 
DSC. The OFS can hence be used as novel measuring device. Additionally, detection of 
these events during lyophilization facilitate online-monitoring. Thus the OFS is a new 
beneficial tool for the development and monitoring of freeze-drying processes. 
 
Keywords 
Freeze-drying, lyophilization, optical fiber system, glass transition, collapse, crystallization, 
monitoring 
 
Abbreviations 
DSC Differential scanning calorimetry 
FBG Fiber bragg grating 
FDM Freeze-drying microscopy 
OFS Optical fiber system 
PAT Process analytical technology 
Tc Collapse temperature 
Tcry Crystallization temperature 
Tg’ Glass transition temperature of the freeze-concentrated solution 
TOFS Temperature of OFS peak during heating 
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1. Introduction 
Freeze-drying is commonly used for the long-term stabilization of biopharmaceuticals which 
cannot be stabilized adequately in the liquid state. Efficient development of freeze-drying 
cycles is of utmost importance as the process is time and cost consuming. Short process 
times without putting the protein stability at risk are desired [1–3]. It is essential to analyze 
the formulation to be freeze-dried regarding critical parameters for the freeze-drying process. 
Typical parameters of amorphous matrices, as formed by the most frequently used 
saccharides for stabilization of proteins, sucrose and trehalose, are the collapse temperature 
(Tc) and the glass transition temperature (Tg’) of the freeze-concentrated solution [4,5]. They 
characterize temperatures at which the mobility of the system greatly increases, either at the 
drying front (Tc) or in the frozen state (Tg’). Tc is typically determined by freeze-drying 
microscopy (FDM) whereas the standard method for Tg’ is differential scanning calorimetry 
(DSC). FDM mimics the freeze-drying process in miniature by freezing and drying small 
volumes of formulation under the microscope. Tc can be defined as either the onset of visible 
collapse or full collapse [5,6]. Tg’ as analyzed by DSC reflects the temperature at which the 
heat capacity of the freeze-concentrated formulation markedly changes [4]. Both values help 
to define the upper limit of the product temperature (Tp) during the primary drying step. In lab 
scale, Tp is typically measured by thermocouples that can only represent the temperature of 
the surrounding environment although the local temperature of the sublimation front might be 
more critical for the occurrence of collapse. Tc values are usually 1 to 3 °C higher than Tg’ 
values and drying above Tc may result in macrocollapse of the lyophilizate. Drying above Tg’ 
but below Tc can be utilized e.g. for highly concentrated protein formulations [7]. It enables 
higher product temperatures, faster drying and thus shorter process times without loss of 
cake structure if protein stability is preserved [7]. Nanoparticle suspensions were also shown 
to increase collapse temperatures [8]. Macrocollapse is not only a question of elegant cake 
appearance, but it can, but not necessarily has to be correlated to higher residual moisture 
levels after the process, destabilization of the API, longer reconstitution time or prolonged 
secondary drying [6,9,10]. Nevertheless, since it is known that an 1 °C increase in Tp can 
shorten primary drying times by about 13%, the interest is to dry at the highest possible Tp 
[11]. Crystalline bulking agents like mannitol not necessarily stabilize proteins but form 
crystalline scaffolds that provide robust and elegant cake structures [12–15]. Their controlled 
and complete crystallization during the freeze-drying process is of interest since partial 
crystallization might induce subsequent crystallization of the amorphous fraction during 
storage leading to potential loss of drug stability [16]. Crystallization occurs mainly during 
thermal treatment before drying starts [17]. In order to force crystallization, an annealing step 
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is usually conducted at temperatures above Tg’ [18]. The temperature at which crystallization 
(Tcry) occurs can be determined by DSC measurements [13]. 
Thus, the correct characterization of the system is of utmost importance. FDM and DSC both 
provide good approximations but are based on low sample volume which is dried in a thin 
film by FDM or freeze/thawed in small aluminum crucibles by DSC not necessarily reflecting 
the several milliliters in a vial during freeze-drying. Furthermore, the high heating rates of 5 to 
20 °C/min in DSC analysis do not correspond to the typical 0.5 to 1 °C/min during 
lyophilization but facilitates the Tg’ analysis due to a more distinct baseline shift [19]. The 
heating rates applied in FDM analysis are lower, however, may still not represent the heating 
rate within the vial [5]. The distance from heating source (shelf) to the product combined with 
the larger sample volume does not lead to a direct transfer of the applied heating rate to the 
whole product container which slows down the real heating rate in contrast to FDM. The 
operator itself affects also FDM results as the analysis is performed visually. 
Higher Tc values compared to FDM were measured by optical coherence tomography based 
freeze-drying microscopy (OCT-FDM) indicating that much higher product temperatures can 
potentially be targeted upon freeze-drying [20]. In OCT-FDM a single vial freeze-dryer 
connected to an OCT based camera enables to measure Tc values directly in the product 
container with the correct filling volume. However, this setup does not represent the 
conditions of a regular freeze-dryer, e.g. shielding effects of surrounding vials. Crystallization 
of mannitol and the impact of sucrose could be shown by through-vial impedance 
spectroscopy (TVIS) [21]. This method enables the monitoring of several vials non-invasively 
and is based on interfacial polarization of glass vials filled with liquid and/or solid. Dielectric 
analysis (DEA) could also analyze eutectic temperatures of mannitol-water and sodium 
chloride water system besides the crystallization of mannitol [22]. There are only few 
approaches for the determination of the aforementioned characteristics directly in the freeze-
dryer [20,21,23]. Apart from TVIS, De Beer et al. implemented an in-line RAMAN system to 
detect mannitol crystallization and to differentiate between different mannitol polymorphs 
[23]. The reader is additionally referred to an excellent recent review on the process 
monitoring devices currently on the market [24]. 
Kasper et al. introduced the optical fiber system (OFS) as potential novel tool to monitor 
freeze-drying processes [25]. The OFS consists of a glass fiber with embedded wavelength 
dependent reflectors, so called fiber bragg gratings (FBGs). FBGs reflect a certain 
wavelength of incoming laser light which is detected by an interrogation unit that at the same 
time acts as light source. The OFS could be established as temperature measuring device by 
shielding the sensors through embedding in stainless steel tubes. This shielding protects the 
sensor from forces which occur e.g. during crystallization to which the OFS is sensitive as 
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well besides temperature. However, unshielded OFS sensors may enable the detection of 
Tg’, Tc or Tcry. Therefore, in this study, temperature and force effects were to be studied by 
shielded and unshielded OFS sensors. Ultimately, the purpose of this work was to evaluate 
the possible application of the OFS to analyze collapse, glass transition and crystallization in 
the product vial in a freeze dryer as well as the potential of the OFS as monitoring device 
during a lyophilization process. 
 
2. Materials and Methods 
2.1. Materials 
Sucrose (Sigma-Aldrich Chemie GmbH, Steinheim, Germany), trehalose (Hayashibara, 
Okayama, Japan), stachyose (A & Z Food Additives, HangZhou, China) and D(-)-mannitol 
(VWR International, Ismaning, Germany) were used in different concentrations (5 %, 10 % or 
20 % [m/V]) as excipient formulations. The excipients were dissolved in purified water (ELGA 
LabWater, Celle, Germany). A monoclonal IgG1 antibody (mAb) and lysozyme were used as 
model proteins. 150 mg/mL mAb with 10 % (m/V) sucrose in 10 mM sodium phosphate buffer 
pH 7.0 and 100 mg/mL lysozyme with 10 % (m/V) trehalose in purified water served as 
protein formulations. All formulations were filtered with 0.2 µm polyethersulfone membrane 
syringe filters (VWR International GmbH, Ismaning, Germany) prior to use. 
 
2.2. The optical fiber system (OFS) 
2.2.1. OFS unit 
The working principle and the design of the used OFS is described elsewhere [25]. An OFS 
unit of two individual OFS sensors was developed (Figure 3-1 A). The temperature was 
measured by a calibrated, metal-shielded OFS sensor (type: os4210, Micron Optics, Atlanta, 
GA, USA; T range: -40 °C - 120 °C, short term accuracy ± 0.2 °C, response time 0.3 s). 
Strain induced events were detected by an unshielded OFS sensor (type: fs-FBG, 
SM1500SC P, polyimide coating removed; INFAP GmbH, München, Germany). OFS data 
were recorded every 10 seconds for the complete run time (ENLIGHT 1.0 Sensing Analysis 
Software by Micron Optics). 
6R or 10R glass vials (FiolaxTM clear, MGlas AG, Münnerstadt, Germany) filled with either 
4 or 6 mL were stoppered for freeze/thawing experiments or semi-stoppered for lyophilization 
runs with corresponding lyophilization stoppers (type: Westar®, West Pharmaceutical 
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Services, Eschweiler, Germany). The OFS unit was mounted through the center of the 
stoppers so that the sensor unit was placed centrally in the solution (Figure 3-1 B). 
Experiments were performed in triplicates at least if not stated otherwise. Two sensor units 
were used. 
 
A  B  
Figure 3-1. A - Scheme of the OFS unit consisting of shielded and unshielded sensor. B – Placement of 
OFS unit in a filled glass vial. 
 
2.2.2. OFS – Determination of the Tc and Tcry during freeze/thawing 
Freeze/thaw cycles between +20 °C and -50 °C at 2.5, 1.0, or 0.5 °C/min with 90 min hold 
times were carried out using an FTS LyoStar™ 3 (SP Scientific, Stone Ridge, NY, USA) 
freeze-dryer. The wavelength numbers of the unshielded sensor were plotted against the 
temperature data of the shielded sensor. Wavelength peaks were determined as OFS peak 
TOFS. 
 
2.2.3. OFS – Use in freeze-drying cycles 
Freeze-drying was performed with the FTS LyoStar™. Non-collapse lyophilization cycles 
were intended to produce lyophilizates with an elegant cake appearance whereas collapse 
lyophilization cycles should induce a collapse of the lyophilizates (Table 3-1). The endpoint of 
primary drying was controlled by comparative pressure measurement (difference ≤ 5 mTorr) 
between capacitance manometer and Pirani gauge sensor. 
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Table 3-1. Collapse and non-collapse freeze-drying cycles of sucrose (20 % / 10 %) and stachyose (20%) 
solutions. 
Freeze-drying cycle Collapse (1) Non-collapse (1) Collapse (2) Non-collapse (2) 
Freezing -50 °C 
1 °C/min
 
1.5 h 
Primary Drying 0 °C 
65 mTorr 
0.1 °C/min 
-25 °C 
30 mTorr 
0.1 °C/min
 
10 °C 
750 mTorr 
1 °C/min 
-15 °C 
120 mTorr 
0.6 °C/min 
Secondary Drying 20 °C 
65 mTorr 
0.1 °C/min 
4 h 
20 °C 
30 mTorr 
0.1 °C/min 
4 h 
20 °C 
750 mTorr 
0.05 °C/min
-
 
4 h 
20 °C 
120 mTorr 
1 °C/min 
4 h 
 
2.3. Differential scanning calorimetry (DSC) 
Tg’ and Tcry were analyzed with a Mettler Toledo DSC 821e (Gießen, Germany). 30 µL 
sample in 40 µL aluminum crucibles were cooled down to -60 °C and heated to +20 °C at 10, 
2.5, 1.0 or 0.5 °C/min. The heating curves were analyzed for Tg’ - as the midpoint of the 
transition - and Tcry peaks. 
 
2.4. Freeze-drying microscopy (FDM) 
Collapse temperatures Tc were determined by FDM (Linkam FDCS 196 freeze-drying stage 
with LinkSys32 software, Linkam Scientific Instruments, Tadworth, United Kingdom) 
equipped with a Duo 2.5 vacuum pump (Pfeiffer Vakuum GmbH, Asslar, Germany) and an 
AxioImager A1 microscope used with a 200-fold magnification (Carl Zeiss AG, Oberkochen, 
Germany). 2 µL of sample was placed on the sample holder together with a spacer and 
covered by a glass slide. Samples were cooled down to -50 °C with 1 °C/min. A pressure of 
0.1 mbar was applied and the samples were heated to -40 °C or -30 °C with 5 °C/min-. The 
sample was held at these conditions to achieve a sufficient thickness of the sublimation front. 
Tc was detected as onset of collapse in the following drying step at 1 °C/min to 0 °C. Pictures 
were taken every two seconds. 
 
2.5. Statistical analysis 
Statistical analysis was carried out using SigmaPlot 12.5 (Systat Software GmbH, Erkrath, 
Germany). One-way ANOVA tests were performed followed by pairwise multiple comparison 
procedures (Holm-Sidak method). 
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3. Results and Discussion 
3.1. OFS thermograms 
Typically, the unshielded OFS sensor detected several events during freezing and thawing of 
a sugar solution (Figure 3-2). Cooling down the solution led to supercooling below the 
freezing point. As ice nucleation started, many small crystals grew, which did not seem to 
expose strain on the sensor. The combination of ice crystal growth, solidification of the 
product and increasing viscosity due to cryoconcentration led to a shift to lower wavelengths 
with decreasing the Tp to -50 °C. During thawing the unshielded OFS sensors showed a 
pronounced peak close to -30 °C, which could be explained by the rapid change in viscosity 
of the amorphous freeze-concentrate and thus release of mechanical strain [25,26]. This 
event occurred at a high rate leading to an overshooting peak after which, with rising 
temperature, the thawing curve approaches the freezing curve. This peak correlated either to 
Tg’ or to Tc. Ice melting led to only a marginal signal and the already reached viscous flow 
around the sensor might cover up the effect of the event. The OFS shielded by a stainless 
steel tube did not exhibit this peak but only a temperature profile which corresponded to 
thermocouple data. 
 
 
Figure 3-2. OFS thermogram of sucrose 20% (m/V). Cooling/heating rate 1 °C/min. Black line: freezing 
scan, gray line: thawing scan. 
 
3.2. Detailed investigation of the TOFS peak 
First, it was to be proven whether the TOFS peak at around -30 °C resulted from the glass 
transition and was not an artifact. Therefore, several excipients with different Tg’ values were 
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investigated. The two commonly used disaccharides sucrose and trehalose both showed Tg’ 
and TOFS values of around -32 °C to -28 °C (Figure 3-4). Stachyose, a rarely used 
tetrasaccharid, showed a Tg’ value of -23.8 ± 0.2 °C and a TOFS peak at -23.8 ± 0.4 °C. Due 
to the shift of both, the Tg’ value and the TOFS peak, to higher temperatures as compared to 
the discaccharides, the TOFS peak can be attributed to the glass transition of the maximally 
freeze-concentrated solution or to the collapse. This differentiation was carried out in 
subsequent experiments (see 3.2.3). 
 
3.2.1. Impact of heating rate on peak location of TOFS 
Tg’ value obtained in DSC analyses shift to higher values with increasing the heating rate 
[4,19]. Typically, in literature heating at 5 to 20 °C/min is performed as the Tg can be 
detected with higher sensitivity and sharpness of the transition as compared to analyzing at 
lower rates [4,27]. Nevertheless it would be beneficial to measure a more realistic Tg’ value 
at slower heating rates e.g. at 1 °C/min. For both sucrose and trehalose solutions, the Tg’ 
shifted to higher values with increasing heating rates in DSC. In contrast, the TOFS peak did 
not shift between 0.5 and 2.5 °C/min (Table 3-2). The highest DSC heating rate of 10 °C/min 
could not be applied in the OFS setup in the freeze-dryer. In subsequent experiments, 
1 °C/min was used as default. 
Table 3-2. TOFS peaks and Tg’ values of sucrose (20 %) and trehalose (20 %, 10 %) solutions at different 
heating rates. Cooling to -50 °C was performed with the same rate as heating. Mean values for n=2, mean 
± SD for n≥3. 
Heating rate 
[°C/min] 
Sucrose 20 % Trehalose 20 % Trehalose 10 % 
TOFS 
[°C] 
Tg‘ 
[°C] 
TOFS 
[°C] 
Tg‘ 
[°C] 
TOFS 
[°C] 
Tg‘ 
[°C] 
10 - -30.6 ± 0.04 - -26.4 ± 0.9 - -27.2 ± 0.3 
2.5 -33.8 ± 0.3 -32.3 ± 0.02 -31.3 ± 0.8 -28.5 ± 0.6 -29.1 -29.0 ± 0.2 
1 -34.1 ± 0.7 -33.1 ± 0.1 -31.2 -29.4 ± 0.6 -28.8 ± 0.5 -29.9 ± 0.3 
0.5 -34.3 ± 0.6 -34.0 ± 0.4 - -30.3 ± 0.9 -30.5 -30.5 ± 0.4 
 
3.2.2. Impact of solute concentration on peak location of TOFS 
Cryoconcentration during freezing should end up at the same solute concentration range of 
the solute in the freeze concentrate, independent of the starting concentration. Nevertheless, 
higher starting concentrations lead to a more pronounced capacity change at Tg’ in DSC 
measurements (Figure 3-3 A,Table 3- 3) which can be explained by the decreasing freeze-
concentrate to ice ratio with decreased solute concentration [19]. The Tg’ value itself was 
independent of the sugar concentration. Also the sensitivity of the OFS was affected by the 
disaccharide concentration. The most pronounced peaks resulted at the highest 
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concentration of 20 % whereas at the pharmaceutically more relevant solid content of 10 % 
and 5 % the peak was flattened and shifted to higher temperature (Figure 3-3 B). The TOFS 
results for 10 % and 20% sugar solutions were similar and close to the Tg’ values. The 
substantially different TOFS for 5 % trehalose (-21.1 ± 2.0 °C) and 5 % sucrose 
(-24.3 ± 1.4 °C) are due to the limited sensitivity of the OFS. In comparison to Kasper et al., 
the sensitivity of the OFS was improved by to the removal of the polyimide coating [25]. But 
with a lower amorphous phase content the change in force on the sensor is less pronounced 
and the sensor more in contact with ice. Since the OFS thermograms of 10 % sugar 
solutions showed distinct peaks this pharmaceutically relevant concentration was used for 
subsequent experiments. 
 
A
 
B
 
Figure 3-3. The effect of total solid content of trehalose solutions on A. Tg’ in DSC and B. TOFS peaks 
during heating. Cooling/heating rates were 1 °C/min; black line: 20 %, dark grey line: 10 %, gray line: 5 %; 
* Tg’and TOFS peak resp. 
 
Table 3- 3. TOFS peaks and Tg’ values of sucrose and trehalose solutions at different concentrations (20 %, 
10 %, 5 %). Cooling/heating rates were 1 °C/min. Mean values for n=2, mean ± SD for n≥3. 
Concentration [% 
(m/V)] 
Sucrose Trehalose 
TOFS 
[°C] 
Tg‘ 
[°C] 
TOFS 
[°C] 
Tg‘ 
[°C] 
20 -34.1 ± 0.7 -33.1 ± 0.1 -31.2 -29.4 ± 0.6 
10 -29.9 ± 1.0 -33.3 ± 0.2 -28.8 ± 0.5 -29.9 ± 0.3 
5 -24.3 ± 1.4 -33.7 ± 0.2 -21.1 ± 2.0 -30.5 ± 0.1 
 
3.2.3. Comparison of OFS with DSC and FDM 
In order to assign the TOFS peak results to either Tg’ or Tc, additionally FDM was performed. 
Sucrose, trehalose and stachyose solutions did not allow to tell since their Tg’ and Tc values 
differed only slightly (Figure 3-4) [19,28]. The Tc and Tg’ values of stachyose solutions were 
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within 1.3 °C and TOFS was only 1.3 °C lower than Tc. Tc and Tg’ values of sugar solutions 
are usually close together [5]. Therefore protein solutions were used to tell whether TOFS 
reflects Tc or Tg’. The presence of protein at higher concentration in disaccharide solutions 
was shown to lead to a much more pronounced increase in Tc as compared to Tg’ [7,29]. 
Consequently, lysozyme 100 mg/mL / 10 % trehalose and mAb 150 mg/mL / 10 % sucrose 
were analyzed with OFS, DSC and FDM. Whereas TOFS and Tc did not show a significant 
difference, Tg’ differed statistically significant (p<0.05). Thus, TOFS
 corresponds to Tc. FDM is 
based on a subjective evaluation of the onset of collapse. In contrast, the OFS peak is simple 
to evaluate which helps to avoid differences between various operators, reduces the 
standard deviation and the OFS unit can easily be placed in the vial filled with formulation. 
 
Figure 3-4. Comparison of Tg’, Tc and TOFS values of different sugar and protein formulations. 
Heating/cooling at 1 °C/min. 
 
3.3. OFS Application to detect crystallization events 
Crystallizing excipients are used in freeze-drying as bulking agents for improved cake 
appearance since they form robust cake structures. Mannitol is the most preferred excipient 
for this purpose [30,31]. Complete crystallization of the bulking agent after lyophilization is a 
prerequisite. Partial crystallization during freezing can cause vial breakage during heating 
due to a secondary crystallization of the non-crystalline fraction and its associated volume 
expansion [32]. Later crystallization upon storage might cause stability problems of the drug 
[33]. Therefore, it is important to monitor the crystallization process during lyophilization. 
Typically, crystallinity is analyzed in the lyophilized product by X-ray powder diffraction, DSC 
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measurements, NIR - or Raman spectroscopy [34]. Mannitol crystallization upon freeze-
drying was thoroughly investigated with these methods [12–14,17,18,23,35–38]. Kasper et 
al. already observed a small peak in OFS thermograms of 5% mannitol solutions during 
freezing and assigned it as mannitol crystallization [25]. However, that OFS was less 
sensitive due to its coating and a more comprehensive investigation of crystallization events 
was targeted in the study at hand. 
 
A 
 
B 
 
Figure 3-5. A. OFS and B. DSC freezing and thawing scans of mannitol 10 % (m/V). Cooling/heating rate at 
1 °C/min; black line: freezing curve, grey line: heating curve. *: TOFS peaks / Tg’; X: crystallization. 
 
The OFS freezing scan of mannitol solutions showed a broad peak at -32.8 ± 0.8 °C, which 
started to arise at -30 °C already and could therefore be attributed to mannitol crystallization 
according to the DSC results (-30.5 ± 0.9 °C) (Figure 3-5). The TOFS peak in the thawing scan 
at -28.1 ± 0.8 °C correlates to Tc of the non-crystalline mannitol fraction. The height of this 
peak was similar to the TOFS peaks obtained for the amorphous sugar systems (Figure 3-
5 A). DSC scans of the mannitol solution rendered two Tg’ values in the same temperature 
range with Tg’1: -29.5 ± 0.2 °C and Tg’2: -24.1 ± 0.9 °C (Figure 3-5 B) which corresponded to 
literature [13,14,39]. Thus, the OFS peak can be assigned to an increased viscous flow of 
the amorphous mannitol fraction. 
A pronounced and broad OFS peak starting at -25 °C and with a maximum at -16.5 ± 0.9 °C 
was observed during thawing. DSC revealed a second exothermic event at -22.6 ± 0.9 °C 
which was in good agreement with literature values for mannitol crystallization (-19.3 °C [13], 
-22.4 °C [14], onset at -22 °C [40]). Accordingly, the OFS peak can be attributed to the 
mannitol crystallization. The height and width of the peak emphasized (1) that the major 
fraction of mannitol only crystallized in the thawing phase and (2) that mannitol crystallization 
exerts substantial force onto the OFS sensor. The high forces of mannitol crystallization are 
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known to lead to vial breakage during freeze-drying [32,41]. Thermal mechanical analysis 
and strain gage techniques demonstrated that volume expansion due to initial crystallization 
and subsequent crystallization during thawing were the trigger for the vial breakage [32]. In 
our studies with 10 % mannitol solutions some experiments ended up in vial breakage, too. 
Vial breakage corresponded to the highest measured OFS peaks. In DSC measurements a 
2-fold higher mannitol crystallization peak area was found during thawing as compared to 
freezing indicating that upon thawing double the amount of mannitol crystallized. Whereas 1 
% mannitol solutions did not show crystallization in DSC thawing curves and were fully 
crystalline already after freezing [14], the amount of non-crystalline mannitol increases with 
higher mannitol concentration (10 %). Annealing, a typically used hold step above Tg’ for 
complete crystallization of bulking agents, led to disappearance of the mannitol crystallization 
peak in the OFS thawing curves. This demonstrated again that the peak can be assigned to 
mannitol crystallization. 
Hence the OFS was able to determine phase transitions from solid to viscous flow as well as 
crystallization of amorphous excipients during freezing and thawing. Thus it can be used as 
alternative analysis tool to FDM and DSC analysis. The OFS might be more representative 
for the reality in freeze-drying, since drying rates, freeze-dryer environment, filling volume, 
and type and size of container correspond to the freeze-drying process. 
 
3.4. OFS Application during lyophilization 
The ultimate goal was to develop the OFS unit into a process monitoring tool for the freeze-
drying process. Kasper already showed that the shielded OFS could be used as a 
temperature monitoring tool complementary to the usual thermocouples [25]. The unshielded 
sensor may offer additional options. Therefore, two types of uncommon lyophilization cycles 
were carried out and monitored with the OFS unit. A slow ramp of 0.1 °C/min was applied 
during the start of primary drying to reach a shelf temperature of 0 °C in order to induce 
collapse during this ramp phase (collapse cycle (1)). For comparison, the same ramp rate but 
to a lower shelf temperature and at lower chamber pressure was carried out in the non-
collapse cycle (1). Faster rates and higher pressure values were necessary to force the 
occurrence of collapse in stachyose samples due to the higher Tc value (collapse cycle (2)). 
The collapse lyophilization cycles demonstrated that collapse can be detected by the 
unshielded OFS. Both tested saccharides, sucrose 20 % and stachyose 20 %, showed a 
peak in the unshielded OFS signal during the primary drying heating ramp (Figure 3-6). After 
lyophilization, collapse could be confirmed visually. The location of the peak was associated 
with the temperature measured by the shielded OFS. Both values were close to the TOFS 
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peaks previously determined in the freezing and thawing experiments. The peak of sucrose 
was broader and less sharp compared to stachyose which was attributed to the slower 
heating ramp. Sucrose 20% did not show any OFS peaks or visual signs of collapse when 
dried utilizing the corresponding non-collapse cycles. For Stachyose 20% a broader 
transition was noted, which depended on the ramp rate, but no marked peak. 
A 
 
B 
 
Figure 3-6. Temperature profiles of A. sucrose 20 % samples (collapse cycle (1)) and B. stachyose 20 % 
samples (collapse cycle (2)) obtained with a conventional thermocouple (TC) or an OFS embedded into a 
stainless steel tube (OFS shielded) in correlation to the unshielded OFS signal. For a better overview, 
only the first 13 hours of the process are shown and pressure values are not included. 
 
Furthermore, the impact of the solute concentration was investigated. For 10 % sucrose 
samples dried with collapse cycle (2) a smaller peak shifted to higher temperatures resulted 
with the unshielded OFS (Figure 3-7). As Tc and TOFS in freezing and thawing cycles were 
not shifted in DSC at this concentration, the sensitivity of the OFS system may be too low to 
detect collapse at this concentration at the correct temperature during primary drying. Thus 
detection of collapse during a freeze-drying run is in general possible, but limited to higher 
solute concentrations and potential broader transitions may make the evaluation more 
complex. 
In order to further develop the OFS as a process monitoring tool, future studies have to focus 
on an algorithm for detection of peaks and transitions based on the readouts. Formulations 
with different excipients and concentrations have to be analyzed. This needs to include 
studies with crystalline bulking agent in combination with an amorphous matrix to learn 
whether also microcollapse can be detected. 
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Figure 3-7. Temperature profiles of sucrose 10 % samples (collapse cycle (2)) obtained with a 
conventional thermocouple (TC) or an OFS embedded into a stainless steel tube (OFS shielded) in 
correlation to the unshielded OFS signal. 
 
4. Conclusion 
In this study, the OFS unit could be successfully established as alternative tool for 
determination of Tc of amorphous systems as well as of Tcry of crystalline phases. The OFS 
unit combines temperature measurement with the ability to detect force or strain in one 
device. We could show that the TOFS peak was in good correlation with FDM results. Since 
the OFS tracks processes that take place in the original sample vial in the freeze-dryer itself 
the data may be more representative for the product and process development than the data 
obtained with other instruments like FDM and DSC on manipulated samples. The results 
furthermore indicate that TOFS/Tc values should be set as the upper limit of the product 
temperature during primary drying rather than Tg’ [7,29]. The OFS unit is a promising tool 
that could potentially be developed into a monitoring tool for the entire freeze-drying process. 
Up to now collapse occurring in the primary drying phase could be detected at high 
concentrations whereas the desired non-collapse is more difficult to define in terms of the 
OFS signal. In order to develop the OFS into a process monitoring tool the sensitivity has to 
be further improved to enable determination of Tc values at lower amorphous excipient 
concentrations, below <10 %. The OFS may also provide further insights into the properties 
of the freeze-concentrate. 
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Abstract 
The thermodynamic state of the final lyophile in freeze-dried formulations directly affects the 
stability of the active pharmaceutical ingredient (API). Crystallization of trehalose and 
mannitol in frozen solutions has been shown to be a function of their initial composition. 
However, to date a detailed study of the effect of concentrations of the API and other 
excipients on the crystallinity of mannitol and trehalose in frozen solutions has not been 
reported. The physical form as well as the crystallinity of mannitol and trehalose during 
freeze-drying can have major effects not only on the morphology of the final lyophile but also 
on the long term stability of the API. The effect of different concentrations of bovine serum 
albumin (BSA), polysorbate 20, and deuterium oxide (D2O) on the crystallinity of mannitol 
and trehalose in frozen solutions was evaluated by differential scanning calorimetry, X-ray 
diffractometry, and FTIR spectroscopy during freezing and annealing. The secondary 
structure of BSA was probed by IR spectroscopy in frozen solutions and by circular dichroism 
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spectroscopy in thawed solutions. Trehalose crystallization was accompanied by unfolding of 
BSA. The addition of BSA delayed and reduced the extent of mannitol and trehalose 
crystallization. Similar effects were observed upon adding D2O (> 5% w/w) and low 
concentrations of polysorbate 20 (< 0.2% w/w) with retention of BSA in its native 
conformation in both frozen and thawed solutions. At high BSA to trehalose mass ratio, the 
protein was able to stabilize itself in the frozen state, but unfolded upon thawing. The API 
and other excipients, in a concentration-dependent manner, influenced the physical state of 
the freeze concentrate as well as the stability of the API during freezing and thawing. 
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1. Introduction 
Freeze-dried protein formulations generally contain several different excipients that serve 
specific functions. This investigation focuses on quantification of the physical and 
thermodynamics states of the bulking agent, and the lyoprotectant (the two main excipients 
in a formulation) in the frozen state, as this directly relates to the stability of the active 
pharmaceutical Ingredient (API) to be stabilized. The bulking agent is desired to be 
crystalline in order to provide structure to the cake in the lyophilized form [1,2]. On the other 
hand, the lyoprotectant must remain amorphous during freeze-drying and the subsequent 
storage period in order to stabilize the API. Crystallization or phase separation of the 
lyoprotectant can impair its ability to protect the API against the stresses experienced during 
freezing and drying [3,4]. Mannitol has a strong tendency to crystallize during freezing and 
therefore, is widely used as a bulking agent [5,6]. Trehalose, a non-reducing glass-forming 
sugar with a high glass transition temperature (~ 117° C), is a popular lyoprotectant [7–10]. 
In the absence of prolonged annealing or external seeding, trehalose could be retained in the 
amorphous state, both during freezing and drying [11,12]. But recently it was shown that in 
the presence of crystallizing co-solutes such as succinic acid and mannitol, trehalose could 
be crystallized from the frozen solution by annealing above the glass transition temperature 
of the amorphous freeze-concentrate (Tg’) [11–13]. Trehalose crystallization can compromise 
the stability of the API in the final product, leading to unfolding and aggregation of the protein 
[1,3,14–16] and thus, loss of biological activity. Additionally, non-crystallizing co-solutes such 
as sucrose and proteins, at high concentrations, could inhibit mannitol crystallization [13,17], 
compromising the structural integrity of the product. We have previously demonstrated that 
crystallization of frozen mannitol-trehalose solutions during annealing above Tg’ was 
exclusively dictated by the mass ratio of mannitol to trehalose (R) in the solution [18]. When 
R < 1, both of the excipients remained amorphous, while both mannitol and trehalose 
crystallized when R ≥ 1. In the past, the effect of both crystallizing and non-crystallizing 
solutes such as NaCl and proteins including lysozyme, human serum albumin and human 
monoclonal antibodies on the extent of mannitol crystallization and in some cases, the 
physical form of the crystalline mannitol has been studied [19–23]. But till date, no report 
exists on the effects of varying concentrations protein and other excipients such as surfactant 
and deuterium oxide on the physical states of both mannitol and trehalose in frozen mannitol-
trehalose solutions and their repercussions on the stability of the protein. 
Presence of proteins can alter the glass transition temperature of the freeze concentrate as 
well as its mobility at the annealing temperature [13,24], consequently influencing the 
nucleation and growth of crystallizing phases. Surfactants, depending on their concentration 
and chemical structure, inhibit or promote the growth of the crystalline phases [25,26]. They 
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are also known to either prevent or promote protein unfolding, and precipitation in the frozen 
state through ice interface coverage, and specific binding to the protein surface [27,28]. 
Polysorbate 20 (hereafter referred to by its popular trade name, Tween 20) is a common 
non-ionic polysorbate surfactant used for stabilization of emulsions and suspensions. 
Deuterium oxide, used frequently as a solvent in spectroscopic studies, has been known to 
effect specific interaction between macro-molecules by changing their surface charge density 
(by H/D exchange) [29,30]. Moreover, D2O has been shown to protect cells and proteins 
against thermal denaturation [31,32]. 
In this study, changes in the secondary and tertiary structures of bovine serum albumin in the 
frozen state caused by crystallization of the lyoprotectant (trehalose) and the bulking agent 
(mannitol) were investigated. We have previously demonstrated that in the absence of an 
API, crystallization of mannitol and trehalose is governed by the mass ratio of mannitol to 
trehalose in the initial solution [18]. We hypothesize here that the addition of the API 
(albumin, in this case) will affect the state (propensity for, and the extent of crystallization as 
well as the physical form of crystallizing phases) of mannitol and trehalose in the frozen 
solution, which will in turn directly affect the stability of the API. We further test this 
hypothesis when certain other excipients (specifically, Tween 20 and D2O) are included in 
the formulation. 
For a comprehensive analysis, a multitude of analytical techniques was employed. 
Differential Scanning Calorimetry (DSC) was used to characterize the physical state of the 
amorphous freeze concentrate before and after annealing. Infrared (IR) spectroscopy 
enabled us to detect solute crystallization in the freeze-concentrated liquid (FCL), and low 
temperature powder X-ray Diffractometry (XRD) was used to identify the crystalline phases. 
IR spectroscopy also provided information on protein hydration level and protein secondary 
structure in the frozen state. Circular dichroism (CD) spectroscopy enabled characterization 
of the secondary structure of the protein in thawed solutions, where the low protein 
concentration rendered IR spectroscopy unreliable. Turbidity analysis was conducted to 
detect the formation of insoluble aggregates, and high performance size exclusion 
chromatography (HPSEC) was used to detect and characterize both soluble and insoluble 
aggregates.  
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2. Materials and Methods 
2.1. Materials 
D-(+)- trehalose dihydrate (MW 378.33 kDa, 99.9% purity, Sigma-Aldrich, St. Louis, MO), 
Bovine Serum Albumin (MW 66.5 Da, ≥ 99% purity, Sigma-Aldrich), deuterium oxide (MW 
20.03 Da, 99.9% purity, Cambridge Isotope Laboratories, Andover, MA), Tween 20 (MW 
1227.54 Da, > 98.0% purity, Biorad Laboratories, Hercules, CA), and D-mannitol (MW 
182.17 Da, ≥ 98% purity, Sigma-Aldrich) were used as received. Aqueous solutions were 
prepared gravimetrically in ultrapure water. 
 
2.2. Differential Scanning Calorimetry (DSC) 
A differential scanning calorimeter (Q2000, TA Instruments, New Castle, DE) equipped with 
a refrigerated cooling accessory was used. The instrument was calibrated using tin. About 
50 mg of the sample solution was weighed in an aluminium pan, which was hermetically 
sealed (Tzero pan and lid with a pin-hole). Dry nitrogen was used as the purge gas at a flow 
rate of 50 ml/min. The solution was initially cooled from room temperature down to -50 °C at 
20 °C/min, held for 2 minutes and then heated at 1 °C/min back to room temperature. When 
there was an annealing step included in the experiment, the solution cooled down to -50 °C 
was heated at 1 °C/min to -18 °C where it was held for 20 hours.  The eutectic melting 
temperature (Te) of trehalose-water binary system is -2.5 °C [33–35] and the glass transition 
temperature of trehalose freeze-concentrate is reported to be in the range of -32 to -40 °C 
[36]. Annealing was conducted at -18 °C. After the annealing period, the experimental 
solution was again cooled rapidly (20 °C/min) to -50 °C and then heated at 1 °C/min back to 
room temperature. The DSC data were analyzed using TA Universal Analysis software. 
 
2.3. Powder X-ray Diffractometry (XRD) 
A powder X-ray diffractometer (D8 ADVANCE; Bruker AXS, Madison, WI) equipped with a 
variable temperature stage (TTK 450; Anton Paar, Graz-Straßgang, Austria) and a Si strip 
one-dimensional detector (LynxEye; Bruker AXS, Madison, WI) was used. In experiments 
including an annealing step, the experimental solution was cooled from RT to -50 °C at 
20 °C/min, held for 2 min and then heated at 1 °C/min back to -18 °C where it was held for 
20 hours. After the annealing period, the solution was heated at 1 °C/min back to room 
temperature. During annealing at -18 °C, XRD patterns were collected continuously with a 
dwell time of 900 s. Solutions were exposed to Cu Kα radiation (40 kV × 40 mA) over an 
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angular range of 5−27° 2θ with a step size of 0.05°. The XRD patterns were analyzed using 
commercially available software (JADE 2010). 
 
2.4. IR Spectroscopy 
The experimental solution (~100 nL) was sandwiched between two CaF2 windows, sealed 
with vacuum grease to generate a thin film, ~ 1 μm thick. The assembly was then transferred 
to the infrared microscope attached to the FTIR spectrometer, (Thermo-Nicolet Continuum 
with a mercury cadmium telluride detector, Thermo Electron, Waltham, MA) equipped with a 
freeze-drying cryostage (FDCS 196, Linkam Scientific Instruments Ltd., UK). Solutions were 
cooled from RT at 10 °C/min and as soon as ice crystallization was microscopically 
observed, the temperature was rapidly brought (at 30 °C/min) back up to -18 °C, where the 
sample was held for 20 hours. IR spectra were acquired at a resolution of 4 cm-1 and a total 
of 128 scans were averaged in the 4000−930 cm-1 wavenumber range. The data was 
collected continuously from a fixed region (25 μm x 25 μm) in the FCL region both during 
equilibrium freezing, and annealing and analyzed using OMNIC (Thermo-Nicolet) software. 
 
2.5. UV Circular Dichrosim 
Spectra were recorded using a J-815 circular dichroism spectropolarimeter (JASCO) using a 
1 cm path length quartz cuvette over the range of 190–260 nm at ambient temperature. Data 
were collected every 0.2 nm with a bandwidth of 1 nm, averaged over 8 scans. An integration 
time of 8 seconds at 50 nm/min and a 2 nm slit width were used. The solutions were diluted 
with ultrapure water to reach a protein concentration of 0.2 mg/mL. The background spectra 
of the solvent medium (identical dilution) were subtracted from the final spectra and data 
were obtained as mean residue ellipticity (Ɵ). To estimate protein secondary structure 
content, analysis of the relevant CD spectra was carried out using the CDPro software. The 
basis set 7 of the CDPro software was used. Analysis was performed using the SELCON 3 
method [37]. 
 
2.6. High Performance Size Exclusion Chromatography 
Size exclusion chromatography was performed using an Agilent 1100 series HPLC system 
equipped with an UV/Vis detector for detection at 280 nm (Agilent Technologies, Santa 
Clara, California, USA). A TSKgel® G3000 SWXL column (dimension: 300 x 7.8 mm, 
TOSOH Bioscience, Stuttgart) and 100 mM sodium phosphate / 150 mM sodium chloride 
buffer at pH 7.4 mobile phase with a flow rate of 0.4 mL/min was used. Samples were 
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annealed in stoppered 2 R vials at -20 °C for 20 hours (heating/cooling rate: 1 °C/min) using 
a FTS Lyostar 3 freeze-drier (SP Scientific, Stone Ridge, USA). Prior to analysis, samples 
were diluted to 1 mg/mL and centrifuged. The integrated peak intensity was determined 
before and after freeze-thawing after blank subtraction. Monomer recovery (in percent) was 
determined by comparing the integrated intensity of the monomers before and after freeze-
thawing. 
 
2.7. Light Obscuration (LO) 
A PAMAS SVSS-35 particle counter with a HCB-LD-25/25 sensor (PAMAS – Partikelmess- 
und Analysesysteme GmbH, Rutesheim, Germany) was used to determine subvisible 
particles. The system was rinsed with highly purified water before each analysis. The rinsing 
volume was 0.2 ml, followed by four measurements of 0.2 ml according to USP 787. PAMAS 
PMA software was used to determine particles ≥ 1 µm, ≥ 10 µm and ≥ 25 µm. The results are 
given in cumulative particles per milliliter. 
 
2.8. Turbidity (A350 nm) 
Turbidity of the freeze-thawed samples was measured by UV/VIS-spectroscopy at 350 nm. A 
NanoDrop 2000 spectrophotometer (PEQLab Biotechnology GmbH, Erlangen, Germany) 
was used. Each formulation was measured as triplicate with its corresponding formulation 
without protein as blank solution. 
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3. Results 
3.1. Glass transition 
We first explored the effect of BSA concentration in solution on the crystallinity (propensity 
and extent) of mannitol in the frozen state. Glass transition temperatures (Tg’) of frozen 
solutions containing mannitol (10% w/w), trehalose (5%) and increasing concentrations of 
BSA were measured using DSC (Table 4-1, Figure 4-1 A). A single glass transition event 
was identified in all unannealed solutions containing BSA. In these samples, immediately 
following glass transition, an exothermic peak attributable to mannitol crystallization was also 
observed. In the absence of BSA, the DSC scan revealed two distinct glass transitions, one 
before and the other after the crystallization exotherm. Mannitol-trehalose systems were 
investigated in detail earlier [18]. Multiple glass transitions suggest heterogeneity in the FCL 
and arise due to partial mannitol crystallization [18]. BSA, in a concentration dependent 
manner, gradually increased the Tg’ of the amorphous FCL. The crystallization onset 
temperature, an indicator of crystallization propensity, increased as a function of BSA 
concentration while the enthalpy of crystallization decreased. Upon further heating, a very 
prominent endotherm attributed to the melting of the ice-mannitol eutectic was observed. 
With increasing BSA concentration, the endotherm shifted to higher temperatures (Figure 4-
1 B).  
 
Table 4-1. Glass transition temperature(s), T’g; onset of crystallization, area under exotherms and 
eutectic-ice melting temperatures during heating of unannealed samples. 
Composition 
Glass Transition 
Temperature(s) 
(°C)* 
Crystallization onset 
temperature (°C)* 
Enthalpy of 
crystallization 
(J/g)* 
Mannitol-ice eutectic 
melting temperature 
(°C)
# 
10%M+5%T (control) 
-42.5 ± 0.1 (Tg’) 
-34.2 ± 0.3 (Tg’’) 
-38.1 ± 0.8 20.8 ± 0.4 -1.6 ± 0.0 
10%M+5%T+2%BSA -36.3 ± 0.4 -33.8 ± 1.2 19.5 ± 0.4 -1.6 ± 0.1 
10%M+5%T+4%BSA -34.3 ± 1.6 -28.7 ± 0.6 16.1 ± 0.6 -1.1 ± 0.2 
10%M+5%T+6%BSA -33.5 ± 1.8 -28.1 ± 0.8 15.4 ± 0.6 -0.8 ± 0.1 
10%M+5%T+8%BSA -33.3 ± 0.3 -26.1 ± 0.9 15.1 ± 0.5 -0.7 ± 0.0 
M mannitol, T trehalose, BSA bovine serum albumin. Samples were cooled from RT to -50 °C at 20 °C/min, held 
for 2 min and warmed back up to RT at 1 °C/min. * Samples analyzed in quadruplicate; 
#
 samples analyzed in 
duplicate. 
 
The effect of annealing the frozen solution at -18 °C was examined and the results are 
presented in Table 4-2. Comparing Tg’s and the associated heat capacity change (ΔCp) 
before and after annealing enabled us to determine the change in the composition and size 
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of the FCL due to solute crystallization during annealing. In the DSC scans collected after 
annealing, no crystallization exotherm was observed, suggesting complete mannitol 
crystallization during annealing (Figure 4-2). Additionally, annealing caused a pronounced 
increase in the Tg’. With increasing BSA concentration, there was a progressive increase in 
Tg’ after annealing (Figure 4-2), while the mass fraction of solute crystallized during 
annealing (change in ΔCp before and after annealing; ΔΔCp) was inversely proportional to the 
BSA concentration. These observations suggest that BSA was predominantly retained in the 
FCL. 
 
A
 
B
 
Figure 4-1. DSC heating curves of frozen solutions containing mannitol, trehalose and BSA. While the 
mannitol (10% w/w) and trehalose (5% w/w) concentrations were fixed, that of BSA was progressively 
increased. A - Glass transitions of the freeze concentrate (blue arrows); B -  Mannitol-ice eutectiv melting 
temperature. Solutions were cooled from room temperature to -50 °C at 20 °C/min, held for 2 minutes and 
then heated at 1 °C/min back to room temperature. The heat flow was recorded during the final heating. 
Data only up to -10 °C (A) / 4 °C (B) is shown. 
 
Table 4-2. Glass transition temperature(s), T’g; and the corresponding heat capacity change, ΔCp, before 
and after annealing at -18 °C for 20 h. 
Composition Tg’ before annealing (°C)* Tg’ after annealing (°C)
# 
% change in ΔCp
# 
10%M+5%T (control) 
-42.5 ± 0.1 (Tg’) 
-34.2 ± 0.3 (Tg’’) 
-32.6 ± 0.3 60.2 ± 1.1 
10%M+5%T+2%BSA -36.3 ± 0.4 -29.6 ± 0.5 51.3 ± 1.2 
10%M+5%T+4%BSA -34.3 ± 1.6 -25.8 ± 0.6 49.2 ± 2.1 
10%M+5%T+6%BSA -33.5 ± 1.8 -23.0 ± 0.6 47.6 ± 1.3 
10%M+5%T+8%BSA -33.3 ± 0.3 -22.4 ± 0.7 45.2 ± 1.8 
M mannitol, T trehalose, BSA bovine serum albumin. Samples were cooled at 20 °C/min to -60 °C, held for 2 min 
and warmed to -18 °C at 1 °C/min. Samples were annealed for 20 h at -18 °C, cooled back to -60 °C at 20 °C/min 
and then warmed back up to room temperature at 1 °C/min. *Samples analyzed in quadruplicate; 
#
 samples 
analyzed in duplicate. 
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Figure 4-2. DSC heating curves of frozen annealed solutions containing mannitol, trehalose and BSA. 
While the mannitol (10% w/w) and trehalose (5% w/w) concentrations were fixed, that of BSA was 
progressively increased. Glass transitions of the freeze concentrate have been denoted by blue arrows. 
Effect of increasing BSA concentration on the thermal behavior of frozen annealed mannitol-trehalose-
BSA solutions during warming. Glass transitions of the freeze concentrate have been denoted by blue 
arrows. Solutions were cooled from room temperature to -50 °C at 20 °C/min, held for 2 min, heated up to 
-18 °C, and annealed isothermally for 20 hours. After annealing, the solutions were cooled back down to 
-50 °C at 20 °C/min, and reheated at 1 °C/min back to room temperature. The heat flow was recorded 
during the final heating. Data only up to -10 °C is shown. 
 
In Table 4-3, the effect of two additives, Tween 20 and deuterium oxide, on the thermal 
behavior of the frozen annealed solutions is summarized. In our earlier investigation, when 
the trehalose and mannitol concentrations were 8 and 10% (w/w) respectively, both the 
solutes crystallized when annealed [18]. However, the solute crystallization was incomplete 
since a Tg’ was observed even in the annealed solutions (Table 4-3). In the presence of BSA, 
both before and after annealing, a single glass transition was observed (Figure 4-3 A). The 
one exception was the sample containing Tween 20 (1% w/w) in which two glass transition 
events were observed (Figure 4-3 A). In the presence of D2O (5% w/w) and low 
concentrations of Tween 20 (up to 0.2% w/w), no exotherms were observed while heating 
the frozen solutions to the annealing temperature (-18 °C). On the other hand, a higher 
concentration of Tween 20 (1% w/w) induced crystallization at a much lower temperature 
during heating and also increased the extent of crystallization (enthalpy of crystallization) 
before annealing more than in solutions without D2O or Tween 20. In samples containing no 
additive, there was a pronounced decrease in ΔCp associated with glass transition post 
annealing (~ 49%) and in samples containing 1% w/w Tween 20, no glass transition could 
not be detected after annealing (Figure 4-3 B). The change in ΔCp was considerably reduced 
(~ 27-39%) in solutions containing D2O and Tween 20 (up to 0.2% w/w). When frozen 
Chapter 4 
70 
solutions containing D2O (>4% w/w) and low concentrations of Tween 20 (up to 0.2% w/w) 
were heated to RT after annealing, the glass transition was followed by a weak crystallization 
exotherm (~ 5 J/g; Figure 4-3 B). This could be attributed to residual mannitol crystallization. 
Crystallization exotherms were absent in all other samples, suggesting complete mannitol 
crystallization during annealing. 
 
Table 4-3. Glass transition temperature(s), Tg’; and the corresponding heat capacity change, ΔCp, before 
and after annealing at -18 °C for 20 h. 
Composition 
Tg’ before 
annealing (°C) 
Tg’ after 
annealing (°C) 
ΔCp before 
annealing 
(kJ/kg K) 
ΔCp after 
annealing 
(kJ/kg K) 
Enthalpy of 
crystallization 
(J/g) 
10%M+8%T -40.2 ± 0.3 -32.1 ± 0.1 0.048 ± 0.003 0.023 ± 0.001 11.2 ± 0.2 
10%M+8%T+4%BSA -39.9 ± 0.3 -27.8 ± 0.2 0.054 ± 0.002 0.026 ± 0.004 9.9 ± 0.4 
10%M+8%T+4%BSA
+0.1% Tween 20 
-37.6 ± 0.3 -35.0 ± 0.3 0.053 ± 0.002 0.038 ± 0.001 - 
10%M+8%T+4%BSA
+0.2% Tween 20 
-41.4 ± 0.2 -34.7 ± 0.2 0.052 ± 0.003 0.037 ± 0.001 - 
10%M+8%T+4%BSA
+1.0% Tween 20 
-45.8 ± 0.2 
-36.4 ± 0.1 
- 
0.055 ± 0.001 
0.062 ± 0.002 
- 14.8 ± 0.3 
10%M+8%T+4%BSA
+5% D2O 
-35.8 ± 0.4 -33.7 ± 0.3 0.051 ± 0.002 0.031 ± 0.003 - 
M mannitol, T trehalose, BSA bovine serum albumin. Note: Blank spaces indicate that either glass transition or 
crystallization exothermic peak was not detected during heating. Samples were cooled at 20 °C/min to -60 °C, 
held for 2 min and warmed to -18 °C at 1 °C/min. Samples were annealed for 20 h at -18 °C, cooled back to 
-60 °C at 20 °C/min and then warmed back up to room temperature at 1 °C/min. All samples were analyzed in 
duplicate. 
 
A
 
B
 
Figure 4-3. DSC heating curves of frozen solutions containing mannitol, trehalose and BSA. The effect of 
excipients (Tween 20 and D2O) on the thermal behavior of the A - frozen, unannealed solutions and B – 
frozen, annealed solutions was determined. Glass transitions of the freeze concentrate have been 
denoted by blue arrows. Solutions were cooled from room temperature down to -50 °C at 20 °C
 
/min, held 
for 2 minutes and then heated at 1 °C/min back to room temperature. The heat flow was recorded during 
the final heating. Data only up to -30 °C is shown. 
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3.2. Infrared Spectroscopy 
In Figure 4-4, transmitted light microscopy images and the fingerprint regions of the 
respective IR spectra of frozen 10%M+8%T+4%BSA (left), and 10%M+8%T+15%BSA (right) 
solutions after 15 hours of annealing are shown. The physical form of mannitol crystallizing 
from both solutions was different, based on both XRD and IR spectroscopy. The thin, long, 
dark brown strands, arranged radially in the 10%M+8%T+4%BSA solution, are mannitol 
hemihydrate crystals. On the other hand, the flat, longitudinal almost translucent structures 
on the ice surface in the 10%M+8%T+15%BSA solution are anhydrous mannitol crystals. 
The bifurcation of the C-H stretching peak (2970-2910 cm-1) in the IR spectra indicated solute 
crystallization [38–42]. Specifically, crystallization of mannitol was detected from bifurcation 
of the C-H in-plane bending peak (1400-1280 cm-1) [38,41]. Likewise, crystallinity of 
trehalose was monitored from bifurcation of its C-O-C stretching peak (1010-975 cm-1) 
[39,40,42] and the shift in its glycosidic peak [18]. 
 
10%M+8%T+4%BSA 
 
 
10%M+8%T+15%BSA 
 
 
Figure 4-4. Transmitted light microscopy images (Row 1) and the corresponding FTIR spectra (Row 2) of 
A - 10%M+8%T+4%BSA, and B - 10%M+8%T+15%BSA solutions at -18 °C after 15 hours of annealing. 
Curves “A” and “B” are the IR spectra taken from a fixed region of the sample at the beginning and the 
end of annealing, respectively. 
 
The peak position of the Amide II band (1570-1530 cm-1) is sensitive to the extent of 
hydrogen bonding of the protein with the polar groups and molecules in its microenvironment 
and thus has been used to determine the hydration level of proteins [43,44]. With enhanced 
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hydration, Amide II shifted to higher wavenumbers. The Amide I (1700-1600 cm-1) band is 
more sensitive to protein secondary structure than Amide II and has traditionally been 
deconvoluted by peak fitting or by secondary derivative analysis in order to yield information 
on the secondary structure content of proteins [45–48]. Second derivative analysis of the 
amide I after subtraction of an ice background, revealed 3 distinct peaks attributed to β-
sheets (1640-1620 cm-1), α-helices (1670-1640 cm-1), and random coils (1695-1670 cm-1). 
The relative fraction of each structure was calculated using their integrated peak areas. 
Addition of D2O into the solution results in splitting of Amide II into the Amide II’ 
(1520-1420 cm-1) and Amide II (1570-1520 cm-1) [49,50]. The extent of deuteration of the 
protein backbone chains can be determined by comparing the peak areas or the intensities 
of these bands. In FTIR analysis, all solutions were rapidly cooled at 10 °C/min, and then 
immediately warmed up to the annealing temperature (-18 °C) as soon as homogenous ice 
crystallization was visually detected through the microscope. The samples were held at 
-18 °C for 15 hours and IR spectra were collected. 
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Figure 4-5. Comparison of trehalose crystallinity, protein hydration, and structure before (black) and after 
(white) annealing (at -18 °C for 15 hours) in frozen aqueous solutions containing X%M+8%T+4%BSA; X = 
2, 8 or 16%. A - Trehalose glycosidic peak location; B – Amide II peak location; C - Percent alpha helix in 
secondary structure; D - Area ratio of Amide II’ and Amide II peaks in the presence of 1% D2O (w/w). 
Compositions that undergo change up on annealing have been marked with *. 
 
In Figure 4-5, the effects of mannitol concentration on the crystallinity of trehalose and 
stability of BSA during annealing are presented. In agreement with our previous studies, at 
R < 1 both mannitol and trehalose remained amorphous until the end of the annealing period. 
The native secondary conformation and the degree of hydration of BSA were preserved 
during annealing. When R > 1, mannitol crystallized as a hemihydrate as soon as the 
annealing temperature was reached and 2 hours later, trehalose crystallized as the dihydrate 
(confirmed by XRD). This was followed (after 2 hours of trehalose crystallization) by a 
decrease in hydration and change in the secondary structure of BSA, which were evidenced 
by the shift in Amide II location (by 2.5 cm-1) and reduced α-helix content (by 14%). An 
identical behavior was observed in samples containing equal concentrations of mannitol and 
trehalose (R = 1) with the only difference being that mannitol crystallization started 
30 minutes into the annealing process. D2O (1% v/v) was added to parallel sample solutions 
of identical composition to obtain information on the tertiary structure of BSA from the relative 
Before annealing After annealing 
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intensities of the Amide II and Amide II’ bands.  When R ≥ 1, unfolding of secondary structure 
was preceded by that of the tertiary structure, which occurred a few minutes before trehalose 
crystallization was detected. 
 
A  B  
C  D  
   
Figure 4-6. Comparison of trehalose crystallinity, protein hydration, and structure before (black) and after 
(white) annealing (at -18 °C for 15 hours) in frozen solutions containing 10%M+8%T+4%BSA+X%D2O 
samples; X = 0, 2 and 5%. A fixed region of the frozen solution was analyzed. A - Trehalose glycosidic 
peak location; B – Amide II peak location; C - Percent alpha helix in secondary structure; D - Area ratio of 
Amide II’ and Amide II peaks in the presence of 1% D2O (w/w). Compositions that undergo change up on 
annealing have been marked with *. 
 
In the absence of BSA, irrespective of trehalose concentration, mannitol crystallized as the 
hemihydrate, as soon as the annealing temperature was reached. On the other hand, when 
BSA was included in the formulations (Figure 4-7), both anhydrous and hemihydrate forms 
crystallized (observed both visually and spectroscopically). There was also a delay in the 
onset of mannitol crystallization (2 - 6 hours) upon holding at -18 °C. The delay time and the 
fraction of anhydrous mannitol formed were directly proportional to the initial BSA 
concentration in the solution. When the BSA concentration was raised to 16% w/w, mannitol 
crystallized entirely in the anhydrous form and trehalose was retained amorphous even after 
Before annealing After annealing 
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15 hours of annealing (determined from the location of the C-O-C glycosidic peak in the IR 
spectra). There was also negligible change in the hydration level and secondary structure (α-
helix content) of BSA at the end of annealing. 
 
A  B  
C  
 
  
 
Figure 4-7. Comparison of trehalose crystallinity, protein hydration, and structure before (black) and after 
(white) annealing of frozen 10%M+8%T+X%BSA samples at –18 °C for 15 hours; X = 4, 8 and 16. A - 
Trehalose glycosidic peak location; B – Amide II peak location; C - Percent alpha helix in secondary 
structure. Compositions that undergo change up on annealing have been marked with *. 
 
Addition of D2O and Tween 20, in a concentration dependent manner, significantly affected 
the crystallinity of both the sugars as well as BSA stability. Upon addition of up to 4% (w/w) 
of D2O (Figure 4-6), no difference in observations was noted from the sample with no 
additives (4%BSA+8%T+10%M). However, an initial D2O concentration of 5% (w/w) and 
higher delayed the onset of mannitol crystallization (as hemihydrate) by about 5 hours, and 
completely suppressed trehalose crystallization throughout annealing. Congruously, the IR 
spectra revealed enhanced stability of BSA in terms of both hydration and secondary 
structure. Very similar results were seen on using Tween 20 as an excipient (Figure 4-8). At 
low concentrations (up to 0.2% w/w), Tween 20 delayed mannitol crystallization (as 
Before annealing After annealing 
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hemihydrate) by at least 6 hours and entirely supressed trehalose crystallization. On the 
other hand, at high concentrations of Tween 20 (> 1% w/w), mannitol started to crystallize in 
the anhydrous form as soon as the temperature was held at -18 °C. One hour into annealing, 
crystallization of trehalose was detected. In the presence of both high and low concentrations 
of the surfactant, BSA appeared to be adequately hydrated throughout annealing despite 
trehalose crystallization. Although hydration of protein was retained, at high concentrations of 
Tween 20 (> 1% w/w), a significant decrease in α helix and increase in β sheet content was 
observed 3 hours into the annealing. 
 
A  B  
C  
 
  
 
Figure 4-8. Comparison of trehalose crystallinity, protein hydration, and structure before (black) and after 
(white) annealing of frozen 10%M+8%T+4%BSA+X%Tween 20 samples at -18 °C for 15 hours; X = 0.1 and 
1. A - Trehalose glycosidic peak location; B – Amide II peak location; C - Percent alpha helix in secondary 
structure. Compositions that undergo change up on annealing have been marked with *. 
 
3.3. X-Ray Diffractometry (XRD) 
XRD enabled characterization of the phases crystallizing from the frozen solutions. 
Trehalose dihydrate was characterized by peaks (Cu Kα radiation; λ=1.5407 Å) at 8.8° 
(10.10 Å), 12.6° (7.00 Å), 13.7° (6.45 Å), and 16.5° 2θ (5.36 Å) while α-anhydrous trehalose 
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Effects of Excipient Interactions on the State of the Freeze-Concentrate and Protein Stability 
77 
was identified by peaks at 16.8° (5.26 Å) and 17.8° 2θ (4.98 Å). Mannitol hemihydrate was 
identified by peaks at 9.6° (4.95 Å) and 20.5° 2θ (4.33 Å) while δ-anhydrous form of mannitol 
was characterized by peaks at 9.7° (9.11 Å) and 24.6° 2θ (3.62 Å). Peaks at 22.7° (3.93 Å), 
24.4° (3.65 Å), 25.8° (3.46 Å), and 33.5° 2θ (2.68 Å) were assigned to hexagonal ice [51]. 
The XRD patterns obtained at the end of annealing period for the 10%M+8%T+15%BSA and 
10%M+8%T+4%BSA solutions are presented in Figure 4-9. 
 
A 
 
B 
 
Figure 4-9. XRD patterns of A - 10%M+8%T+15%BSA, and B - 10%M+8%T+4%BSA solutions after 20 hours 
of annealing at -18 °C. 
 
The conclusions drawn from IR analysis were supported by the XRD data. In the presence of 
high concentrations of BSA (15% w/w), the δ anhydrous form of mannitol was detected 
6 hours into annealing. No peaks attributable to crystalline trehalose could be detected 
throughout annealing. On the other hand, in the frozen solution without additives 
(10%M+8%T+4%BSA), in addition to ice crystallization, mannitol hemihydrate peaks 
appeared after 1 hour of annealing. Two hours following the onset of mannitol crystallization, 
peaks attributable to trehalose dihydrate were detected. 
 
3.4. Circular Dichroism (CD) Analysis of the Thawed Samples 
Structural stability of BSA in aqueous state was studied by CD. Sample solutions of 
composition identical to those used in IR spectroscopy and XRD experiments, were 
refrigerated at -20 °C for a prolonged duration (20 hours). Far-UV circular dichroism is 
sensitive to the backbone conformation of proteins. CD was used for structural 
characterization of BSA in both freshly prepared solutions and in thawed solutions after 
annealing. Differences in secondary structure of BSA due to annealing and thawing, 
estimated from CD spectra, are shown in Table 4-4. CD analysis also helped determine if 
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refolding of BSA occurred upon thawing the samples (reversibility of freezing induced 
denaturation). Turbidity in some of the solutions, immediately following ice melting, indicated 
solute crystallization. These crystals usually dissolved within 5 minutes of thawing. 
 
Table 4-4. Change in the secondary structure of BSA due to freezing and annealing = (% in fresh 
solution) - (% in thawed solution). 
Composition H (r) H (d) S (r) S (d) Turns Unordered 
4%BSA+8%T 1 ± 0.1 1 ± 0.0 -1 ± 0.1 0 ± 0.1 -1 ± 0.0 -3 ± 0.0 
4%BSA+8%T+2%M 2 ± 0.1 0 ± 0.1 -1 ± 0.2 0 ± 0.1 -2 ± 0.1 -1 ± 0.1 
4%BSA+8%T+10%M 15 ± 0.3 4 ± 0.1 -8 ± 0.3 -4 ± 0.1 -5 ± 0.2 -3 ± 0.1 
8%BSA+8%T+10%M 17 ± 0.2 5 ± 0.1 -11 ± 0.4 -4 ± 0.1 -5 ± 0.2 -1 ± 0.1 
8%BSA+4%T+10%M 24 ± 0.3 8 ± 0.0 -17 ± 0.3 -6 ± 0.1 -5 ± 0.3 -4 ± 0.0 
4%BSA+8%T+10%M+ 
1.0%Tween 20 
16 ± 0.3 8 ± 0.2 -6 ± 0.4 -4 ± 0.1 -4 ± 0.3 -10 ± 0.1 
4%BSA+8%T+10%M+ 
0.2%Tween 20 
4 ± 0.2 2 ± 0.1 -4 ± 0.2 -5 ± 0.2 -1 ± 0.2 -1 ± 0.2 
4%BSA+8%T+10%M+ 
0.1%Tween 20 
4 ± 0.2 1 ± 0.1 -1 ± 0.2 0 ± 0.1 -1 ± 0.2 -3 ± 0.1 
4%BSA+8%T+10%M+5%D2O 4 ± 0.3 0 ± 0.2 -1 ± 0.3 1 ± 0.2 0 ± 0.2 6 ± 0.2 
H(r) → Regular Helix, H(d) → Distorted helix, S(r) → Regular Sheet, S(d) → Distorted Sheet. Solutions were 
frozen and annealed at -18 °C for 20 hours. All samples were analyzed in duplicate. 
 
Firstly, mannitol concentration was increased, keeping BSA and trehalose concentrations 
fixed at 4% and 8% w/w, respectively. When R < 1, solutions appeared completely 
transparent as soon as they were thawed, suggesting that solute crystallization had not 
occurred during freezing. Simultaneously, no significant change in the secondary structure of 
BSA was observed upon thawing. When mannitol concentration was increased to 8% w/w, 
the thawed solutions, even those containing additives (Tween 20 or D2O), displayed 
temporary increase in turbidity. This was also the case when the BSA concentration was 
raised to 10% w/w. CD analysis revealed a significant decrease in α-helix (20%) content and 
a concomitant increase in β-sheet content (12%). A slight increase in the fractions of 
unordered structures and turns was noted for most of these solutions. An interesting 
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observation from the CD data is that the decrease in regular α-helix content and increase in 
the regular β-sheet content were more pronounced than the changes in the distorted 
fractions of both structures. The unfolding was exacerbated on increasing the mass ratio of 
protein to trehalose from 0.5 to 1 and 2. With the addition of D2O or low concentrations of 
Tween 20 (up to 0.2% w/w), unfolding of BSA was sufficiently inhibited. When surfactant 
concentration was increased to 1% w/w and above, unfolding of BSA was worsened. 
 
3.5. Characterization of Aggregates 
Samples with different trehalose to BSA mass ratios at a constant mannitol concentration of 
10% were analyzed post freezing and thawing. After annealing at -20 °C for 20 hours, the 
formation of both soluble and insoluble aggregates was investigated. Since the freezing step, 
depending on the formulation, facilitates the unfolding of BSA in the freeze-concentrate, 
subsequent aggregation represents a critical parameter for formulation development. 
Macroscopic appearance, turbidity and the number of subvisible particles were investigated 
as indication for protein precipitation.  
The macroscopic appearance was unchanged after annealing of all the tested formulations. 
The solutions were clear without signs of aggregate formation. Since the insoluble particles 
scatter the light at 350 nm, the solution turbidity was measured. An increased absorbance 
would hence indicate insoluble particles in the sample. There was no difference between 
unstressed and annealed samples. An increasing BSA concentration resulted in increasing 
absorbance values both at 280 and 350 nm whereby the turbidity values of all formulations 
investigated were below 0.06 absorbance units indicating the absence of aggregates larger 
than approx. 35 nm (1/10 of the wavelength of 350 nm) [52]. 
Light obscuration was used to characterize the subvisible particles. Particles ≥ 1 µm, ≥ 10 µm 
and ≥ 25 µm did not show a significant change between stressed and unstressed samples. 
For particles ≥ 1, 10 and 25 µm, the number of particles per mL was below 30,000, 200 and 
110, respectively. Overall, light obscuration did not indicate that annealing at -20°C for 20 h 
induced subvisible particle formation. 
Subsequently, two factors were evaluated with HP-SEC analysis: (1) formation of soluble 
higher molecular weight species and (2) monomer recovery. The analysis did not indicate the 
formation of soluble higher molecular weight aggregates. Since these are soluble and can be 
separated by HP-SEC they usually consist only of a few aggregated protein molecules [53]. 
Concerning monomer recovery, three compositions had a significant lower recovery after 
annealing (Figure 4-10). These were the two formulations with the highest BSA to trehalose 
ratio with and without mannitol (10%BSA+2%T and 10%BSA+2%T+10%M), as well as the 
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composition with 2% Tween 20 (4%BSA+8%T+10%M+2%Tween 20). Adding 10% mannitol 
led to even lower monomer recovery (15.1% monomer loss with mannitol vs. 11.4% without 
mannitol). 
 
  
Figure 4-10. Monomer recovery from fresh samples (white bars) and samples annealed at -20 °C for 
20 hours (grey bars) determined by HP-SEC at 280 nm (n=3). Mean ± SD. * P < 0.05. 
 
As already shown with CD, high Tween 20 concentrations are detrimental to BSA structure. 
This could be confirmed by HP-SEC analysis. 2% Tween 20 showed a monomer recovery of 
89.6% whereas the recovery of the surfactant free formulation (4%BSA+8%T+10%M) and 
the formulation only containing 0.2% Tween 20 was almost complete (99.8% and 99.0%, 
respectively). Formulations with lower BSA to trehalose ratios also showed a comparable 
protein recovery before and after annealing. 
The HP-SEC results, in agreement with IR analysis, indicated changes in the secondary 
structure of BSA in these formulations after annealing. As described above, three 
formulations showed a monomer loss > 10% determined by HP-SEC, but no increase in 
soluble higher molecular weight aggregates was detected. Thus, one could assume a higher 
aggregate size and hence an increase in insoluble particles. However, macroscopic 
appearance and the turbidity and light obscuration results ruled this out. We consequently 
assume that the unfolded BSA molecules are still soluble. However, their increased 
Before annealing After annealing 
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hydrophobicity leads to retention on the HPLC column preventing elution and hence 
detection. 
 
4. Discussion 
Upon adding BSA to mannitol-trehalose systems, the protein in a concentration dependent 
manner, delayed the onset, as well as the kinetics of mannitol crystallization. The relative 
extent of mannitol crystallization in various compositions can be determined from the 
temperature at which the melting endotherm is detected in the DSC scans while heating the 
frozen samples. The mannitol-ice eutectic melting usually occurs at -2.2 °C [54,55] while ice 
melts at a higher temperature (0 °C). The measured shift in the melting endotherm to higher 
temperatures, with increasing BSA concentration (Figure 4-1 B), was due to increasing 
contribution of ice melting to the endotherm which indicated reduced extent of mannitol 
crystallization. 
It has been previously reported that freezing and lyophilization of solutions containing 
mannitol in the presence of proteins such as monoclonal antibodies, lysozyme and human 
serum albumin, substantially reduced the extent of mannitol crystallization in a concentration 
dependent manner [19–22]. Pharmaceutical proteins such as monoclonal antibodies have 
also been shown to inhibit mannitol crystallization during spray drying [56,57]. Inhibition of 
crystallization by BSA could be due to its surface activity similar to that of a surfactant by 
virtue of its affinity for interfaces [58]. Moreover, DSC scans showed that glass transition of 
the freeze concentrate broadened in solutions containing BSA. This could be due to 
increased entropy of the solution in the presence of BSA, and/or some specific interaction 
between mannitol and BSA.  
At low surfactant concentrations, mannitol crystallization was delayed and trehalose 
crystallization was inhibited in spite of a relatively mobile FCL phase at -18 °C (i.e., lower Tg’) 
[59–61]. This could be attributed to adsorption of surfactant molecules to crystal surfaces, 
which impeded further propagation [26], and the reduced interactive forces between the 
solute molecules [62–64]. At high concentrations, Tween 20 appeared to not only facilitate 
crystallization of mannitol but also increased the extent of trehalose crystallization (for 
example, after annealing, no glass transition could be detected). Critical micelle 
concentration (CMC) of Tween 20 is 0.008% w/w at 25 °C [65]. At lower temperatures, CMC 
is known to increase [66]. Thus, at an initial solution concentration of 1% w/w, a very large 
number of micelles can be expected to form in the FCL. Micelles have been associated with 
increased supersaturation of the crystallizing solute and reduced interfacial tension, both of 
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which accelerate the rate of nucleation [25,67–69]. Surfactant assemblies can also promote 
crystallization by acting as templates for nucleation and growth of crystals [70,71]. Besides, a 
very low Tg’ indicates a comparatively mobile (less viscous) FCL at the annealing 
temperature, ideal for crystal growth [59–61]. Mobility of the FCL (diffusivity of any species) is 
directly proportional to the magnitude of the difference between the annealing and glass 
transition temperatures (Ta-Tg’) [59–61,72]. An important observation from the thermal 
behavior of frozen solutions before and after annealing is that in the presence of low 
concentrations of Tween 20 and D2O, mannitol crystallization was incomplete. This was 
obvious from the % change in ΔCp (Table 4-2) due to annealing as well as from the 
appearance of exotherms after annealing during warming (Figure 4-3 B). Retention of 
amorphous mannitol in the freeze-dried cake could have repercussions such as the 
formation of a mechanically fragile final product with low collapse temperature [14], and 
release of the sorbed water during storage [21], which can increase the mobility in the FCL 
and result in API instability. 
At high concentrations, Tween 20 and BSA induced the formation of δ-anhydrous mannitol 
form instead of the hemihydrate. Presence of additives including surfactants has been known 
to affect the physical form  of the crystallizing phases [73,74]. Additives either promote or 
inhibit propagation of the crystals along certain directions by engaging in specific interactions 
(e.g. hydrogen bonding) with functional groups along crystal faces. In the presence of solutes 
such NaCl and proteins such as HSA, mannitol has been found to crystallize as the δ-
anhydrous form. High concentrations of BSA (15% w/w), and D2O (5% w/w) effectively 
prevented crystallization of trehalose. A possible explanation for this is that both BSA and 
D2O increased Tg’ values, reducing (Ta-Tg’) and hence the mobility of the FCL at the 
annealing temperature. Surface coverage action of BSA could also be a factor, as explained 
before. This also explains the observed delay in mannitol crystallization. 
Post-thaw analysis by CD mostly concurred with the changes in protein conformation 
measured by IR spectroscopy in the frozen state. It has been reported previously that while 
cold denaturation and chemical denaturation of proteins in tumour cells and monoclonal 
antibodies is reversible [75,76], cold denaturation of ovalbumin is irreversible [77]. It was 
comprehensively proven that crystallization of trehalose destabilizes protein in the frozen 
state and the subsequent protein unfolding was not reversed upon thawing. Crystallization of 
trehalose signified that the lyoprotectant could no longer interact with and stabilize the API in 
accordance with the water replacement theory [78,79]. Besides, proteins have been known 
to be susceptible to aggregation at interfaces [80,81], and crystal formation gives rise to 
higher interface area. At high BSA and D2O concentrations, the protein was found to retain 
its hydration and native conformation in the frozen state. One reason could be that 
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crystallization of trehalose was avoided in these formulations. Besides, there is evidence that 
D2O protects cells and proteins against thermal denaturation and heat shock [31,32]. 
 
Table 4-5. Effect of thawing rate of 10%M+4%T+8%BSA sample on the secondary structure of BSA. = 
(% in fresh solution) - (% in thawed solution). 
Heating rate H (r) H (d) S (r) S (d) Turns Unordered 
Fast thaw 9 ± 0.6 2 ± 0.3 -6 ± 0.8 -2 ± 0.4 -1 ± 0.3 -2 ± 0.7 
Ambient 24 ± 0.3 8 ± 0.1 -17 ± 0.3 -6 ± 0.1 -5 ± 0.3 -4 ± 0.0 
Slow thaw 21 ± 0.4 5 ± 0.6 -14 ± 0.3 -5 ± 0.5 -4 ± 0.6 -3 ± 0.5 
H(r) > Regular Helix, H(d) > Distorted helix, S(r) > Regular Sheet, S(d) > Distorted Sheet. Solutions were frozen 
and annealed at -18 °C for 20 hours and thawed at different rates. The sample was immersed in a water bath at 
60 °C for fast thaw, kept at room temperature for ambient thaw and immersed in a water bath with melting ice 
(0 °C) for slow thaw. All solutions were analyzed in duplicate. 
 
An argument in case of samples with high protein to trehalose mass ratios is that there are 
very few trehalose molecules per protein molecule in the FCL for the lyoprotectant to be 
effective, in spite of being amorphous. BSA has been shown previously to protect itself (as 
well as other more labile proteins) against freezing induced stresses by acting as a molecular 
chaperon [82,83] and by accumulating at crystalline surfaces (forming almost a sacrificial 
layer) due to its strong affinity for interfaces [58,84]. CD and HPSEC results revealed protein 
unfolding in the thawed solutions at high BSA to trehalose mass ratios. This implied that self-
stabilization of BSA, which was effective in the frozen state, lost its effectiveness during 
thawing. During thawing, recrystallization occurs, especially at slower thawing rates 
(< 20 °C/min), perturbing the stability of the proteins at the rapidly changing ice–solution 
interface [85,86]. All frozen solutions analyzed by CD were thawed slowly by leaving them 
exposed to ambient temperatures. This hypothesis was later verified when 3 samples of the 
composition (10%M+4%T+8%BSA) were thawed at different rates, after freezing and 
annealing (Table 4-5). The first frozen sample was rapidly thawed by immersing it in a water 
bath maintained at 60 °C, the second was thawed by leaving it exposed to room 
temperature, while the third was thawed very slowly by immersing it in water in equilibrium 
with ice (0 °C). While no difference was observed in the protein structure between the 
samples thawed at RT and at 0 °C, structural changes of protein in the rapidly thawed 
sample were significantly reduced. 
In previous studies of Zakharov et al. on ice recrystallization in the presence of BSA, it has 
been claimed that BSA inhibits ice recrystallization at warmer temperatures [87]. But the 
thermal protocols used for both studies are very different. In the work of Zakharov et al., 
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frozen BSA samples were very rapidly warmed (at 6 °C/min) to the temperature of interest 
and held. On the other hand, in the current study, frozen samples were thawed very slowly to 
room temperature under ambient conditions before CD analysis. This should cause an 
increased extent of ice recrystallization and thus acoount for its effect on the structure of BSA 
during thawing, as observed in this study. As discussed previously, samples that were 
thawed rapidly showed significantly reduced effects of recrystallization, in agreement with the 
findings of Zarkharov et al. Reports have shown that although a higher concentration of 
protein increases the glass transition temperature of the freeze concentrate (and thus the 
collapse temperature during drying), the protein concentration in the freeze-drying 
formulation is usually limited in order to ensure a higher weight ratio of stabilizer (> 1) to 
protein for its stability during storage [14]. A molar disaccharide to protein ratio of 350-400 
has been reported to be sufficient to ensure protein stabilization during freeze- and spray-
drying [88,89]. This should not be a limitation for a self-stabilizing API such as BSA. 
At low concentrations of Tween 20, no signs of unfolding and aggregation of BSA could be 
detected. The possible mechanisms of protein stabilization by surfactants are ice interface 
coverage (protects against aggregation at crystalline interfaces [27]), screening of the 
hydrophobic attractive forces between proteins, and enhancement of hydration and 
electrostatic repulsive forces between the proteins [90]. On the other hand, at an initial 
concentration of 1% w/w, Tween 20 proved to be even more detrimental to protein structure. 
Free surfactant micelles promote protein aggregation and precipitation due to the attractive 
depletion force between the protein and micelle complexes [90–92]. Aggregates composed 
of non-native β-sheet structures have been identified while freezing globular proteins with 
non-ionic surfactants due to direct unfavourable binding of surfactant with protein surface 
and interaction with micelles [28]. 
Distortion in the geometry of α-helices and β-sheets arise when a few residues (about 3-4) at 
the end of each coil/sheet exposed to the solvent are twisted away from the solvent region to 
maximize their H-bonding capacity. These few residues do not conform to the regular helical 
geometry of the coil or the planar geometry of the sheets. A very interesting observation from 
secondary structure characterization was that in some thawed solutions (where BSA was 
denatured) there was an increase in the relative fraction of distorted α-helix content (vs. 
regular). This led us to believe that not only did the α-helices reduce in quantity but they were 
also structurally reorganized (distorted) into shorter coils. Shortening in length of α-helix coils 
has been identified as a consequence of denaturation [93,94]. Simultaneously, the relative 
fraction of regular β-sheets (vs distorted) was found to increase in the same thawed solutions 
implying that the β-sheets got reorganized into more robust non-native β aggregates 
[37,95,96]. 
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Deuterium oxide has been used to quantify tertiary structure unfolding by monitoring the 
H/D exchange [45,97,98]. When a folded protein with a well-defined 3 dimensional structure 
is exposed to D2O environment, the hydrophobic polypeptide chains buried in the interior of 
the protein remain essentially unchanged and the outer hydrophilic chains get preferentially 
deuterated, which is reflected in the Amide II’ peak. When the 3-D tertiary structure starts to 
unfold, the inner hydrophobic chains get exposed to the solvent causing more H/D exchange 
to occur. The increased extent of deuteration is manifested as an increase in peak intensity 
(and area) of the Amide II’ at the expense of the Amide II. Comparing integrated peak area of 
the Amide II’ and Amide II bands, it was shown that tertiary unfolding was a precursor to 
secondary structure unfolding in BSA. This was in agreement with the mechanism and 
pathways of unfolding of membrane proteins, and RNA reported previously [98–100]. 
Formation of aggregates is often a consequence of protein association due to irreversible 
denaturation. Turbidity analysis conducted after 30 minutes (ensuring dissolution of excipient 
crystals) of thawing did not reveal presence of any insoluble aggregates of BSA. This is not 
unlikely since BSA is known to mostly form water soluble aggregates, which cannot be 
detected via turbidity studies [101]. A significant decrease in the monomer content was 
obtained in thawed solutions, especially the ones with high BSA to trehalose mass ratio (5:1) 
and those with high initial Tween 20 concentrations (2% w/w). These observations concurred 
with the post thaw CD analysis. However, no large aggregates could be detected in spite of a 
decrease in the monomer content. Furthermore, SEC analysis demonstrated that higher 
molecular weight BSA oligomers did not form upon freezing and annealing (no higher 
molecular species peak or significant void peak formation). Thus, the unfolded protein must 
have interacted with the column and retained in it on account of enhanced hydrophobicity. 
Chapter 4 
86 
5. Conclusions 
Addition of surfactant (at low concentrations), protein and D2O delayed crystallization of 
mannitol and inhibited crystallization of trehalose in a concentration dependent manner. On 
the other hand, adding high concentrations of surfactant increased the extent of 
crystallization of both sugars. It was established that unfolding of BSA occurred when 
trehalose crystallized. When solutions with high protein to trehalose mass ratio (> 1) were 
frozen, BSA retained its native structure due to self-stabilization. But during thawing, the self-
stabilization effect of BSA diminished and BSA unfolded in the thawed solutions. In the 
presence of D2O and low concentrations of Tween 20, BSA did not undergo structural 
changes either in frozen state or in thawed solutions. When Tween 20 concentration was 
increased to 1% w/w, denaturation of BSA was worsened due to micelle formation. 
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6. Additional Data 
To gain more insight into possible stress mechanisms that lead to unfolding of BSA, 
formulations of mannitol with either trehalose or sucrose were stressed by freezing and 
thawing or by lyophilization. These data were generated post publication. 
 
Additional Material and Methods 
Lyophilization 
1.2 mL of each formulation was freeze-dried in 2 R vials (Fiolax®, Schott AG, Mainz, 
Germany), semi-stoppered with lyophilization stoppers (B2-TR coating, West Pharmaceutical 
Services Deutschland GmbH & Co. KG, Eschweiler, Germany). A FTS Lyostar 3 (SP 
Scientific, Stone Ridge, USA) was used. Samples were first annealed at -20 °C shelf 
temperature set point for 20 hours (cooling rate 1 °C/min) to expose the samples to the same 
procedure as in the freeze-thaw study. Freezing was performed at -50 °C for 1 hour and a 
cooling rate of 1 °C/min. Duration of primary drying (-30 °C, 0.5 °C/min) was controlled by 
comparative pressure measurement between Pirani and MKS sensor (difference <5 mTorr). 
Secondary drying was conducted at +20 °C for 8 hours (heating rate 0.2 °C/min). Drying was 
performed at 60 mTorr. 
 
Freeze-Thawing 
2.0 mL of each formulation were frozen and annealed for 20 hours at -20 °C in a lab scale 
freeze-dryer (FTS Lyostar 3,SP Scientific, Stone Ridge, USA) in 2 R vials (Fiolax®, 
Schott AG, Mainz, Germany), closed with lyophilization stoppers (B2-TR coating, West 
Pharmaceutical Services Deutschland GmbH & Co. KG, Eschweiler, Germany). Heating and 
cooling rate was 1 °C/min. One or five freeze-thaw cycles were conducted. 
 
Results and Discussion 
The macroscopic appearance of the freeze-dried Man/Tre/BSA samples (compositions as 
shown in Figure 4-10) was homogenous within the different formulations and no cake defects 
could be detected. The liquid formulations before freeze-drying and reconstitution of the 
lyophilizates were clear, did not show formation of visible particles, sub-visible particles or 
increase in turbidity as did freeze-thawing (see 3.5). Freeze-drying did not lead to a decrease 
in monomer content in low trehalose or high Tween 20 samples (10%BSA+2%T, 
10%BSA+2%T+10%M and 4%BSA+8%T+10%M+2%Tween 20 as freeze-thawing. CD 
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analysis also revealed that BSA suffered less structural changes by freeze-drying than by 
freezing, annealing and thawing. 
In contrast to trehalose formulations, unfolding of BSA was not found in formulations that 
contained sucrose and were annealed at -20 °C and thawed except of the formulation that 
included 2% Tween 20. This high surfactant formulation resulted in decreased α-helix 
content after one annealing cycle. Macroscopic appearance, turbidity, sub-visible particle 
numbers and soluble aggregate content was unchanged, also after five freeze-thaw cycles. 
20 hours of annealing at -20 °C followed by thawing to ambient temperature was compared 
to the same process but followed by drying and rehydration instead of thawing. Differences 
were detected in HP-SEC and CD analysis only for the freeze-thawed low trehalose or high 
Tween 20 samples and not in freeze-dried samples. Thus, BSA degradation cannot only be 
attributed to the annealing step above Tg’ and the crystallization of mannitol and trehalose, 
but thawing induced stress played a major role. Not only ice formation and its corresponding 
interfaces led to unfolding as described in literature [27,80,102] but also the composition of 
the freeze-concentrate. Crystallization of the usually amorphous stabilizer trehalose affected 
the stability of BSA during the thawing process. The dilution of the freeze-concentrated 
solution upon thawing led to slow dissolution of the ice-freeze-concentrate interface including 
the trehalose and mannitol crystals. The stabilization by sucrose could be attributed to its 
less pronounced crystallization tendency [12,16].  
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Abstract 
Mannitol/sucrose formulations are employed to generate lyophilizates for biopharmaceuticals 
with an elegant cake appearance. The aim of this study was to dry protein/mannitol/sucrose 
formulations as fast as possible without loss of cake appearance and protein stability. 
Glycerol was included as potential additional protein stabilizer. Three proteins (lysozyme and 
two monoclonal antibodies) at low and high concentration were analyzed comparing fast with 
conservative freeze-drying. Freeze-drying cycle development was carried out with 
mannitol/sucrose formulations. A product temperature (Tp) close to the Te of mannitol and 
clearly above the Tg’ of sucrose was targeted. Protein formulations were exposed to the final 
fast lyophilisation process and to a conservative freeze-drying cycle. Lyophilizates were 
characterized by differential scanning calorimetry, Karl-Fischer titration and X-ray 
diffractometry. Additionally, macroscopic cake appearance and reconstitution times were 
evaluated. Protein stability was characterized by UV/Vis spectroscopy, light obscuration and 
size exclusion chromatography. The fast freeze-drying cycle resulted in a primary drying time 
of 7 hours (Tp: -10 °C) and a secondary drying time of 2 hours in contrast to 47 hours (Tp: 
-39 °C) and 12 hours for the conservative cycle. Lyophilizates showed Tg values above 
60 °C, a residual moisture level of 1%, reconstitution times of less than 35 seconds, δ-
mannitol and elegant cake appearance. Mannitol/sucrose ratios below 4/1 did not lead to 
complete mannitol crystallization and were therefore not suitable for the selected process 
conditions. Characterisation of protein stability rendered low aggregation and particle levels 
for both, fast and conservative freeze-drying conditions. It was shown that fast freeze-drying 
of mannitol/sucrose formulations above Tg’ at a Tp of -10 °C resulted in good protein process 
stability and appropriate cake characteristics at maximum time reduction. 
 
Keywords 
Freeze-drying, cycle development, bulking agent, mannitol, sucrose, glycerol, protein 
stability, glass transition, collapse, crystallization  
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Abbreviations 
A Annealing step 
aFD After freeze-drying 
API Active pharmaceutical ingredient 
AUC Area under the curve 
bFD Before freeze-drying 
CN Controlled nucleation 
F Freezing step 
FD Freeze-drying 
Gly Glycerol 
hh hemihydrate 
HP-SEC High performance size exclusion chromatography 
HPW Highly purified water 
LO Light obscuration 
Lyso Lysozyme 
mAb Monoclonal antibody 
Man Mannitol 
mDSC Modulated differential scanning calorimetry 
PD Primary drying step 
RM Residual moisture 
SD Standard deviation / secondary drying step 
Suc Sucrose 
Tc Collapse temperature 
Te Eutectic temperature 
Tg Glass transition temperature of the freeze-dried cake 
Tg’ Glass transition temperature of the freeze-concentrated solution 
Tp Product temperature 
XRPD X-Ray powder diffraction 
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1. Introduction 
Freeze-drying is frequently used to achieve long-term storage stability of sensitive 
biopharmaceuticals. More than 40% of the marketed biologicals are currently freeze-dried, a 
number which is expected to even increase in the future [1,2]. The manufacturing process is 
time- and cost-intensive with regular process times of several days or even weeks [3]. 
Especially for drugs in high demand and full capacity utilization, faster drying would enable 
higher throughput at preferably reduced production costs. Several approaches were already 
investigated with respect to process optimization at high sublimation rates and product 
temperatures. Amorphous formulations were dried above the glass transition temperature of 
the freeze concentrate (Tg’) but below the collapse temperature (Tc) [2,4]. Highly 
concentrated protein formulations benefitted more since Tc was raised more than Tg’ with 
increasing protein concentration. That enabled drying at higher product temperature (Tp) of 
up to -10 °C at 100 mg/mL mAb with a Tc of -8 °C. A 5 mg/mL protein formulation could only 
be dried at a Tp below -30 °C [2]. Another approach was to combine mannitol (Man) with 
sucrose (Suc) and dry at high Tp so that the amorphous matrix of Suc and protein collapsed 
while Man formed a crystalline scaffold without macroscopic visible defects such as e.g. 
eutectic melting [5]. Man and Suc are regularly combined due to their complementary 
characteristics. Suc probably the most frequently utilized protein stabilizer replaces water 
binding sites of proteins and decreases protein mobility in the dried state by vitrification [6–8]. 
Upon freeze-drying Suc remains amorphous which is a prerequisite for protein stabilization 
[8]. In contrast, the bulking agent mannitol crystallizes during the process while losing its 
stabilization properties [9]. The crystalline scaffold leads to an elegant cake without 
shrinkage or cracks [10] and helps to increase the mass of the cake or to achieve the desired 
tonicity of the rehydrated formulation [11,12]. Typically, Man and Suc have to be combined at 
a Man/Suc ratio of at least 4/1 due to inhibition of Man crystallization by Suc at lower 
Man/Suc ratios [5,13]. Moreover, proteins also suppress bulking agent crystallization [14]. 
At high ratios of Man to Suc, the crystallization of mannitol minimizes the potential collapse of 
amorphous sucrose, eliminates the need to conduct primary drying below the Tg’ or Tc, and 
thereby, provides the option to perform drying at higher temperatures and enables shorter 
processing times. Drying of crystalline excipients to products of appropriate macroscopic 
appearance is limited by their eutectic temperature (Te), in case of Man -1.5 °C [5]. It has 
already been demonstrated that collapse of the stabilizers is not necessarily coupled with 
protein destabilization [15–21]. To which extent macroscopic appearance should be 
accepted given that the protein stability is not affected is an ongoing discussion but complete 
collapse is not acceptable if not induced intentionally [22]. Thus, freeze-drying cycle 
development should aim at adequate cake appearance, unless protein stability is superior in 
collapsed cake structure. 
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The small molecular weight plasticizing agents glycerol  and sorbitol  were found to be 
beneficial for protein stability in the dried state [23–25]. Their potential lies in the prolongation 
of ß-relaxation times or local motions [23,25–27]. Due to their small size they might be able 
to reduce free volumes and increase the packing density better than larger stabilizers 
[26,28]. Because of their low Tg values (glycerol: -93 °C and sorbitol: 0 °C [29,30]) they 
would lead to macroscopic collapse if used as single component in a formulation. They would 
also lower Tg’ values of Suc formulations to a considerable extent. As a consequence, fast 
drying at high product temperatures would be difficult in Suc/Glycerol formulations without 
macroscopic collapse. The appearance of crystalline mannitol reduces the potential for gross 
collapse, and provides the additional advantage of faster drying. In this study, glycerol was 
included as an additional stabilizer in a matrix comprising of amorphous sucrose and 
crystalline mannitol. Glycerol replaced 5% / 10% of the amorphous Suc as these low 
concentrations showed antiplasticizing effects in previous studies [31]. 
All process steps were accelerated (that is, faster cooling or heating rates) to minimize the 
cycle duration. The freezing step plays an important role for the whole process because it 
determines ice crystal growth, size and distribution, as well as the crystallization behavior of 
the excipients [13,32,33]. Annealing above Tg’ is commonly performed to ensure complete 
mannitol crystallization or to force the formation of a certain Man polymorph [13,34,35]. 
Moreover, it can be effectively utilized to minimize the effects of the inter-vial variability in the 
ice nucleation temperature, which causes differences in the ice structures (size of the 
crystals) across a batch of vials [33]. Annealing results in a more homogeneous (or uniform) 
ice structure and reduces the inter-vial heterogeneity. Hence the freezing step already 
determines characteristics of the dried matrix. Primary drying (PD) is the step with the 
highest optimization potential due to its long duration [2]. The last step, secondary drying, 
takes only a few hours [3]. Nevertheless, the final residual moisture (RM) content and the 
conversion of potentially formed Man hemihydrate into the anhydrous form depends on 
selection of sufficiently high secondary drying temperature and duration [5]. Thus, the 
characteristics of freeze-dried products are mainly influenced by the FD cycle conditions and 
the formulation composition, but are also affected by further parameters such as container, 
stoppers or filling volume which are not discussed here [36]. 
This study aimed at a cycle development of a fast freeze-drying cycle with Man/Suc 
formulations that were indistinguishable from conservative dried formulations regarding their 
physical characteristics. Protein formulations were investigated to show that a high Tp during 
PD, likely coupled to higher protein mobility, does not negatively impact protein process 
stability. For a comprehensive analysis, freeze-dried protein formulations were characterized 
by DSC, Karl-Fischer titration and XRD, checked for macroscopic appearance and 
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reconstitution time, and protein stability was tested by LO, turbidity and HP-SEC. After 
development of the fast cycle with Man/Suc/Glycerol formulations, the results were compared 
to conservative freeze-drying conditions that provided non-collapsed amorphous matrices. 
Lysozyme and two monoclonal antibodies in different concentrations enabled a detailed 
study on impact of formulation and process. Lower Man/Suc ratios were tested with focus on 
complete Man crystallization and the impact of different freezing protocols. 
 
2. Materials and Methods 
2.1. Materials 
Stock solutions of mannitol (Man) (VWR International, Ismaning, Germany), sucrose (Suc) 
(Sigma-Aldrich Chemie GmbH, Steinheim, Germany) and glycerol (AppliChem GmbH, 
Darmstadt, Germany) were prepared in 10 mM L-histidine (Sigma-Aldrich Chemie GmbH, 
Steinheim, Germany) pH 7.0 formulation buffer. Different mannitol/sucrose/glycerol 
(Man/Suc/Gly) weight ratios were investigated: 40/10/0, 40/9.5/0.5, 40/9/1, and 40/0/0 
[mg/mL]. Protein formulations contained protein, mannitol, sucrose and glycerol. For the 
second study, different Man/Suc ratios dissolved in highly purified water (HPW) were 
examined without protein: 20/30, 25/25, 30/20, 40/10 [mg/mL]. All formulations were filtered 
with 0.2 µm polyethersulfone (PES) membrane syringe filters (VWR International GmbH, 
Ismaning, Germany) prior to use. 
Hen egg white lysozyme (MW 14.3 kDa, ε = 38.94 mL mg-1 cm-1, Dalian Greensnow Egg 
Products Development Co., Ltd., Dalian, China) and two different monoclonal IgG1 antibodies 
(MW ~ 150 kDa, ε = 1.49 mL mg-1 cm-1, referred to as mAb1 and mAb2) served as model 
proteins within the Man/Suc/Glycerol formulations. mAb 1 was used at lower concentration 
as it results in viscous formulations at high concentration. Lysozyme was dissolved in 
formulation buffer whereas the stock solutions of the mAbs were prepared by tangential flow 
filtration in MinimateTM capsules (30 kDa Omega membrane, PALL Life Science, Port 
Washington, NY, USA) out of lower concentrated bulk solutions. Each protein was 
formulated at 2 mg/mL and, additionally, lysozyme at 100 mg/mL, mAb1 at 7.5 mg/mL and 
mAb2 at 80 mg/mL. 
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2.2. Methods 
2.2.1. Lyophilization 
Lyophilization stoppers (B2-TR coating, West Pharmaceutical Services Deutschland GmbH & 
Co. KG, Eschweiler, Germany) and DIN 2R Vials (Fiolax®, Schott AG, Mainz, Germany) 
were cleaned with highly purified water and dried for 8 hours at 100 °C and 60 °C, 
respectively. A filling volume of 1.2 mL was dispensed into the vials which were semi-
stoppered subsequently. The two outer rows of vials were not used for subsequent analysis. 
Thermocouples in different vial positions on the shelf recorded temperature values during 
freeze-drying. 
The protein formulations were freeze-dried according to the given freeze-drying protocols 
(Table 5-1, Process 1 and Process 8). Controlled nucleation (CN) according to Geidobler et 
al. was conducted [37]. The vials were equilibrated at -5 °C for 1.5 h. At a Tp of -4 °C to 
-4.5 °C, the chamber pressure was reduced to 4 mbar. CN was induced by ventilation via the 
condenser chamber. The method was selected to enable potential scale up to larger freeze-
dryers avoiding potential adjustments to the individual formulations. The different Man/Suc 
ratios were investigated with the fast freeze-drying cycle conditions (Process 8) and two 
variations of the freezing step: (1) equilibration at -5 °C, but without CN or (2) including an 
annealing step at -20 °C for 2 hours. Process variations performed with Man/Suc/Glycerol 
formulations are summarized in Table 5-1. A FTS Lyostar 3 (SP Scientific, Stone Ridge, NY, 
USA) and an Epsilon 2D-6 LSCplus (Martin Christ Gefriertrocknungsanlagen GmbH, 
Osterode am Harz, Germany) were used. The FTS freeze-dryer was used for chamber 
pressure values of up to 1.1 mbar while the Christ freeze-dryer was utilized at 1.1 mbar 
higher chamber pressure or above. The end of primary drying was controlled by comparative 
pressure measurement between Pirani and MKS sensor (FTS) or set manually (Christ). Vials 
were stoppered after secondary drying under nitrogen atmosphere at 800 mbar, crimped with 
flip off seals and stored at 4-8 °C. 
 
2.2.2. Macroscopic Appearance 
Images of the lyophilizates were taken with a Nikon D5300 camera (Nikon GmbH, 
Düsseldorf, Germany) in a black photobox.  
 
2.2.3. Modulated Differential Scanning Calorimetry (mDSC) 
The glass transition temperature (Tg) of the lyophilizates and of the freeze-concentrate (Tg’) 
were determined with a Mettler Toledo DSC 821e (Mettler-Toledo GmbH, Giessen, 
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Germany) using aluminum 40 µL crucibles which were sealed hermetically. For Tg’ 
measurement, 30 µL liquid formulation were cooled down to -60 °C and heated to +20 °C at 
10 °C/min without modulation. Regarding Tg determination, samples were prepared under 
controlled humidity conditions, < 10% rel. humidity. 5 to 15 mg of crushed cake were 
weighted into aluminum crucibles and sealed hermetically. The DSC scan was conducted 
from 25 °C to 100 °C or 140 °C at 2 °C/min and modulation with an amplitude of ± 1 °C every 
120 s. Tg and Tg’ were determined as the midpoint of the transition using the Mettler StarE 
Software. 
 
2.2.4. Karl-Fischer Titration 
Karl Fischer titration was used to determine the residual moisture (RM) of the lyophilizates. It 
was performed with an Aqua 40.00 titrator (Analytik Jena AG, Halle, Germany) using a 
headspace oven set at 100 °C. Samples were prepared under controlled humidity conditions, 
< 10% rel. humidity. 10 to 20 mg of crushed cake were analyzed in 2 R vials. 
 
2.2.5. X-Ray Powder Diffraction (XRPD) 
The phase behavior of freeze-dried cakes was determined using X-ray powder diffractometry 
(XRPD). An XRD 3000 TT diffractometer (Rich. Seifert & Co. GmbH &Co. KG, Ahrensburg, 
Germany) was used equipped with a copper anode (40 kV, 30 mA, λ = 0.154178 nm) and a 
scintillation detector at 1000 V. The freeze-dried samples were crushed and smoothened 
homogenously on copper sample holders at 0.2 mm height. Samples were analyzed in steps 
of 0.05° using 2 seconds per step from 5-45° 2-Θ. The three polymorphic forms of Man (α, ß, 
δ) and Man-hemihydrate were analyzed according to their main reference peaks: α- (9.3°, 
13.7°, 17.2°, 18.7°), β- (10.4°, 14.6°, 16.8°, 18.8°, 20.3°, 23.4°), δ-mannitol (9.7°, 20.4°, 
22.0°, 24.6°, 25.3°) and mannitol hemihydrate (9.6°, 17.9°, 23.1°, 25.7°) [13,38,39]. Peaks 
used for identification are underlined. 
 
2.2.6. Reconstitution Time 
Reconstitution time was determined by dissolving the lyophilizates with the required volume 
of HPW. The required reconstitution volume was calculated based on the formulation density 
and solid content. The time from adding HPW to complete dissolution of the cake was 
considered as reconstitution time. Complete dissolution was determined visually. During 
reconstitution, the vials were gently rolled by hand to ensure wetting of the complete 
lyophilizate. 
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2.2.7. Turbidity 
Turbidity of the samples before freeze-drying and after reconstituion was measured by 
UV/Vis-spectroscopy at 350 nm. A NanoDrop 2000 spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA) was used. Each formulation was measured as triplicate with 
its corresponding formulation without protein as blank solution.  
 
2.2.8. Light Obscuration (LO) 
A PAMAS SVSS-35 particle counter with a HCB-LD-25/25 sensor (PAMAS - Partikelmess- 
und Analysesysteme GmbH, Rutesheim, Germany) was used to determine the number of 
subvisible particles before freeze-drying and after reconstitution of the lyophilizates. The 
system was cleaned with HPW between the analyses. The rinse volume was 0.2 ml, followed 
by four measurements of 0.2 ml according to USP 788 [40]. PAMAS PMA software was used 
to determine particles ≥ 1 µm, ≥ 10 µm and ≥ 25 µm. 
 
2.2.9. High Performance Size Exclusion Chromatography (HP-SEC) 
Size exclusion chromatography was performed with an Agilent 1100 series HPLC system 
equipped with an UV/Vis detector for detection at 280 nm (Agilent Technologies, Santa 
Clara, CA, USA). A TSKgel® G3000 SWXL column (dimension: 300 x 7.8 mm, TOSOH 
Bioscience GmbH, Stuttgart) and 100 mM sodium phosphate / 100 mM sodium sulfate buffer 
at pH 6.8 mobile phase with a flow rate of 0.5 mL/min was used. Prior to analysis, samples 
were diluted to 1 mg/mL (lysozyme) or 2 mg/mL (mAb1 and mAb2) and centrifuged (5 min, 
4000 rpm, Sigma 1-15 microfuge, Sigma Laborzentrifugen GmbH, Osterode am Harz, 
Germany). The integrated peak intensity was determined before and after freeze-drying after 
blank subtraction using the ChemStation Software (Agilent Technologies, Santa Clara, CA, 
USA) and relative monomer recovery was determined. Soluble aggregates and fragments 
were referred to the AUC of monomer before freeze-drying.  
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3. Results and Discussion 
3.1. Development of a Fast Freeze-Drying Cycle 
The first aim of this study was to find optimized freeze-drying cycle conditions for a fast 
freeze-drying cycle that results in lyophilizates with an elegant cake appearance and the 
desired physico-chemical characteristics, crystallinity of the bulking agent, adequately high 
Tg approximately 40 °C above intended storage temperature of 2-8 °C and low RM close to 
1% [3]. Man as crystalline bulking agent was combined with the amorphous stabilizer Suc at 
40/10, as this weight ratio is known to lead to fully crystalline Man after freeze-drying [5,13]. 
Furthermore, glycerol was included as a secondary stabilizer in addition to Suc (primary 
stabilizer), at 5% or 10% of the Suc concentration employed in the formulations. [26]. As pure 
crystalline bulking agent reference, also Man as single component was investigated. 
Table 5-1 gives a comprehensive overview of all process variations performed combined with 
the corresponding results. A target Tp of -10 °C was identified such that the Tp was much 
higher than the Tg’ (or Tc) of Suc (Tg’: -32 °C [41], Tc: -31 °C [42]) , but was still below the 
Te of Man (-1.5 °C [5]). Tp values during drying are strongly affected by the applied chamber 
pressure. This was achieved with the chamber pressure increased to 2.2 mbar and the shelf 
temperature set to +20 °C. Further increase in chamber pressure to 4.3 mbar led to meltback 
at the bottom of the vials while 10 mbar induced “blow out” of the formulations out of the vial 
due to exceeding Te (Tp during PD: 7.3 °C) and thus melting. 
As the selected formulations were to be dried at Tp values clearly above the Tg’ value of 
Suc, complete crystallization of the bulking agent was important to generate a scaffold which 
does not show gross collapse despite the collapse of the amorphous Suc phase. The ß-
polymorph of Man is considered thermodynamically more stable while α-, δ-, as well as the 
hemihydrate form are the metastable [43]. The transformation of Man-hemihydrate into 
anhydrous α, ß or δ-Man during storage bears the risk of increased protein instability as 
more water molecules are available as potential reaction partners and the Tg of the 
amorphous phase decreases [44]. 
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Table 5-1. Process variations and the corresponding results of macroscopic appearance, RM, crystallinity of Man, reconstitution times and Tg. Results are given as 
mean ± SD for n=3. For n=2, mean values are given. Process changes compared to the previous run are written in bold. V = elegant cake appearance. CN was 
performed at -4.0 °C. 
Run 
No. 
Process Variations Freeze-drying cycle conditions 
Run 
Time 
 [h] 
Tp 
 in PD 
[°C] 
Man/Suc/Gly 
weight 
ratio [mg/mL] 
Macroscopic 
appearance 
RM [%] 
Mannitol 
polymorphism 
Reconstitution 
time 
 [s] 
Tg 
 [°C] 
1 Starting point  CN, F1 -50 °C, 1 °C/min, 1 h 100 -39 40/10/0 V 0.8 ± 0.1 δ, hemihydrate 19 ± 5 71.3 ± 2.1 
 
(conservative) A -20 °C, 1 °C/min, 2 h 
 
  40/9.5/0.5 
 
0.9 ± 0.2 δ, hemihydrate 21 ± 4 66.8 ± 4.2 
 
  F2 -50 °C, 1 °C/min, 2 h 
 
  40/9/1 
 
0.6 ± 0.2 δ, hemihydrate 25 ± 3 61.9 ± 0.4 
 
  PD -35 °C, 0.5 °C/min, 0.05 mbar, 47 h 
 
  40/0/0 
 
0.4 ± 0.1 ß 12 ± 1 - 
  SD 25 °C, 0.1 °C/min to 5 °C, 0.2 °C/min         
 
  to 25 °C, 0.05 mbar, 12 h                 
2 increased chamber  CN, F1 -50 °C, 1 °C/min, 1 h 29 -20 40/10/0 V 1.3 ± 0.1 δ, hemihydrate 68 ± 3 52.6 ± 4.1 
 pressure, A -20 °C, 1 °C/min, 2 h   40/9.5/0.5  1.2 ± 0.1 δ, hemihydrate 68 ± 6 44.2 ± 1.9 
 
increased PD shelf  F2 -50 °C, 1 °C/min, 2 h 
 
  40/9/1 
 
1.0 ± 0.1 δ, hemihydrate 79 ± 12 44.5 ± 7.3 
 temp, PD 0 °C, 0.5 °C/min, 0.53 mbar, 12.5 h   40/0/0  - - - - 
 
reduced drying time SD 25 °C, 0.1 °C/min to 5 °C, 0.2 °C/min 
 
  
  
 
   
 
  to 25 °C, 0.53 mbar, 4 h                 
3a increased chamber  CN, F1 -50 °C, 1 °C/min, 1 h 29 -15.4 40/10/0 V 1.7 δ, hemihydrate 39 ± 3 50.1 ± 0.4 
 pressure, A -20 °C, 1 °C/min, 2 h   40/9.5/0.5  1.5 δ, hemihydrate 64 ± 10 45.9 ± 0.4 
 
increased PD shelf  F2 -50 °C, 1 °C/min, 2 h 
 
  40/9/1 
 
1.5 δ, hemihydrate 38 ± 15 41.5 ± 0.4 
 temp, PD 10 °C, 0.5 °C/min, 1.1 mbar, 9.5 h   40/0/0  1.0 ß 21 ± 4 - 
 
reduced drying time SD 25 °C, 0.2 °C/min, 1.1 mbar, 4 h 
 
  
   
   
 
3 different SD shelf 
  
  
   
   
 
temps (3a-3c) 
 
                
3b   as 3a, but prolongation of SD at 40 °C  35 -15.4 40/10/0 V 1.1 δ, less hemihydrate 28 ± 13 57.2 ± 1.1 
 
   for 4 h 
 
  40/9.5/0.5 
 
0.9 δ, less hemihydrate 47 ± 22 65.9 ± 3.6 
 
    
 
  40/9/1 
 
0.5 δ 42 ± 13 62.9 ± 0.7 
 
        40/0/0 
 
0.8 ß 28 ± 6 - 
3c   as 3b, but prolongation of SD at 60 °C  41 -15.4 40/10/0 V 0.2 δ 22 ± 5 66.0 ± 5.4 
 
   for 4 h 
 
  40/9.5/0.5 
 
0.4 δ 25 ± 3 58.4 ± 1.2 
 
    
 
  40/9/1 
 
0.3 δ 37 ± 25 52.4 ± 2.3 
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Run 
No. 
Process Variations Freeze-drying cycle conditions 
Run 
Time 
 [h] 
Tp 
 in PD 
[°C] 
Man/Suc/Gly 
weight 
ratio [mg/mL] 
Macroscopic 
appearance 
RM [%] 
Mannitol 
polymorphism 
Reconstitution 
time 
 [s] 
Tg 
 [°C] 
3c         40/0/0   0.2 ß 18 ± 3 - 
4 increased chamber  CN, F1 -50 °C, 1 °C/min, 1 h 28 -14 40/10/0 V 0.3 ± 0.1 δ 40 ± 28 64.8 ± 2.1 
 
 pressure A -20 °C, 1 °C/min, 2 h 
 
  40/9.5/0.5 
 
0.3 ± 0.1 δ 34 ± 5 56.4 ± 2.1 
 
  F2 -50 °C, 1 °C/min, 2 h 
 
  40/9/1 
 
0.3 ± 0.1 δ 33 ± 14 48.9 ± 1.0 
 
  PD 10 °C, 0.5 °C/min, 2.2 mbar, 6.3 h 
 
  40/0/0 
 
0.3 ± 0.1 ß 23 ± 5 - 
 
  SD 57 °C, 0.2 °C/min, 2.2 mbar, 4 h                 
5 annealing step  CN, F1 -50 °C, 1 °C/min, 2 h 24 -12.5 40/10/0 V 0.1 ± 0.1 δ 36 ± 8 68.7 ± 4.6 
 
skipped, PD 10 °C, 0.5 °C/min, 2.2 mbar, 6.3 h 
 
  40/9.5/0.5 
 
0.1 ± 0.1 δ 21 ± 6 52.1 ± 2.1 
 
accelerated SD 57 °C, 0.2 °C/min, 2.2 mbar, 4 h 
 
  40/9/1 
 
0.1 ± 0.1 δ 29 ± 8 46.2 
 
freezing       40/0/0   0.3 ± 0.1 ß 17 ± 4 - 
6 accelerated drying  CN, F1 -50 °C, 1 °C/min, 2 h 20 -13 40/10/0 V 0.1 ± 0.1 δ 29 ± 2 62.4 ± 1.4 
 
 ramps PD 10 °C, 1 °C/min, 2.2 mbar, 6.3 h 
 
  40/9.5/0.5 
 
0.1 ± 0.1 δ 26 ± 3 53.0 
 
  SD 57 °C, 0.5 °C/min, 2.2 mbar, 4 h 
 
  40/9/1 
 
0.1 ± 0.1 δ 17 ± 3 42.4 
 
        40/0/0   0.2 ± 0.1 ß 18 ± 3 - 
7 accelerated drying  CN, F1 -50 °C, 1 °C/min, 2 h 18 -10 40/10/0 V 0.9 ± 0.1 δ 36 ± 8 66.0 ± 1.4 
 ramps, PD 20 °C, 1 °C/min, 2.2 mbar, 7 h   40/9.5/0.5  0.6 ± 0.1 δ 21 ± 6 57.5 
 
increased PD shelf  SD 40 °C, 1 °C/min, 2.2 mbar, 4 h 
 
  40/9/1  0.5 ± 0.1 δ 29 ± 8 57.9 
 temp,    40/0/0   1.0 ± 0.1 ß 17 ± 4 - 
 
decreased SD shelf  
  
        
 temp,          
 prolongation of PD          
 
time             
8 reduced SD drying  CN, F1 -50 °C, 1 °C/min, 2 h 15.7 -10 40/10/0 V 1.1 ± 0.1 δ 17 ± 5 73.8 ± 0.6 
 time, PD 20 °C, 1 °C/min, 2.2 mbar, 7 h   40/9.5/0.5  0.9 ± 0.1 δ 34 ± 4 66.0 ± 0.1 
 
fast freeze-drying  SD 40 °C, 1 °C/min, 2.2 mbar, 2 h 
 
  40/9/1  0.8 ± 0.1 δ 17 ± 6 63.5 ± 2.3 
 
 cycle 
  
  40/0/0   0.9 ± 0.1 ß 17 ± 3 - 
CN – controlled nucleation step performed according to Geidobler et al. [37], F – freezing step, A – annealing step, PD – primary drying step, SD – secondary drying step, Tp  - 
product temperature in the steady state of PD.
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The addition of amorphous excipients led to modified crystallization behaviour of Man. In all 
formulations including an amorphous phase, Man crystallized mainly as δ-Man as it was 
shown by Johnson et al. for the Man/Suc 40/10 ratio [5]. The small amount of glycerol had no 
measurable effect on Man crystallization. In contrast, pure Man resulted in the ß-form with 
the applied cooling rate of 1 °C/min. Kim et al. reported that slow freezing (0.2 °C/min) of 
10% Man led to a mixture of α- and ß-Man, fast freezing in liquid nitrogen  to mainly δ-Man 
whereas a 5% solution formed to ß-Man confirming our results [45]. Which Man modification 
forms thus depends on freezing protocol, process conditions, Man concentration and 
additional excipients [5,13,45,46]. 
The secondary drying temperature apparently affected the amount of hemihydrate left in the 
lyophilizate after drying. Secondary drying temperatures above or equal to 40 °C  forced 
most likely the transformation of the hemihydrate into anhydrous Man forms as no 
hemihydrate could be detected by XRD. High annealing temperatures during freezing were 
also shown to impact the formation of Man-hemihydrate more than the secondary drying 
temperature [13]. This emphasizes the complexity of factors that determine the formation of 
hemihydrate in the final lyophile. 
 
Man/Suc/Glycerol ratio  40/10/0 40/9.5/0.5 40/9/1 40/0/0 
Conservative FD 
    
Fast FD 
    
Figure 5-1. Macroscopic appearance of Man/Suc/Glycerol lyophilizates that differ in Man/Suc/Glycerol 
ratio and freeze-drying cycle (Table 1, Process 1 / Process 8). 
 
All lyophilizates exhibited an elegant macroscopic appearance without defects due to the 
crystalline Man scaffold. Collapse of the amorphous fraction was not visible (Figure 5-1). RM 
could be set into the required target value of about 1%. Tg values were in the expected 
range of Suc above 50 °C with the given RM. As expected Tg decreased with addition of the 
plasticizing agent glycerol. Reconstitution was fast and did not change throughout the 
process development. Annealing could be skipped without any change in the product 
characteristics. As controlled nucleation (CN) was performed, we assume that the 
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equilibration time in the supercooled state and the ice nucleation itself play a major role in 
facilitating Man crystallization making the annealing step redundant. Additionally, increased 
heating or cooling rates of 1 °C/min were not detrimental for product quality. Consequently, 
this cycle fulfilled all the requirements for a fast cycle without loss in product quality. The total 
run time in the final fast freeze-drying process was 15.7 hours. 
 
3.2. Investigation of Different Mannitol/Sucrose Ratios 
40/10 ratio of mannitol to sucrose was used for cycle development as this is known to be 
beneficial for complete mannitol crystallization [5,13]. However, a higher percentage of the 
amorphous stabilizer sucrose would be advantageous in order to achieve a high stabilizer to 
protein ratio, in particular for high concentrated protein formulations. A molar ratio of protein 
to sucrose of 3600:1 has been shown to be necessary for lyophilized mAb formulations [47]. 
In our accelerated cycle conditions the Tp of -10 °C was 25 °C, hence clearly, above the Tg’ 
value of mannitol [10]. Therefore, the crystallization tendency of mannitol might be favored. 
Previous studies on different Man/Suc ratios were performed at a Tp below the Tg’ of 
mannitol [13,48,49]. Therefore, lower Man/Suc ratios were first tested in the fast freeze-
drying cycle regarding their potential for complete mannitol crystallization.  
Both the freezing step, in particular the nucleation technique or an annealing step, affect the 
crystallization of mannitol [33,35,50–53]. Therefore, three different freezing techniques were 
also tested: (i) isothermal hold at -5C for 1 h (no CN), (ii) shelf ramp cooling followed by 
annealing at -20 °C for 2 h, and (iii) isothermal hold at -5 °C for 1 h followed by CN. [37]. 
 
Macroscopic Appearance 
Figure 5-2 shows representative images of the lyophilized samples obtained from different 
freezing protocols and different Man/Suc ratios. Samples subjected to CN exhibited better 
cake appearance, in particular at the low Man/Suc ratios (20/30, 25/25). Once the Man/Suc 
ratio was sufficiently high an appropriate (30/20) or good (40/10) cake appearance was 
found. CN samples did not show macroscopic collapse at all Man/Suc ratios although large 
pores and skin formation pointed at incomplete Man crystallization upon freezing at the low 
Man/Suc ratios (20/30, 25/25). 
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Man/Suc ratio  20/30 25/25 30/20 40/10 
CN 
    
Hold for 1 h at -5 °C 
    
Annealing for 2 h at 
-20 °C 
    
Figure 5-2. Macroscopic appearance of Man/Suc lyophilizates that differ in Man/Suc ratio and freezing 
protocol. The fast freeze-drying cycle (Table 5-1, Process 8) was performed with adjusted freezing 
protocols. 
 
Phase behavior of mannitol XRD diffractograms demonstrated that Man crystallization 
occurred at all Man/Suc ratios with all three freezing protocols (Figure 5-3). Within one 
freezing procedure, the crystallization behavior of the four different Man/Suc ratios was 
similar. CN led to a mixture of ß-Man, δ-Man and Man-hemihydrate, whereas samples that 
were held at -5 °C for one hour were dominated by the ß-polymorphs and less δ-Man and 
Man-hemihydrate, with annealing at -20 °C ß-Man resulted. Thus, the freezing protocol has a 
major impact on the product characteristics of the lyophilizate which is in accordance with 
literature [43] whereas the Man to sucrose ratio had less effect. Crystalline Man was found in 
all lyophilizates although the macroscopic appearance indicated collapse at all Man/Suc 
ratios of 25/25 and lower. This indicates delayed Man crystallization in the PD and not during 
freezing. Incomplete scaffold formation by the crystalline Man would be another explanation. 
 
Differential Scanning Calorimetry 
In DSC only Man/Suc 40/10 samples did not show an exotherm during the first heating scan 
indicating complete mannitol crystallization (Figure 5-3). At lower Man/Suc ratio 
recrystallization peaks occurred, demonstrating crystallization of amorphous mannitol while 
they were less pronounced at Man/Suc 30/20 compared to the lower ratios of 25/25 and 
20/30. We speculate that small amounts of amorphous Manl remained at the 30/20 Man/Suc 
ratio. The second DSC scan did not show an exothermic peak in all formulations indicating 
complete mannitol crystallization after the first heating scan. Correspondingly, with increasing 
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mannitol content and thus higher mannitol crystallinity, Tg values increased. Samples of the 
lowest Man/Suc ratio of 20/30 showed a Tg value of 27.9 °C after different freezing protocols 
whereas at Man/Suc 40/10 ratio and holding for one hour at -5 °C resulted in a Tg of 55.2 °C. 
A Tg value of 12 °C is reported for dry amorphous mannitol and of 75 °C for amorphous 
sucrose [13,54]. Thus, the Tg value of the 20/30 ratio was probably decreased by amorphous 
mannitol while the Tg value of Man/Suc 40/10 was dominated by only sucrose due to 
complete mannitol crystallization. 
Resulting from this study, Man/Suc 40/10 was used for subsequent experiments since 
complete mannitol crystallization is a prerequisite which can be further diminished by 
proteins and should be avoided. 
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 Mannitol polymorphism DSC scan 
CN 
  
 
Hold for 1 h at 
-5 °C 
  
 
Annealing for 2 h 
at -20 °C 
  
 
 
Man/Suc  
Figure 5-3. XRPD and DSC of Man/Suc lyophilizates that differ in Man/Suc ratio and freezing protocol. The 
fast freeze-drying cycle was performed with adjusted freezing protocols (Table 5-1, Process 8). Mannitol 
polymorphs are marked, * refers to mannitol-hemihydrate. 
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3.3. Comparison Study of Fast and Conservative Freeze-Drying 
Cycle 
The fast freeze-drying cycle with Tp during PD above Tg’ of the amorphous phase was 
compared to a conservative cycle with Tp below Tg’ (see Table 5-1, processes 8 and 1).With 
Tg’ values of -33.7 °C, -37.2 °C and -38.2 °C of Man/Suc/Glycerol 40/10/0, 40/9.5/0.5, and 
40/9/1, respectively, threshold Tp of -39 °C was chosen for PD below Tg’ for all formulations. 
Three different proteins were investigated at two concentrations and four different 
Man/Suc/Glycerol ratios. 
 
3.3.1. Physical Characterization of the Lyophilizates 
 
Macroscopic Appearance 
The macroscopic appearance of lyophilizates is an important characteristic although it does 
not determine protein stability [16,17,55,56]. Furthermore, it is up to discussion which 
appearance is acceptable [22]. 
 
Figure 5-4. Macroscopic appearance of Protein/Man/Suc (x/40/10) formulations after conservative (Table 
5-1, Process 1) and fast (Table 5-1, Process 8) freeze-drying. 
 Placebo 
mAb1 mAb2 Lysozyme 
2 mg/mL
 
7.5 mg/mL
 
2 mg/mL
 
80 mg/mL
 
2 mg/mL
 
100 mg/mL
 
Conservative 
FD 
       
Fast FD 
       
 
Vials containing Protein/Man/Suc x/40/10 formulations are shown in Figure 5-4. Independent 
of the freeze-drying cycle, the protein type and content, the protein formulations at different 
Man/Suc/Glycerol ratios showed similar adequate cake appearance (see supplementary 
material). At higher protein concentration, especially in products dried with the fast cycle, 
fogging was observed. This creeping of product at the inner vial surface is related to the 
presence of surface active ingredients (surfactants or a surface active API). At higher protein 
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content the surface pressure may be higher [57] and change in surface pressure could foster 
fogging. Regularly, fogging is caused by maragoni flow in the liquid state and could not be 
caused by the drying process. It occurs on the hydrophilic vial surface and could be avoided 
by using hydrophobic vials [36]. We used regular type I borosilicate glass after cleaning with 
HPW. Long time periods between liquid filling and the start of freeze-drying are critical 
enabling creeping at the inner vial surface. 
 
Sample morphology (XRPD) 
Additionally, the lyophilizates were characterized regarding the Man polymorphs (Table 5-2). 
Proteins as well as other formulation components are able to suppress or modify the 
crystallization behavior of Man [13,14,34,49,58]. Pure Man exhibited the ß-Man after both 
freeze-drying processes while the addition of protein induced the formation of mainly δ-Man. 
Grohganz et al. demonstrated the same behavior for lysozyme [49]. Our results also showed 
that the mAbs and Suc ± Glycerol as excipients without protein induced the same shift to δ-
Man. Typically, the formulation with the highest protein content showed lower peak heights 
corresponding to crystalline Man (see supplementary material, Figure 8-4). 
 
Table 5-2. Mannitol modifications in Protein/Man/Suc/Glycerol lyophilizates. Formulations were freeze-
dried with conservative (Table 5-1, Process 1) or fast (Table 5-1, Process 8) process conditions. 
Formulation 
Man/Suc 
40/10 
Man/Suc/Glycerol 
40/9.5/0.5 
Man/Suc/Glycerol 
40/9/1 
Man 
40 
 
Cons 
FD 
Fast FD Cons FD Fast FD Cons FD Fast FD 
Cons 
FD 
Fast FD 
Placebo δ, hh δ, ß
1
,hh
1
 δ, hh δ, ß δ, hh δ, ß
1
 ß ß 
mAb1
 
2 mg/mL
 
δ δ δ, hh δ δ δ δ δ 
7.5 mg/mL δ, hh δ δ, hh δ δ, hh δ δ δ 
mAb2 
2 mg/mL δ, hh δ δ, hh δ δ δ δ δ 
80 mg/mL
 
δ
1 
δ
1
 δ
1
 δ
1
 δ
1
 δ
1
 δ
1
 δ
1
 
Lyso
 
2 mg/mL
 
δ, hh δ δ, hh δ δ, hh δ δ δ, ß 
100 mg/mL
 
δ
1
 δ
1
 δ
1
 δ
1
 δ
1
 δ
1
 δ
1
 δ
1
 
hh refers to mannitol-hemihydrate, 
1
 only weak signal. 
 
Almost all samples prepared with the conservative freeze-drying cycle also showed the 
hemihydrate peak at 17.9°. This was probably due to the lower secondary drying 
temperature (20 °C) as compared to the fast freeze-drying cycle (40 °C). During development 
of the fast freeze-drying cycle (Table 5-1, Process 3) the hemihydrate content decreased 
with increasing secondary drying temperature. 
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Tg and RM 
Figure 5-5 shows that the RM values of the formulations processed with the fast freeze-
drying cycle lay within the targeted range of 1%. The conservative freeze-drying cycle 
showed consistent results. Thus, the samples produced by the fast freeze-drying cycle 
rendered the same Tg and RM as samples dried by the conservative process. The Tg of a 
multi component system depends on the ratio of the individual components and their specific 
Tg [59]. Both water (Tg: -108 °C / -137 °C [60,61]) and glycerol (Tg: -93 °C [29]) act as 
plasticizing agents and decrease the Tg but were present at only low concentrations in the 
samples. The measured Tg values are characterized by the main amorphous compound Suc 
(Tg: 75 °C [54], Figure 5-5) due to the low RM values. 
 
A. Man/Suc 40/10 B. Man/Suc/Glycerol 40/9.5/0.5 
  
C. Man/Suc/Glycerol 40/9/1 D. Man 40 
  
Figure 5-5. Tg (symbols) and RM (bars) of Protein/Man/Suc/Glycerol lyophilizates. A-D shows the different 
Man/Suc/Glycerol ratios. Formulations were freeze-dried with conservative (black, Table 5-1, Process 1) 
or fast (grey, Table 5-1, Process 8) process conditions. n≥3: mean ± SD; n=2: mean. 
 
Reconstitution Time 
Reconstitution time is an important quality attribute and depends on protein concentration, 
crystallinity and wettability of the excipients, chosen reconstitution method or storage 
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conditions, for example [62–65]. The process itself has little influence unless the process 
influenced the crystallinity of the excipients. It was described that fast freezing in liquid 
nitrogen enabled faster reconstitution than slow freezing with a 0.2 °C/min ramp [45]. This 
was explained by the different distribution of Man polymorphs on the one hand, and on the 
other hand by the number and size of the ice crystals that lead to different specific surface 
area. Annealing can both improve [35] or prolong [66] reconstitution. Recent studies indicate 
that not annealing but the cooling rate during freezing affects the reconstitution time by 
changing the pore size of the dried matrix [67]. Thus, not the surface area but the ability to 
penetrate into pores explains the reconstitution behaviour. Improved reconstitution times by 
CN were also explained by the changed cake morphology and hence better wettability and 
penetration of the liquid into the pores [68]. 
 
 
Figure 5-6. Reconstitution times of Protein/Man/Suc/Glycerol lyophilizates. Formulations were freeze-
dried with conservative (black circles, Table 5-1, Process 1) or fast (grey squares, Table 5-1, Process 8) 
process conditions. n≥3: mean ± SD. Data of placebo formulations can be found inTable 5-1, Process 8; 
Process 1. 
 
All samples showed fast reconstitution within less than 100 seconds (Figure 5-6). A clear 
difference of the freeze-drying cycles could be detected. Placebo and low concentrated 
lysozyme (2 mg/mL) formulations reconstituted within 30 s. All other formulations 
reconstituted within the same time when dried with the conservative cycle but significantly 
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slower when dried with the fast freeze-drying cycle. It appears that the collapsed amorphous 
phase consisting of Suc, protein and glycerol hinders the access of water to non-dissolved 
matrix. However, the prolonged reconstitution was not observed for placebo formulations and 
for low concentrated lysozyme formulations. Thus, the incorporation of protein into the 
amorphous matrix seems to play a role. The total mass of collapsed amorphous matrix was 
increased in the high concentrated protein formulations. Since the low concentration mAb 
formulations differed from the lysozyme formulations also the protein characteristics are 
important. Bosch measured also different reconstitution times of lyophilizates that were dried 
at different chamber pressures [17]. Increased chamber pressure during drying prolonged 
reconstitution times to a small degree in phenylalanine - trehalose lyophilizates. Others 
described that reconstitution times did not differ between collapsed and non-collapsed 
lyophilizates [15,18]. 
 
3.3.2. Protein Process Stability 
The formulations were characterized regarding their protein stability after freeze-drying in 
terms of insoluble and soluble aggregates. 
 
Turbidity – A350 nm 
Absorbance at 350 nm was measured before freeze-drying and after reconstitution since 
insoluble aggregates larger than 35 nm scatter the light at this wavelength [69]. All 
formulations were clear upon visual inspection of any sign that large aggregates formed upon 
freeze-drying. This was confirmed by the low turbidity values below 0.06 AU except for the 
highly concentrated protein formulations (mAb2 80 mg/mL, lysozyme 100 mg/mL) which 
resulted in higher absorbance. There was no difference between samples dried with fast or 
conservative cycle. 
 
Sub-Visible Particle Analysis 
Sub-visible particles were characterized by light obscuration. Placebo formulations did not 
show an increase in particle numbers after freeze-drying and reconstitution. In contrast, 
particles ≥ 1 µm increased to 30.000 - 40.000 particles per mL in the mAb formulations and 
to approximately 10.000 particles per mL in the lysozyme formulations. Concentration of the 
protein, formulation composition or freeze-drying cycle conditions showed no significant 
impact on the number of particles. This increase and the number of particles after freeze-
drying is commonly observed if no surfactant is included in the formulation [70]. All 
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formulations showed 50 – 200 particles per mL ≥ 10 µm and thus numbers below the 
specification given in the pharmacopoeias (<6000 per mL [40,71]). Only the 80 mg/mL mAb2 
formulations showed a pronounced increase to approximately 1000-2000 particles per mL for 
all formulations regardless of the applied freeze-drying cycle. Similarly, the formulations 
exhibited less than 50 particles per mL, but 100-150 particles per mL for mAb2 80 mg/mL for 
particles ≥ 25 µm without impact of the lyophilisation cycle. 
 
Soluble Aggregates 
HP-SEC indicated no loss in monomer recovery after freeze-drying for both freeze-drying 
protocols. Probably due to the total absence of surfactants, the formulations exhibited a slight 
increase in higher molecular weight species to less than 1% aggregates and less than 1.5% 
in Man 40 formulations without amorphous phase (Figure 5-7). 
 
Figure 5-7. Soluble aggregates of mAb/Man/Suc/Gly formulations determined by HP-SEC. Formulations of 
conservative (black bars, Table 5-1, Process 1) and fast (grey bars, Table 5-1, Process 8) freeze-drying 
cycles are shown. n=3: mean ± SD. 
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3.4. Impact of Glycerol on Protein/Man/Suc/Glycerol formulations 
Glycerol was chosen as formulation component as it was previously shown that there might 
be additional protein stabilizing effects due to prolonged ß-relaxation times [25,26,72]. 
Macroscopic appearance, reconstitution times, mannitol crystallinity and also protein process 
stability did not change significantly with addition of glycerol. Only a decrease of Tg values 
was determined as expected. Still, long time stability improvement of the proteins cannot be 
excluded, however, could not be confirmed in this study. 
 
4. Conclusion 
This study focused on maximum time reduction of the conservative freeze-drying process 
without losing protein process stability. The crystalline Man scaffold was used to gain elegant 
cake appearance while Suc acted as amorphous protein stabilizer. High Tp during PD led to 
collapse of the amorphous phase which was already shown not to be detrimental for protein 
stability [15–21]. The freeze-drying process could be shortened tremendously, e.g. PD time 
from 47 hours at -39 °C Tp to 7 hours at -10 °C Tp. Man crystallization was mainly affected 
by different Man/Suc ratios. Only a Man/Suc 40/10 ratio rendered complete Man 
crystallization. RM, Tg values, Man crystallinity, macroscopic appearance and also 
reconstitution times showed good results. The comparison of conservative and fast freeze-
drying with different protein formulations showed that collapse of the amorphous phase did 
not lead to instabilization of the proteins during the process. Thus the fast freeze-drying 
process enabled fast process times without defects of cake appearance and protein process 
stability. 
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Abstract 
Bulking agents as mannitol (Man) and glycine (Gly) require high bulking agent to stabilizer 
ratios to ensure their crystallization during the freeze-drying process. The aim of this study 
was to investigate several amino acids (AA) as potential alternative bulking agents in low AA 
to sucrose (Suc) ratios. A fast freeze-drying process was performed above the collapse 
temperature (Tc) of the amorphous phase challenging the crystalline AA scaffold. 
Lyophilizates and liquid formulations were characterized by differential scanning calorimetry. 
Karl-Fischer titration and X-ray powder diffraction as well as macroscopic cake appearance 
and reconstitution times were evaluated. Stability of a monoclonal antibody was investigated 
by UV-Vis spectroscopy, light obscuration and size exclusion chromatography. 
Phenylalanine (Phe), leucine (Leu) and isoleucine (Ile) crystallized upon freeze-drying at 5/45 
and 10/40 AA/Suc ratios. 2.5/47.5 AA/Suc ratio showed less pronounced crystallization. 
Crystallization peaks were not suppressed by 2 or 50 mg/mL antibody in Leu and Ile 
lyophilizates. Reconstitution times could be improved by addition of surfactant. No signs of 
protein aggregation were detected after freeze-drying. Man and Gly yielded inacceptable 
cake appearance when dried with the fast freeze-drying cycle in such low bulking agent to 
Suc ratios. Leu, Ile and Phe can be used as alternate bulking agents at lower bulking agent 
to Suc ratios compared to Man or Gly. The selected AAs provided promising cake 
characteristics and good protein process stability. 
 
Keywords 
Freeze-drying, lyophilization, amino acid, leucine, isoleucine, phenylalanine, mannitol, 
bulking agent, crystallization, sucrose, protein stability, glass transition, collapse 
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Abbreviations 
AA Amino acid 
AU Absorbance unit 
aFD After freeze-drying 
API Active pharmaceutical ingredient 
AUC Area under the curve 
bFD Before freeze-drying 
FD Freeze-drying 
Gly Glycine 
His Histidine 
HP-SEC High performance size exclusion chromatography 
HPW Highly purified water 
Ile Isoleucine 
Leu Leucine 
LO Light obscuration 
mAb Monoclonal antibody 
Man Mannitol 
DSC Differential scanning calorimetry 
Met Methionine 
Phe Phenylalanine 
PS 20 / 80 Polysorbate 20 / 80 
RM Residual Moisture 
SD Standard deviation 
Suc Sucrose 
Tc Collapse temperature 
Te Eutectic temperature 
Tg Glass transition temperature of the freeze-dried cake 
Tg’ Glass transition temperature of the maximally freeze-concentrated 
solution 
Tp Product temperature 
XRPD X-Ray powder diffraction 
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1. Introduction 
Freeze-drying of biopharmaceuticals is one approach to prolong their shelf life [1]. In order to 
achieve acceptable cake appearance drying below the glass transition temperature of the 
freeze-concentrate (Tg’) or at least below the collapse temperature (Tc) is recommended 
[2,3]. Operating at product temperatures (Tp) below Tg’ and Tc may correspond to long 
drying times depending on the choice of excipients and the protein concentration [2–4]. In 
fact, high protein concentrations were reported to increase both, Tg’ and specifically Tc, 
enabling faster drying at higher Tp [3]. Drying at even higher Tp would be favourable, 
especially at low protein concentration, but the resulting macrocollapse would result in 
rejected batches [5]. Collapse of freeze-dried matrices was already reported not to be 
detrimental for protein stability in some cases [6–10]. The use of crystalline bulking agents 
can solve this problem. Bulking agents are typically used to cover undesired cake 
appearance as “fillers” if the API dosage is low and they can also help to adjust tonicity [11–
13]. Drying of crystalline bulking agents is not limited by Tg’, but by their eutectic melting 
temperature (Te) which is markedly higher [14]. Since the crystalline excipients do not 
provide stabilization of the API like the amorphous cryo- and lyoprotectants, low 
concentrations are preferred. Unfortunately, the crystallisation is affected by the other 
formulation components such as the sugars used as cryo-and lyoprotectant, buffer 
components and the protein drug itself [12,15–17]. Mannitol (Man) as one of the common 
used bulking agents typically requires a 4/1 ratio of Man to sucrose (Suc) for complete 
crystallization [18,19]. Incomplete crystallization can lead to subsequent crystallization during 
storage which might induce instability reactions or lead to inadequate cake appearance due 
to collapse of the whole matrix. Highly concentrated protein formulations can facilitate 
incomplete crystallization despite high Tc of the formulation. Thus, the essential ratio of 
bulking agent to amorphous stabilizer needs to be established in order to ensure crystallinity 
of the bulking agent. A lower bulking agent concentration would hence be favoured in 
exchange for a higher stabilizer concentration without loss of cake appearance if dried above 
Tc in a fast feeze-drying cycle. 
A few amino acids (AA) are known for their crystallization tendency upon freeze-drying. 
Table 6-1 gives an overview of the common AAs ordered by hydrophobicity. Their 
crystallization tendency upon freeze-drying was investigated in a few studies. The most 
comprehensive studies are based on glycine (Gly) [6,20–28]. Although it shows a higher 
crystallization tendency than Man [22], the essential Gly/Suc ratio to induce Gly 
crystallization is still approximately 5/2 [20]. Recently, a variety of AAs was compared to Suc 
regarding their potential to stabilize proteins [29]. Almost all AAs showed beneficial results 
upon two months storage of lyophilizates at 50 °C. Crystallinity of the products was not 
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evaluated. Arginine, glutamine, Gly and histidine showed crystallization tendency with 
substantial impact of the counter-ion in case of arginine combined with citric acid [30–34]. 
Table 6-1. Physico-chemical characteristics of AAs and Man. They are sorted by their hydrophobicity. 
Man was included for comparison purposes. 
Amino Acid / 
Additive 
Hydro-
phobicity 
[35] 
Sample morphology aFD of 
pI [36] 
pka1 
(COOH) at 
25 °C 
[36–38] 
pka2 (NH4
+
) 
at 25 °C 
[36,39] 
Solubility at 
25 °C 
[g/100 g] 
[38,40] 
pure AA 
solution 
[41,42] 
AA/Suc 
2.5/47.5 
solutions [8] 
Isoleucine 1.000 Crystalline Crystalline 6.05 2.32 9.76 4.12 
Phenylalanine 0.951 Crystalline Amorphous 5.49 2.16 9.18 2.97 
Valine 0.923 Crystalline - 6.00 2.29 9.74 8.86 
Leucine 0.918 Crystalline Crystalline 6.01 2.33 9.74 2.19 
Methionine 0.811 Crystalline Crystalline 5.74 2.13 9.28 3.38 
Alanine 0.806 Crystalline - 6.11 2.35 9.87 16.51 
Glycine 0.770 Crystalline Amorphous 6.06 2.35 9.78 24.99 
Cysteine 0.721 Crystalline - 5.05 1.92 10.78 - 
Proline 0.678 Crystalline - 6.30 2.95 10.65 162.3 
Threonine 0.634 Crystalline - 5.60 2.09 9.10 - 
Serine 0.601 Crystalline - 5.68 2.19 9.21 5.02 
Histidine 0.548 Tg = 37 °C Amorphous 7.60 1.80 9.33 4.29 
Glutamic acid 0.458 - - 3.15 2.10 9.47 0.84 
Glutamine 0.430 - - 5.65 2.17 9.13 - 
Aspartic acid 0.417 - - 2.85 1.99 9.90 0.50 
Lysine 0.263 Tg = 68 °C - 9.60 2.16 9.78 - 
Arginine 0.000 Tg = 42 °C Amorphous 10.76 1.82 8.99 - 
Mannitol - Crystalline  - - 13.5 - 21.6 
AA – Amino acid, aFD – after freeze-drying. 
Phenylalanine is a promising candidate. Vacuum-drying time could be accelerated if Phe was 
included into Suc/rhG-CSF formulations due to Phe crystallization, without losing protein 
stability [43]. Phe, leucine (Leu), isoleucine (Ile) and methionine (Met) combined with 
trehalose and sucrose showed crystalline structures after “aggressive” freeze-drying [8]. A 
low AA/stabilizer ratio of only 2.5/47.5 was sufficient to detect crystallization peaks via XRPD. 
An acceptable macroscopic appearance and considerably lower residual moisture levels 
compared to other AAs were found. Consequently, in the present study, Phe, Leu, Ile and 
Met were evaluated as potential crystalline bulking agents that could be used at much lower 
concentrations compared to the typical bulking agents Man and Gly. Additionally, the 
crystalline AA scaffolds should be mechanically stable enough to enable fast drying at high 
Tp above Tc of the amorphous phase. The cycle may require optimization including a 
potential annealing step to foster crystallization in terms of best balance between fast 
process and satisfying AA crystallization [24,44,45]. 
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One of the drawbacks of the AAs with a higher crystallization tendency is their poor solubility 
in water due to their mainly hydrophobic character (Table 6-1). Their use in high 
concentrations is hence additionally limited. Furthermore, AAs can react sensitively on 
changes of the pH environment because of their dipolar character. Consequently, also the 
effect of pH on the bulking agent properties of the AAs was to be evaluated. 
For this study, three AA/Suc ratios with increasing AA content were investigated: 2.5/47.5, 
5/45 and 10/40 with Phe, Ile, Leu, and Met. The aim of this study was to establish alternative 
bulking agents that (1) crystallize in low bulking agent to Suc ratio and (2) crystallize at fast 
freeze-drying cycle conditions above the formulations’ Tg’. It was further focused on the 
impact of pH, annealing step, chamber pressure and protein concentration on AA 
crystallization and other cake characteristics as macroscopic appearance, glass transition 
temperature (Tg) or reconstitution time. 
 
2. Materials and Methods 
2.1. Materials 
Stock solutions of L-glycine (m/V) (VWR International, Ismaning, Germany), L-isoleucine 
(m/V) (Sigma-Aldrich Chemie GmbH, Steinheim, Germany), L-leucine (m/V) (Sigma-Aldrich 
Chemie GmbH), L-methionine (m/V) (Sigma-Aldrich Chemie GmbH), L-phenylalanine (m/V) 
(Sigma-Aldrich Chemie GmbH), D-mannitol (m/V) (VWR International), Poloxamer 188 (m/m) 
(Kolliphor® P188, BASF AG, Ludwigshafen am Rhein, Germany), polysorbate 20 (m/m) 
(Tween® 20, VWR International), polysorbate 80 (m/m) (Tween® 80, VWR International), 
and sucrose (m/V) (Sigma-Aldrich Chemie GmbH) were prepared in highly purified water 
(HPW) or in 10 mM L-histidine (Sigma-Aldrich Chemie GmbH) buffer pH 6.0 if protein was 
included in the formulation. The pH of aqueous solutions without histidine was adjusted with 
sodium hydroxide or hydrochloric acid. Different bulking agent/sucrose (AA/Suc or Man/Suc) 
weight ratios were investigated: 2.5/47.5, 5/45 and 10/40 [mg/mL]. Bulking agents were 
amino acids or mannitol. The formulations were filtered with 0.2 µm polyethersulfone 
membrane syringe filters (VWR International GmbH) prior to use. 
A monoclonal IgG1 antibody (MW ~ 150 kDa, ε = 1.49 mL mg
-1 cm-1, referred to as mAb) 
served as model protein. A 81 mg/mL (for 5/45 AA/Suc formulations) or 94 mg/mL (for 10/40 
AA/Suc formulations) mAb stock solution in 10 mM L-histidine buffer pH 6.0 was prepared by 
tangential flow filtration in MinimateTM capsules (30 kDa Omega membrane, PALL Life 
Science, Port Washington, NY, USA). The protein was formulated at 2 mg/mL and 
50 mg/mL. 
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2.2. Methods 
2.2.1. Lyophilization 
Lyophilization stoppers (Westar®, B2-TR coating, West Pharmaceutical Services 
Deutschland GmbH & Co. KG, Eschweiler, Germany) and ISO 2R Vials (Fiolax®, Schott AG, 
Mainz, Germany) were cleaned with HPW and dried for 8 hours at 100 °C and 40 °C, 
respectively. 1.2 mL sample per vial were investigated. The two outer rows of vials in the 
batch were not used for subsequent analysis: this is due the fact they are also heated by 
radiation from chamber walls, beside the shelf, and, thus, additional and uncontrolled 
overheating may occur. Thermocouples were placed center bottom in different vials within 
the freeze-dryer. 
The formulations were freeze-dried according to the protocols given in Table 6-2 to Table 6-
5. At first, the operating conditions were selected in such a way that the limit product 
temperature is trespassed in all the formulations investigated (Table 6-2; Table 6-3), and the 
influence of the annealing step in the freezing stage was investigated. Then, with the goal of 
improving cake appearance, the original cycle was modified in such a way that product 
temperature is lowered: chamber pressure was decreased to reach this goal, at first to 0.52 
mbar (Table 6-4) and, then, to 0.4 mbar (Table 6-5). An FTS Lyostar 3 (SP Scientific, Stone 
Ridge, USA) and an Epsilon 2D-6 LSCplus (Martin Christ Gefriertrocknungsanlagen GmbH, 
Osterode am Harz, Germany) were used. The end of primary drying was controlled by 
comparative pressure measurement between Pirani and MKS sensor (FTS) or set manually 
(Christ). After secondary drying, the vials were stoppered under nitrogen atmosphere at 
800 mbar, crimped with flip-off seals and stored at 2-8 °C. 
Table 6-2. Freeze-drying cycle with annealing step ran on the Christ freeze-dryer (Cycle 1). 
Step Ramp [°C min
-1
] Shelf temperature [°C] Pressure [mbar] Hold Time [min] 
Freezing 1 1 -50 - 60 
Annealing 1 -20 - 120 
Freezing 2 1 -50 - 120 
Primary Drying 1 20 2.2 420 
Secondary Drying 1 40 2.2 120 
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Table 6-3. Freeze-drying cycle without annealing step ran on the Christ freeze-dryer (Cycle 2). 
Step Ramp [°C min
-1
] Shelf temperature [°C] Pressure [mbar] Hold Time [min] 
Freezing 1 -50 - 120 
Primary Drying 1 20 2.2 420 
Secondary Drying 1 40 2.2 120 
 
Table 6-4. Freeze-drying cycle without annealing step and at reduced chamber pressure of 0.52 mbar ran 
on the FTS freeze-dryer (Cycle 3). 
Step Ramp [°C min
-1
] Shelf temperature [°C] Pressure [mbar] Hold Time [min] 
Freezing 1 -50 - 120 
Primary Drying 1 20 0.52 750 
Secondary Drying 1 40 0.52 120 
 
Table 6-5. Freeze-drying cycle without annealing step and at reduced chamber pressure of 0.40 mbar ran 
on the Christ freeze-dryer (Cycle 4). 
Step Ramp [°C min
-1
] Shelf temperature [°C] Pressure [mbar] Hold Time [min] 
Freezing 1 -50 - 120 
Primary Drying 1 0 0.40 1200 
Secondary Drying 1 40 0.40 120 
 
2.2.2. Macroscopic Appearance 
Macroscopic appearance was evaluated visually and pictures were taken with a Nikon digital 
camera D5300 (Nikon GmbH, Düsseldorf, Germany) in a black photobox. 
 
2.2.3. Digital Microscopy 
Digital microscopy was performed with the digital microscope Keyence VHX-500F (Keyence 
Corporation, Osaka, Japan). The lyophilizates were extracted from the vial without 
destruction of the cake. A 50-fold magnification was recorded. 
 
2.2.4. Differential Scanning Calorimetry (DSC) 
Glass transition temperatures (Tg) of the lyophilizates were determined with a Mettler Toledo 
DSC 821e (Mettler-Toledo GmbH, Giessen, Germany). Samples were prepared under 
controlled humidity conditions (< 10% r. h.). 5 to 15 mg of crushed cake were weighted into 
aluminum crucibles and sealed hermetically. The modulated DSC scan was conducted from 
25 °C to 100 °C or 140 °C at 2°C/min and modulated with an amplitude of ± 1°C every 120 s. 
The Mettler StarE Software was used for data analysis. 
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Glass transition temperatures of maximally freeze-concentrated solutions (Tg’) were 
evaluated with the same instrument and additionally with a DSC 204 Phoenix (Netzsch, Selb, 
Germany). 30 µL of the liquid formulations were investigated in hermetically sealed crucibles. 
Samples were cooled at 10 °C/min from 20 °C to -60 °C (Mettler) and -100 °C (Netzsch), 
respectively, and heated to 20 °C at the same rate. 
 
2.2.5. Karl-Fischer Titration 
Karl Fischer titration was used to determine the residual moisture (RM) of the freeze-dried 
cakes. It was performed with an Aqua 40.00 titrator (Analytik Jena AG, Halle, Germany) 
connected to a headspace oven set at constant temperature of 100 °C. For analysis, 5 to 
20 mg of crushed cake were transferred to 2 R vials under controlled humidity conditions 
(< 10% r. h.). 
 
2.2.6. X-Ray Powder Diffraction (XRPD) 
Crystallinity of the excipients was determined by XRPD. An XRD 3000 TT diffractometer 
(Rich. Seifert & Co. GmbH &Co. KG, Ahrensburg, Germany) equipped with a copper anode 
(40 kV, 30 mA, λ = 0.154178 nm) and a scintillation detector at 1000 V was used. The 
freeze-dried samples were crushed and smoothened homogenously on copper sample 
holders of 0.2 mm height. Samples were analyzed in steps of 0.05° 2-Θ for 2 s/step from 
5 to 45° 2-Θ. Reference peaks used for identification of the crystalline phases are listed in 
Table 6-6. 
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Table 6-6. Reference XRPD peaks of the excipients. 
Excipient Main peaks [° 2-θ] References 
Sucrose 11.8 12.7 13.1 18.9 20.9 24.8 25.2  [46–48] 
Phenylalanine hydrate 6.4 14.7 17.4 21.3     [8] 
hydrate 6.8 10.9 15.2 17.9 21.7 24.1 26.6 27.9 [49] 
hydrate 6.4 8.4 13.8 17.4 19.3 20.7 22.4 27.5 [50] 
 anhydrate 5.7   17.1  22.8 28.6 34.5 [49] 
 anhydrate 5.5   16.9 17.7 22.6 28.4 34.3 [50] 
Isoleucine 6.5 13.0  25.7 32.4    [51] 
6.4 12.8 19.1 25.4 32.3 38.6   [8,52] 
Leucine 6.1        [8] 
6.5  19.2 24.4 30.6    [51] 
6.4 12.3 19.1 24.4 30.7    [53] 
Methionine 5.8        [8] 
6.1 23.6 35.2      [51] 
Mannitol α 9.3 13.7 17.2 18.7     [54–56] 
ß 10.4 14.6  18.8 20.3 23.4   
δ 9.7    20.4 22.0 24.6 25.3 
 hemihydrate 9.6  17.9   23.1  25.7 
 
2.2.7. Reconstitution Time 
Reconstitution times were determined by dissolving the lyophilizates with the required 
volume of HPW. The reconstitution volume was calculated based on formulation density and 
solid content. The time until complete dissolution of the cake was considered. The vials were 
gently rolled to ensure wetting. 
 
2.2.8. Turbidity 
Turbidity of the samples before freeze-drying and after reconstitution of the lyophilizates was 
measured with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA, USA) at 350 nm. Each formulation was measured as triplicate with its corresponding 
placebo without protein as blank solution. 
 
2.2.9. Light Obscuration (LO) 
A PAMAS SVSS-35 particle counter with a HCB-LD-25/25 sensor (PAMAS – Partikelmess- 
und Analysesysteme GmbH, Rutesheim, Germany) was used to determine the number of 
subvisible particles before freeze-drying and after dissolution of the lyophilizates. The system 
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was cleaned with HPW between the analyses. The rinsing volume was 0.2 mL, followed by 
four measurements of 0.2 ml according to USP 788 [57]. PAMAS PMA software was used to 
determine the number of particles ≥ 1 µm, ≥ 10 µm and ≥ 25 µm per mL. 
 
2.2.10. High Performance Size Exclusion Chromatography (HP-SEC) 
Size exclusion chromatography was performed with an Agilent 1100 series HPLC system 
equipped with an UV/Vis detector for detection at 280 nm (Agilent Technologies, Santa 
Clara, CA, USA). A TSKgel® G3000 SWXL column (dimension: 300 x 7.8 mm, TOSOH 
Bioscience GmbH, Stuttgart) and 100 mM sodium phosphate / 100 mM sodium sulfate buffer 
at pH 6.8 mobile phase with a flow rate of 0.5 mL/min  was used. Prior to analysis, 50 mg/mL 
samples were diluted to 2 mg/mL. All samples were centrifuged (5 min, 4000 rpm, Sigma 1-
15 microfuge, Sigma Laborzentrifugen GmbH, Osterode am Harz, Germany). After blank 
subtraction the integrated peak intensity was compared before and after freeze-drying using 
the ChemStation software (Agilent Technologies, Santa Clara, CA, USA). Soluble 
aggregates and fragments were also referred to the AUC of monomer before freeze-drying. 
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3. Results and Discussion 
3.1. Characterization of AA - Suc Formulations 
Crystalline bulking agents are desirably used in concentrations as low as possible if their only 
purpose is the coverage of unwanted cake appearance. At the 2.5/47.5 AA/Suc ratio 
crystallization of several AAs has been shown [8]. As proteins or amorphous excipients as 
sugars are able to suppress bulking agent crystallization and higher portions of crystalline 
material may also be required for mechanical cake stabilization, increased AA/Suc ratios 
(5/45 and 10/40 AA/Suc ratio) were also included into the study design to favour complete 
AA crystallization. The crystallizing AAs were selected based on literature 
[20,21,29,34,41,43]. Phe, Leu, Ile, Gly, and Met were investigated as potential crystallizing 
AAs. Man was tested at the same bulking agent/Suc ratios for comparison although a 
Man/Suc ratio of 4/1 is considered essential for complete Man crystallization [18,19]. 
 
3.1.1. DSC of Freeze-Concentrated AA/Suc Formulations 
Formulations in the frozen state were characterized by DSC. Increasing AA/Suc ratios of 
Phe/Suc and Leu/Suc formulations resulted in increased Tg’ values indicating that the 
individual Tg’ value of the AA was higher than the one of pure Suc (Table 6-7). A Tg’ of 
-10.5 °C was reported for Phe [8]. Tg’ values of Leu, Ile and Met were not found in literature 
and could not be measured since the AAs crystallized already during cooling. Ile/Suc 
mixtures showed Tg’ values close to that of pure Suc. Ile was either already crystalline below 
-33 °C or the Tg’ value of pure Ile is close to the one of Suc. Gly, Met and Man were 
investigated at the 10/40 ratio only. Tg’ values were close to the results of Suc for Man/Suc 
(-34.5 °C) and for Met/Suc (-33.5 °C). Tg’ values of Gly/Suc were lower than pure Suc 
samples in accordance with a Tg’ of -51.5 °C recorded to Gly/Suc 5/2 reported by [20]. 
 
Table 6-7. Tg’ values of AA/Suc and Man/Suc formulations. For n≥3: mean ± SD, for n=2: mean. n. d.: not 
determined. 
AA/Suc ratio 
Tg’ [°C] 
Phe/Suc Ile/Suc Leu/Suc Gly/Suc Met/Suc Man/Suc 
0/50 -32.9 ± 0.3 
2.5/47.5 -32.0 ± 0.2 -33.3 ± 0.3 -33.1 ± 0.2 n. d. n. d. n. d. 
5/45 -31.0 ± 0.6 -32.9 ± 0.5 -32.5 ± 0.5 n. d. n. d. n. d. 
10/40 -29.6 ± 0.6 -33.0 ± 0.6 -28.5 ± 0.8 -37.6 ± 0.8 -33.5 -34.5 ± 0.5 
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Exothermic crystallization peaks were detected in the heating scans of Phe/Suc 10/40 at 
-18.3 ± 0.2 °C, Ile/Suc 10/40 at -14.4 ± 1.7 °C, Leu/Suc 10/40 at -20.8 ± 0.2 °C and 
Met/Suc 10/40 at -17.1 °C. During cooling, peaks were detected for all AAs at approximately 
-30 °C. Thus, DSC analysis of the liquid samples pointed at pronounced crystallization 
tendencies of the selected AAs but also at the potential for incomplete crystallization after 
freezing. 
 
3.1.2. Screening of AAs and the Impact of Annealing on the Lyophilizates 
AA/Suc formulations were freeze-dried applying a fast freeze-drying cycle with or without 
annealing (Table 6-2,Table 6-3). 
Macroscopic and Microscopic Appearance 
Phe, Ile and Leu lyophilizates showed promising macroscopic appearance at 5/45 and 10/40 
AA/Suc while the 2.5/47.5 cakes were shrunken (Figure 6-1). Cakes with Leu, Ile and Met 
were lifted up from the bottom probably due to the high chamber pressure of 2.2 mbar 
resulting in fast sublimation. The microscopic structure of Phe/Suc 10/40 and Leu/Suc 10/40 
lyophilizates could not be differentiated by the selected freezing protocol and homogeneous, 
dense cakes were detected (Figure 6-2). The two typical bulking agents Man and Gly 
resulted in collapsed matrices except of the annealed 10/40 Man/Suc formulation. 
Microscopy confirmed a slightly improved cake appearance of Man/Suc 10/40, but still, many 
visible larger pores were evident. The bulking agent/Suc ratio was below the crystallization 
threshold of Gly and Man of Man/Suc ≥4/1 and Gly/Suc ≥2/5 [6,20,55]. Except for the 
annealed 10/40 Man/Suc formulation, annealing did not improve the macroscopic and 
microscopic appearance of the AA/Suc cakes indicating the crystallization of the AAs without 
the need of an additional annealing step. 
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- Annealing + Annealing  - Annealing + Annealing 
2.5/47.5 5/45 10/40 2.5/47.5 5/45 10/40  2.5/47.5 5/45 10/40 2.5/47.5 5/45 10/40 
Phe/Suc  Gly/Suc 
  
 
  
Ile/Suc  Met/Suc 
  
 
  
Leu/Suc  Man/Suc 
  
 
  
Figure 6-1. Macroscopic appearance of AA/Suc and Man/Suc lyophilizates freeze-dried with (Table 6-2) or 
without annealing (Table 6-3). 
 
 - Annealing + Annealing 
Phe/Suc 
10/40 
  
Leu/Suc 
10/40 
  
Man/Suc 
10/40 
  
Figure 6-2. Microscopic Appearance of Phe/Suc 10/40, Leu/Suc 10/40 and Man/Suc 10/40 lyophilizates 
freeze-dried with (Table 6-2) and without annealing step (Table 6-3). The bar refers to a 2.0 mm length. 
 
XRPD 
AA based lyophilizates with an acceptable macroscopic appearance (Phe, Ile, Leu and Met), 
in our study the most important quality attribute, were further investigated by XRPD (Figure 
6-3 A-D). Peaks that indicated AA crystallization were detected (Table 6-6). Man/Suc 10/40 
showed crystalline Suc and Man peaks (data not shown). Independent of the annealing step 
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the higher the AA/Suc ratio the more pronounced was the peak pattern. Ile and Leu showed 
significant peaks also at the lowest AA/Suc ratio of 2.5/47.5 while detection of Phe peaks 
was more difficult and at 2.5/47.5 no peaks could be assigned. 
A  B  
C  D  
Figure 6-3. XRD diffractograms of A - Phe/Suc, B - Ile/Suc, C - Leu/Suc, D - Met/Suc lyophilizates freeze-
dried with (Table 6-2, grey lines) or without annealing step (Table 6-3, black lines). 
 
DSC of Freeze-Dried AA/Suc Systems 
Tg values of the freeze-dried formulations were above 25 °C for all AA/Suc ratios and 
above 50 °C for the 10/40 AA/Suc ratio (Table 6-8). Annealing had no impact on the Tg 
values since the amorphous phase was not affected. Higher AA/Suc ratios showed higher Tg 
values compared to the 2.5/47.5 AA/Suc ratios. Microcollapse of these formulations was a 
possible reason for insufficient drying behaviour leading to higher RM values and hence 
lower Tg values (Table 6-9). 
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Table 6-8. Tg values of freeze-dried AA/Suc formulations. The formulations were freeze-dried with (Table 
6-2, + Annealing) or without annealing step (Table 6-3, - Annealing). For n=3: mean ± SD, for n=2: mean. 
AA/Suc ratio 
Tg [°C] 
- Annealing + Annealing 
Phe/Suc 10/40 67.4 ± 0.6 69.7 ± 1.1 
5/45 66.1 ± 2.4 67.2 
2.5/47.5 58.8 62.1 
Ile/Suc 10/40 54.7 54.9 
5/45 36.3 ± 2.3 47.0 
2.5/47.5 29.7 28.2 
Leu/Suc 10/40 50.5 51.4 
5/45 50.9 51.0 
2.5/47.5 38.9 43.4 
Met/Suc 10/40 51.0 50.9 
5/45 55.4 55.4 
 
Reconstitution Times 
Reconstitution times are an important quality attribute of freeze-dried formulations although 
they are not directly coupled to API stability and a diversity of different reconstitution times 
has been reported [59–63]. Prolonged times can be due to the API itself, e.g. high 
concentrated protein formulations, or due to excipients. Approaches for improvement are 
addition of wetting agents, adapted freezing procedures, heated reconstitution media or 
reconstitution with the 2-fold volume [60–66]. The reconstitution times differed significantly 
(Figure 6-4 A-B) whereas Phe/Suc lyophilizates dissolved in less than one minute. Most 
other lyophilizates required one to two minutes increasing with higher AA portion and 
annealed Leu/Suc 10/40 needed about four minutes for complete reconstitution. 
Compromised wetting behaviour was observed for Leu and Ile lyophilizates (Figure 6-4 C). 
Dissolution was not hindered as long as the lyophilizate was submersed. As soon as the 
outer cake region dissolved and the cake became detached from the vial wall, floating 
occurred and reconstitution was retarded. 
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A B 
 
 
 
 
C 
Figure 6-4. Reconstitution times AA/Suc formulations freeze-dried with (A, Table 6-2) or without annealing 
step (B, Table 6-3). Phe/Suc - black squares, Ile/Suc - white circle, Leu/Suc - black triangles and Met/Suc - 
black cross. For n=3: mean ± SD, for n=2: mean. C - Leu/Suc 10/40 lyophilizate during reconstitution after 
loss of contact with the vial wall. 
 
The reconstitution times were in an acceptable range of less than five minutes. Nevertheless, 
different approaches were tested to improve the rehydration, in particular for Leu/Suc and 
Ile/Suc 10/40 lyophilizates (Figure 6-5 A-D). The hydrophobic character of the selected AAs 
implied poor wetting and dissolution behavior of the crystalline phases. However, 
reconstitution of Phe lyophilizates was clearly faster than the reconstitution of Ile and Leu 
lyophilizates. In order to improve solubility, the reconstitution medium was adjusted to the 
pKa and pKb values of the AAs (Table 6-1). The reconstitution times of Ile/Suc 10/40 
decreased at pH 2.33 and 9.75 compared to the reconstitution at pH 6.0 while the ones of 
Leu/Suc did not change significantly (Figure 6-5 A). 
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A  B  
C  D  
Figure 6-5. Reconstitution times of AA/Suc 10/40 lyophilizates freeze-dried without annealing step (Table 
6-3). For n≥3: mean ± SD, for n=2: mean. A - pH adjustment of reconstitution medium. B - Pressure 
adjustment within the sample container. C – Addition of surfactant to reconstitution medium. D – Addition 
of surfactant to the formulation. Phe/Suc 10/40 - black squares, Ile/Suc 10/40 – white circles and Leu/Suc 
10/40 – black triangles. 
 
Werk et al. reported that reconstitution times decreased if a warmed reconstitution medium 
was utilized [65]. However, for the AA/Suc lyophilizates, a prewarmed reconstitution medium 
of 40 °C resulted in the same reconstitution times as water at ambient temperature. 
Bhatnagar showed that vacuum within the sample container could help to improve 
reconstitution times if complete disintegration of the cake was caused by the incoming liquid 
flow [60]. Ile and Leu lyophilizates showed slightly, but not significantly faster reconstitution 
when the sample container was stoppered at 100 mbar after freeze-drying instead of 
ventilation of the vial before reconstitution (Figure 6-5 B). Since the limiting factor was the 
wetting of the cake and the contact with water, neither warmer HPW and pH adjustment nor 
vacuum could increase the contact area with the lyophilizate and hence the rate determining 
floating of the cake was not prevented. 
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Surfactants are commonly used in freeze-dried formulations to cope with the interface related 
stress such as at the ice-freeze concentrate interface during freezing [67–70]. Surfactants at 
high concentration in the reconstitution medium act as wetting agents and decrease 
reconstitution times [62,63]. The reconstitution times of Leu/Suc 10/40 decreased only if 
surfactant concentrations of 0.2% and higher were used (Figure 6-5 C). Reconstitution of the 
other lyophilizates was not affected by the addition of surfactant because floating of the cake 
could not be prevented. As an alternative, 0.02% or 0.2% polysorbate 80 in the solutions to 
be lyophilized were evaluated (Figure 6-5 D). Reconstitution was facilitated, in particular for 
the Ile/Suc 10/40 formulation. Phe/Suc 10/40 and 5/45 lyophilizates did not benefit as they 
dissolved already fast without surfactant. Phe/Suc 5/45 and Leu/Suc 5/45 suffered shrinkage 
when 0.2% PS80 was included. In addition, in combination with Ile, 0.2% PS80 induced the 
formation of crystalline Suc at both AA/Suc ratios. Thus, the addition of 0.2% PS80 could 
improve the reconstitution time but it affected other important quality attributes negatively. As 
a compromise, lower polysorbate concentrations were added to the formulations for the 
following experiments. 0.04% PS20 was chosen in order to avoid shrinkage and Suc 
crystallization. 
Thus, the screening of the AAs demonstrated that Phe, Ile and Leu resulted in lyophilizates 
with appropriate physical characteristics when combined with Suc in different ratios. Higher 
AA/Suc ratios of 5/45 and 10/40 were superior with respect to macroscopic appearance and 
crystallinity compared to the 2.5/47.5 AA/Suc ratio. Annealing did not improve these 
characteristics. Inclusion of polysorbate into the formulations could improve the reconstitution 
times of the poorly wetting Ile/Suc and Leu/Suc lyophilizates. Phe/Suc lyophilizates 
reconstituted faster in spite of comparable hydrophobicity (Table 6-1). Higher Tg values may 
correlate to a different lyophilizate structure enabling better wetting and hence reconstitution. 
 
3.1.3. Impact of pH on Physical Characteristics of AA/Suc Lyophilizates 
Solubility and crystallization of the amphoteric AAs strongly depend on pH. Indeed, the 
macroscopic appearance of lyophilizates based on AA/Suc mixtures was affected by the 
formulation pH especially at lower AA/Suc ratio (Figure 8-5). In general, pH conditions from 
pH 5 to pH 7 resulted in better cake appearances than more extreme acidic or basic 
conditions. Met/Suc and Gly/Suc lyophilizates did not improve macroscopic appearance 
under the applied pH conditions. Within the formulations with good cake structure, the 
crystallization tendencies were not affected, except of Phe/Suc 10/40 which showed a 
different peak pattern at a formulation pH equal to the pKa of Phe despite comparable 
macroscopic appearance (Figure 8-6). The peaks could be assigned to the anhydrous form 
of Phe, whereas the common form of crystalline Phe after freeze-drying is the monohydrate 
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[8]. Physical instabilities of these two Phe forms in lyophilizates have not yet been described 
in literature. Potentially, release of the hydrate upon storage might induce degradation 
reactions, however, only its formation occurred at low pH. The known Maillard reaction was 
also favoured at acidic pH condition [72,73] and was detected by browning of the acidic 
Phe/Suc formulations after few days of storage at ambient temperature. Leu/Suc 10/40 at a 
pH equal to pKa did show additional peaks that could not be assigned to further typical Leu 
reference peaks. In contrast to Phe, no other Leu modification could be found in literature. 
The peaks were also not in accordance with Suc peaks. Thus, macroscopic appearance and 
AA crystallinity were affected only by extreme pH conditions but not in the pH region of 
interest. Tg values decreased at pH values equal to the pKa, pKb, pKa+1 and pKb-1, but were 
stable in the pH region of pH 5 – 7. (Table 8-1). Reconstitution times were comparable over a 
broad pH range (pH 5 - 7) (Figure 8-7). Only Leu/Suc 10/40 showed an improved 
reconstitution in the extreme basic or acidic region. A formulation pH of 6.0 resulted in the 
best characteristics regarding appearance, crystallinity, Tg values and reconstitution times 
for Phe/Suc, Ile/Suc and Leu/Suc lyophilizates. 
 
3.1.4. Impact of Lower Tp on the Quality of AA:Suc Lyophilizates 
As cake shrinkage and lifted cakes were detected during the screening experiments, the 
freeze-drying cycle was adapted to improve macroscopic appearance without losing AA 
crystallinity at still short process time. First, the chamber pressure was reduced from 
2.2 mbar to 0.52 mbar (Table 6-4) resulting in a reduction of Tp from -10 °C to -20 °C during 
primary drying. Thus, the Tp was still markedly above the Tg’ of Suc. Alternatively, the 
chamber pressure was set to 0.40 mbar and the shelf temperature set to 0 °C instead of 
20 °C during primary drying (Table 6-5) resulting in a Tp of -27 °C, only slightly above Tg’. 
At the reduced chamber pressures settings lifting of the lyophilizates could be prevented 
whereas the cake appearance was not changed (Figure 6-6). Phe/Suc 5/45 dried at 
0.52 mbar and Ile/Suc 5/45 dried at 0.40 mbar formed shrunken cakes. A decreased Tp 
seemed to hinder the arrangement of AA crystals (Figure 6-7). However, Phe/Suc 5/45 was 
not collapsed at a Tp of -27 °C despite of an amorphous XRD pattern since the Tp was close 
to the Tg’ of the formulation. Thus, crystallization of the AAs was not completed after the 
freezing step, but was favoured at increased Tp during primary drying. The crystallization 
tendency depended on the AA portion. Low AA/Suc ratio combined with low Tp during 
primary drying prevented AA crystallization. 
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Pressure set point during PD [mbar] 
2.2 0.40  2.2 0.52 0.40  2.2 0.52 0.40  0.40 
Phe/Suc 2.5/47.5  Phe/Suc 5/45  Phe/Suc 10/40  Suc 50 
 
 
 
 
 
 
 
Ile/Suc 2.5/47.5  Ile/Suc 5/45  Ile/Suc 10/40   
 
 
 
 
 
  
Leu/Suc 2.5/47.5  Leu/Suc 5/45  Leu/Suc 10/40   
 
 
  
  
Figure 6-6. Macroscopic Appearance of AA/Suc and Suc lyophilizates dried at different chamber pressure 
settings (Table 6-3 - Table 6-5). 
 
Phe/Suc 5/45 
 
Ile/Suc 5/45 
 
Figure 6-7. XRD diffractogram of Phe/Suc 5/45 and Ile/Suc 5/45 lyophilizates freeze-dried according to 
Table 6-3 – Table 6-5. The chamber pressure set points during PD are given. 
 
Tg values correlated to the RM levels (Table 6-9). Fast freeze-drying cycle at the highest Tp 
of -10 °C led to the highest RM levels in Ile/Suc and Leu/Suc formulations. This cycle was 
implemented for Man/Suc 4/1 formulations with acceptable RM levels [74]. For Phe/Suc 
10/40 RM below 0.5% resulted. For Ile/Suc and Leu/Suc freeze-dying at 0.52 mbar resulted 
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in lower RM levels and hence higher Tg values. The lack of crystalline bulking agent in 
AA/Suc 2.5/47.5 resulted in collapse and as a consequence in higher RM and lower Tg 
values. A chamber pressure of 0.52 mbar resulted in the most suitable RM levels of 0.1 –
 0.7% leading to Tg values above 55 °C. 
Table 6-9. Tg values and residual moisture levels of AA/Suc freeze-dried at different chamber pressure 
settings according to Table 6-3-Table 6-5. For n=3: mean ± SD, for n=2: mean. – not determined. 
AA/Suc ratio 
Tg [°C] Residual Moisture [%] 
2.2 mbar 0.52 mbar 0.40 mbar 2.2 mbar 0.52 mbar 0.40 mbar 
Phe/Suc 10/40 67.4 ± 0.6 70.9 68.9 ± 2.0 0.1 ± 0.1 0.1 ± 0.1 0.3 ± 0.1 
5/45 66.1 ± 2.4 39.9 62.1 ± 2.2 0.5 ± 0.1 0.7 ± 1.1 1.0 ± 0.3 
2.5/47.5 58.8 - 55.3 ± 3.6 - - 1.3 ± 0.4 
Ile/Suc 10/40 54.7 55.1 61.5 ± 5.0 1.7 0.6 ± 0.5 0.8 ± 0.2 
5/45 36.3 ± 2.3 56.4 52.6 ± 2.2 2.8 ± 0.02 0.3 ± 0.3 1.9 ± 0.3 
2.5/47.5 29.7 - 50.1 ± 2.4 - - 1.5 ± 0.3 
Leu/Suc 10/40 50.5 62.8 58.3 ± 5.9 1.6 ± 0.1 0.3 ± 0.2 0.7 ± 0.1 
5/45 50.9 55.3 65.9 ± 2.3 2.5 ± 0.05 0.3 ± 0.2 0.7 ± 0.2 
2.5/47.5 38.9 - 51.6 ± 6.7 - - 1.3 ± 0.2 
Suc 50 - - 51. 1 ± 4.1 - - 2.3 ± 0.4 
 
Reconstitution times were measured for these cycles as well, but did not lead to significant 
differences between the freeze-drying cycles. 
Thus, a lower chamber pressure of 0.52 mbar leading to a Tp of -20 °C prevented lifting of 
the cakes and led to acceptable cake appearances, Tg values and RM levels in most 
formulations. AA crystallinity was detected in all AA/Suc formulations processed with this 
cycle except of Phe/Suc 5/45. An even lower pressure set point of 0.40 mbar resulting in a 
Tp of -27 °C reduced crystallinity of the AAs, higher RM levels and lower Tg values. The low 
2.5/47.5 AA/Suc ratio led to crystalline AAs but the ratio of crystalline to amorphous phase 
was not investigated quantitatively. The macroscopic appearance was also not acceptable in 
the 2.5/47.5 AA/Suc ratios. As a consequence, protein runs were only performed with two 
AA/Suc ratios, 5/45 and 10/40, dried at 0.52 mbar. 
 
3.2. Freeze-Drying of the Model mAb in AA/Suc Formulations 
To test whether the AA/Suc formulations were able to stabilize proteins upon freeze-drying a 
model mAb was investigated at two different concentrations (2 mg/mL and 50 mg/mL). 
Phe/Suc, Ile/Suc and Leu/Suc formulations were evaluated (AA/Suc 5/45 and 10/40). 0.04% 
Polysorbate 20 was included in the formulations for improvement of the reconstitution times. 
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The resulting lyophilizates were characterized in terms of their physical properties. 
Furthermore, protein process stability was examined regarding aggregate formation. Freeze-
drying was carried out at 0.52 mbar with a Tp of -20 °C during the 12 h primary drying step 
(Table 6-4). 
 
3.2.1. Physical characterization 
Lyophilizates with 50 mg/mL mAb did not suffer any cake defects independent of the chosen 
AA (Figure 6-8). This was due to the high total solid content of 100 mg/mL. The 10/40 
AA/Suc ratio resulted in acceptable macroscopic appearance for all formulations and marked 
AA crystallinity. In contrast, for the 5/45 AA/Suc ratio and 2 mg/mL mAb, best cake 
appearance was given for Leu/Suc 5/45 followed by Ile/Suc 5/45 and Phe/Suc 5/45 which 
suffered shrinkage. The crystallization tendency of Phe was strongly affected by the protein 
while Ile and Leu crystallized at both mAb concentrations (Figure 6-9). The higher mAb 
concentration of 50 mg/mL suppressed Phe crystallization completely whereas Ile/Suc and 
Leu/Suc lyophilizates showed crystalline Ile and Leu, respectively. Thus, Ile and Leu had a 
stronger crystallization tendency in contrast to Phe and were less affected by crystallization 
suppressing excipients as protein or surfactant. 
 
mAb concentration [mg/mL] 
  0 2   50   0 2   50 
Phe/Suc 5/45 Phe/Suc 10/40 
  
Ile/Suc 5/45 Ile/Suc 10/40 
  
Leu/Suc 5/45 Leu/Suc 10/40 
  
Figure 6-8. Macroscopic Appearance of AA/Suc lyophilizates at different protein concentrations (0 mg/mL, 
2 mg/mL and 50 mg/mL) freeze-dried according to Table 6-4. 
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Phe/Suc 
 
Ile/Suc
 
Leu/Suc 
 
Figure 6-9. XRD diffractograms of Phe/Suc, Ile/Suc and Leu/Suc lyophilizates at different mAb 
concentrations (0 mg/mL – black, 2 mg/mL – grey, 50 mg/mL dark grey). * mark reference peaks according 
to Table 6-6. 
 
Tg values and RM contents complemented macroscopic appearance and XRPD (Table 6-
10). Inacceptable cake appearance was accompanied by high RM levels and low Tg values 
(Phe/Suc 5/45). The mAb concentration of 50 mg/mL led to better cake appearance, 
improved drying behavior and hence low RM levels and higher Tg values. Similar results 
were achieved by Ile/Suc and Leu/Suc in this AA/Suc ratio of 5/45. The higher AA/Suc ratio 
of 10/40 resulted in consistently lower residual moisture levels coupled to higher Tg values. 
Table 6-10. Impact of protein concentration on Tg values and RM levels of AA/Suc lyophilizates freeze-
dried according to Table 6-4. n=3: mean ± SD, n=2: mean, -: not detected. 
AA/Suc Ratio 
Tg [°C] RM [%] 
0 mg/mL 2 mg/mL 50 mg/mL 0 mg/mL 2 mg/mL 50 mg/mLL 
Phe/Suc 10/40 67.4 ± 2.8 59.0 75.0 0.1 ± 0.1 0.1 0.1 
5/45 39.1 43.6 88.0 2.3 2.4 0.1 
Ile/Suc 10/40 67.4 ± 2.4 72.8 87.2 0.1 ± 0.2 0.3 0.04 
5/45 57.9 ± 4.6 52.5 - 0.7 0.7 0.1 
Leu/Suc 10/40 65.1 ± 2.2 57.0 46.3 0.2 ± 0.2 0.1 0.0 
5/45 61.4 67.5 65.5 0.4 0.4 0.03 
 
Reconstitution times of formulations with only 2 mg/mL protein concentration were below 
30 s for AA/Suc 5/45 and below 100 s for AA/Suc 10/40 and comparable to protein free 
formulations independent of the AA. In contrast, 50 mg/mL protein induced a pronounced 
prolongation of the reconstitution as described in literature [60,62,64]. 
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AA/Suc 5/45 
 
AA/Suc 10/40 
 
Figure 6-10. Impact of protein concentration on reconstitution times of AA/Suc 5/45 and 10/40 
lyophilizates freeze-dried according to Table 6-4.Phe/Suc – black squares, Ile/Suc – white circles, Leu/Suc 
– black triangles. 
 
3.2.2. Protein stability 
Insoluble aggregates larger than 35 nm can be detected due to their scattering of light at 
350 nm [75]. After freeze-drying and reconstitution the formulations were clear without 
indications of visible aggregate formation. Absorbance values before and after freeze-drying 
were comparably low at 0.06 AU for all formulations. Thus, no insoluble aggregates were 
formed during freeze-drying. Light obscuration was used to determine the amount of sub-
visible particles. The particle numbers were below 25,000 particles per mL (≥ 1 µm), below 
250 particles per mL (≥ 10 µm) and below 20 particles per mL (≥ 25 µm) and did not increase 
with freeze-drying. The amount of soluble aggregates before and after freeze-drying and 
reconstitution was below 1% for all samples without significant impact of freeze-drying at 
both protein concentrations (Figure 6-11). 
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2 mg/mL 
 
50 mg/mL 
 
Figure 6-11. Soluble aggregates of mAb/AA/Suc formulations freeze-dried according to Table 6-4. n=3: 
mean ± SD. bFD - black bars, aFD - grey bars. 
 
Thus, the analysis of mAb process stability did not show any significant protein aggregation. 
As only a small amount of bulking agent was used in comparison to other common crystalline 
bulking agents, sufficient amorphous Suc was present. Upon storage, the high fraction of 
amorphous Suc should provide adequate stabilization. It has to be ensured that Suc remains 
amorphous upon storage and that AA crystallization, if amorphous, is avoided. 
4. Conclusions 
The aim of this study was to investigate several AAs as alternatives to the typical bulking 
agents Man and Gly which require high bulking agent/Suc ratios. Low AA/Suc ratios were 
freeze-dried above Tg’ to enable fast freeze-drying. The amino acids Phe, Ile and Leu 
showed better crystallization characteristics than the typical bulking agents Man and Gly at 
the essential bulking agent to Suc ratio freeze-dried above Tg’. At 2.5/47.5 AA/Suc 
acceptable cake appearance could not be achieved despite of crystalline Ile and Leu peaks. 
5/45 and 10/40 AA/Suc offered a substantially improved lower bulking agent concentration at 
high stabilizer content. Annealing at -20 °C could not enhance crystallization in contrast to 
varied Tp during primary drying. Lower Tp decreased the crystallization tendencies of the 
AAs. Thus, fast freeze-drying at -20 °C for 12 hours primary drying time rendered the best 
physico-chemical characteristics of the AA/Suc lyophilizates. A pH range of pH 5 to pH 7 was 
suitable at the tested AA/Suc ratios while extreme pH conditions induced collapse. 
Reconstitution times were longer in Ile and Leu lyophilizates compared to Phe and Man due 
to poor wettability and floating of the cakes containing the hydrophobic AAs. Including 
surfactants in the formulation improved the reconstitution behaviour. The protein was 
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protected by the high amount of sucrose. The crystallization tendency of Phe was reduced by 
protein in contrast to Ile and Leu. 
Concluding, the three AAs Ile, Leu and Phe were found to be alternative bulking agents to 
Man and Gly enabling fast drying at high stabilizer content but low bulking agent 
concentration. In contrast to other crystallizing excipients, Ile and Leu crystallization was not 
suppressed by protein enabling also increased protein concentrations. 
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Chapter 7 
Final Summary 
The present thesis focused on the reduction of the freeze-drying process time without 
detrimental impact on protein stability and macroscopic cake appearance. Therefore, 
different crystalline bulking agents were investigated: (1) the already well established 
mannitol (Man) to develop a fast freeze-drying cycle (Chapter 5) and (2) crystallizing amino 
acids as potential alternative bulking agents to Man (Chapter 6). Further aspects as the 
characterization of the freeze-concentrate play an important role for understanding of protein 
stability during freeze-drying as described in Chapter 4. A novel measuring device for the 
collapse temperature (Tc) was the focus of Chapter 3. 
Monitoring of the freeze-drying process is an important aspect for improved process 
understanding. The optical fiber system (OFS) was investigated as potential detection tool for 
the Tc in freeze/thawing and freeze-drying studies (Chapter 3). OFS results were compared 
to the current standard measuring tools DSC and FDM. Suc, Tre and stachyose solutions as 
well as highly concentrated IgG1 and lysozyme formulations were used to identify that the 
TOFS peak during thawing was in accordance with Tc and not with Tg’. Crystallization 
behaviour of Man measured by OFS in vials correlated well to DSC analysis. Thus, the OFS 
can be used as alternative method for Tc determination or crystallization in the product 
container. During freeze-drying experiments collapse of 20% sucrose or stachyose solutions 
could be detected with the OFS but not for lower sugar concentrations. Thus, detection of Tc 
and crystallization in freeze/thaw and collapse of highly concentrated freeze-dry solutions 
can be provided by the OFS as measuring device although the sensitivity of the sensor can 
still be improved. 
Freezing and annealing are both steps that can affect protein stability in the final lyophilisate 
(Chapter 4). Excipients, in particular, crystallizing agents, can have a major impact on 
unfolding and hence aggregation of the protein. This was investigated in a study with Man, 
trehalose (Tre) and BSA at an annealing temperature of -20 °C for 20 hours. Differential 
scanning calorimetry (DSC), X-ray diffraction and FTIR spectroscopy demonstrated the 
diverse crystallization behaviour of Man and Tre at different concentrations of BSA, 
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polysorbate 20 and deuterium oxide. The secondary structure of BSA was measured by IR 
spectroscopy in frozen solution and by circular dichroism in thawed solutions. Unfolding of 
BSA occurred if Tre crystallization took place. However, increased BSA content delayed and 
reduced both, Man and Tre crystallization. Polysorbate 20 (< 0.2% w/w) and deuterium oxide 
(> 5% w/w) similarly induced crystallization behaviour. The extent of excipient crystallization 
was directly coupled to retention of BSA in its native conformation in frozen and thawed 
solution. BSA unfolding could not be correlated to particle or aggregate formation. 
Nevertheless, the physical state of the freeze-concentrate should be studied in future at 
different excipient and protein concentrations. 
In the subsequent part of the thesis fast freeze-drying at high product temperature (Tp) was 
evaluated (process development, Chapter 5) targeting good protein stability and elegant 
cake appearance at the same time (formulation development, Chapter 5 and Chapter 6). 
Fast freeze-drying is usually limited as the typical protein stabilizer sucrose (Suc) collapses 
at high Tp above its collapse temperature (Tc). Crystalline bulking agents can prevent 
macrocollapse, however, do not stabilize the proteins. Short freeze-drying cycles save time 
and costs. First, 4/1 Man/Suc formulations were used to develop of a fast freeze-drying cycle 
above Tg’ of the formulation (Chapter 5). At a Tp of -10 °C during primary drying (PD) this 
phase was completed in only 7 hours. The Tp was only slightly below the eutectic 
temperature of Man preventing macrocollapse of the formulation. The cake characteristics 
were adequate with Tg values above 60 °C, a residual moisture level of 1%, reconstitution 
times about 30 seconds, crystalline δ-mannitol and elegant appearance. A lower Man/Suc 
ratio and hence a higher stabilizer content was prevented by incomplete Man crystallization. 
Protein process stability was shown using lysozyme and two monoclonal IgG1 antibodies at 
two concentrations each. Characterisation of protein stability rendered low aggregation and 
particle levels for both, the fast and a long conservative freeze-drying process with a Tp of 
-39 °C, without defects in macroscopic appearance. Thus, fast freeze-drying of 4/1 Man/Suc 
formulations above the Tg’ at a Tp of -10 °C resulted in good protein process stability and 
appropriate cake characteristics at substantial process time reduction. 
The high Man fraction was necessary to ensure crystallization, but limited Suc concentration, 
although more protein stabilizer could be beneficial, particularly for highly concentrated 
protein formulations. Crystallizing amino acids (AA) could be a promising alternative to Man 
enabling lower bulking agent/Suc ratios (Chapter 6). Glycine (Gly), phenylalanine (Phe), 
methionine (Met), leucine (Leu) and isoleucine (Ile) were freeze-dried at low bulking 
agent/Suc ratios of 2.5/47.5, 5/45 and 10/40 with the fast freeze-drying cycle and compared 
to Man at the same ratios. Both, Man/Suc and Gly/Suc formulations suffered macrocollapse 
with incomplete crystallization. Phe/Suc, Leu/Suc and Ile/Suc crystallized at 5/45 and 10/40, 
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but showed less pronounced crystallization in 2.5/47.5 AA/Suc ratio leading to unacceptable 
cake structures. Annealing did not enhance crystallization and a broad pH screen showed 
superior macroscopic appearance and AA crystallization at pH 5 - 7. Crystallization peaks 
were not suppressed by protein in Leu and Ile lyophilizates. Protein stability after freeze-
drying was not affected either. Leu and Ile as bulking agents resulted in prolonged 
reconstitution time compared to Phe due to the insufficient wetting of these AAs and floating 
of the cakes. The reconstitution behaviour could be improved by addition of surfactant. The 
physic-chemical properties Tg, residual moisture, cake appearance and crystallinity of the 
lyophilizates were adequate. Additionally, process stability was shown for a monoclonal 
antibody. Thus, two novel bulking agents, Ile and Leu were identified which can be used at 
clearly lower bulking agent/Suc ratio as compared to Man enabling fast freeze-drying at Tp 
above Tg’. 
 
In summary, this thesis provided several new findings regarding the freeze-drying of proteins. 
Bulking agents enable to dry Suc formulations at Tp above Tg’ without losing cake 
appearance. A higher stabilizer concentration is facilitated by the crystallizing AAs Phe, Leu 
and Ile as bulking agents. But crystallization of Man and Tre in the freeze-concentrate affects 
protein stability. Furthermore, the OFS as measuring device for Tc and crystallization in the 
product container could be established while interpretation of the OFS signal during freeze-
drying is still a challenging task. 
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1. Supplementary Material of Chapter 5 
 Placebo 
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Figure 8-1. Macroscopic appearance of Protein/Man/Suc/Gly (x/40/9.5/0.5) formulations after conservative 
(Table 5-1, Process 1) and fast (Table 5-1, Process 8) freeze-drying. 
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Figure 8-2. Macroscopic appearance of Protein/Man/Suc/Gly (x/40/9/1) formulations after conservative 
(Table 5-1, Process 1) and fast (Table 5-1, Process 8) freeze-drying. 
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 Placebo 
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Figure 8-3. Macroscopic appearance of Protein/Man (x/40) formulations after conservative (Table 5-1, 
Process 1) and fast (Table5-1, Process 8) freeze-drying. 
 
 
Figure 8-4. Exemplary XRD diffractograms of selected Man/Suc 40/10 formulations. Formulations freeze-
dried with the conservative FD cycle are depicted in black while formulations processed with the fast FD 
cycle are in grey. Peaks marked with * represent peaks of mannitol-hemihydrate. 
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2. Supplementary Material of Chapter 6 
pH  pH 
pKa pKa+1 5 6 7 pKb-1 pkb  pKa pKa+1 5 6 7 pKb-1 pkb 
Phe/Suc 2.5/47.5 
 
Ile/Suc 2.5/47.5 
  
Phe/Suc 5/45 Ile/Suc 5/45 
  
Phe/Suc 10/40 Ile/Suc 10/40 
  
 
pH  pH 
 
pH 
pKa pKa+1 5 6 7 pKb-1 Pkb  pKa 6 pKb pKa 6 pKb 
Leu/Suc 2.5/47.5 
 
Gly/Suc 2.5/47.5 Met/Suc 2.5/47.5 
   
Leu/Suc 5/45 Gly/Suc 5/45 Met/Suc 5/45 
   
Leu/Suc 10/40 Gly/Suc 10/40 Met/Suc 10/40 
   
Figure 8-5. Macroscopic Appearance of AA/Suc lyophilizates at different formulation pH freeze-dried 
without annealing step (Table 6-3). 
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Phe/Suc 10/40 Ile/Suc 10/40 Leu/Suc 10/40 
   
Phe/Suc 5/45 Ile/Suc 5/45 Leu/Suc 5/45 
   
Phe/Suc 2.5/47.5 Ile/Suc 2.5/47.5 Leu/Suc 2.5/47.5 
   
Figure 8-6. XRD diffractograms of Phe/Suc, Ile/Suc and Leu/Suc lyophilizates at different formulation pH 
values freeze-dried without annealing step (Table 6-3). * mark reference peaks of the AAs, # mark the 
anhydrous form of Phe (Table 6-6). 
 
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
pKa
7.0
*
*
* **
*
*
*
pKa+1
5.0
6.0
pK
b
*
*
*
*
* *
*
*
*
*
*
*
*
*
pK
b
-1
*
**
*
* *
*
#
#
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
7.0
*
*
*
* **
*
*
*
pKa+1
5.0
6.0
pK
b
*
*
*
*
*
*
*
*
*
*
*
*
pK
b
-1
*
*
*
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
pKa
7.0
*
*
*
* **
*
*
*
pKa+1
5.0
6.0
pK
b
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
pK
b
-1
*
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
7.0
*
*
*
* *
5.0
6.0
pK
b
pK
b
-1
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
7.0
*
*
*
*
*
*
*
*
pKa+1
5.0
6.0
pK
b
*
*
*
*
*
*
* *
pK
b
-1
*
*
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
7.0
*
*
*
*
*
*
*
*
*
pKa+1
5.0
6.0
pK
b
*
*
*
*
*
*
*
*
*
pK
b
-1
*
*
*
**
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
7.0
5.0
6.0
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
7.0
5.0
6.0
*
*
*
*
*
2-theta [°]
5 10 15 20 25 30 35
R
e
la
ti
v
e
 i
n
te
n
s
it
y
 [
A
U
]
7.0
5.0
6.0
*
*
*
*
*
*
*
Appendix 
175 
Table 8-1. Tg values of freeze-dried AA/Suc formulations at different formulation pH. The formulations 
were freeze-dried without annealing step (Table 6-3). For n=3: mean ± SD, for n=2: mean. c. collapsed. 
AA/Suc ratio 
pH 
Tg [°C] 
pKa+1 5.0 6.0 7.0 pKb-1 pKb 
Phe/Suc 10/40  62.7 63.1 67.4 ± 0.6 67.2 59.2 c. 
5/45  c. 67.1 66.1 ± 2.4 67.1 67.1 c. 
Ile/Suc 10/40  c. 51.2 54.7 47.1 47.3 43.3 
5/45  c. 47.6 36.3 ± 2.3 35.7 35.9 35.3 
Leu/Suc 10/40  43.0 47.4 50.5 47.4 39.9 c. 
5/45  c. 43.8 50.9 47.2 39.8 32.0 
 
 
AA/Suc 5/45 
 
AA/Suc 10/40 
 
    
Figure 8-7. Reconstitution times of Phe/Suc (black squares), Ile/Suc (white circles) and Leu/Suc (black 
triangles) formulations with different formulation pH freeze-dried without annealing step (Table 6-3). For 
n=3: mean ± SD, for n=2: mean. 
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